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Abstract 
 
Multimodal analgesia has been proposed as a useful strategy to reduce 
postoperative pain while decreasing opioid consumption and thus opioid 
adverse events. Gabapentin is one such agent although previous results have 
been heterogeneous. This thesis aimed to review randomised controlled trials 
of gabapentin for reducing pain, opioid adverse effects and the haemodynamic 
response to intubation while attempted to predict clinical effectiveness from 
these trials using meta-regression. Extending this principle, we evaluated other 
multimodal analgesic agents to identify whether heterogeneity could be 
explained by various clinical and methodological covariates. 
 
Our gabapentin review included 133 randomised controlled trials and 
demonstrated its efficacy in reducing pain scores, opioid consumption and 
opioid adverse events such as nausea, vomiting and pruritus. However, 
gabapentin increased the risk of sedation. Gabapentin was effective at reducing 
the haemodynamic response to intubation in 29 randomised controlled trials 
although trials failed to report on clinically relevant outcomes. Gabapentin 
exhibited no pre-emptive analgesic effect in 4 randomised controlled trials.  
 
There was evidence of considerable statistical heterogeneity on meta-analysis 
of gabapentin for pain scores and 24-hour morphine consumption. Meta-
regression analysis showed however that baseline risk predicted the majority of 
the heterogeneity between studies. Extending this approach to other 
multimodal analgesics from 344 randomised controlled trials; we demonstrated 
this was true for analgesic agents in general. In addition to baseline risk, 
methodological limitations, especially inadequate allocation concealment, 
explained some of the residual heterogeneity.  
 
There was evidence of funnel plot asymmetry for most analgesic agents, 
suggesting publication bias. However, this may be a product of trials with 
higher baseline risk having larger standard errors, rather than true publication 
bias. Indeed, when we simulated meta-analyses with no publication bias, with 
both effect size and standard deviations dependent on baseline risk, funnel plot 
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asymmetry was still evident (p<0.001). Therefore, conventional funnel plots 
may be an unsuitable method of detecting publication bias where baseline risk 
predicts between-study heterogeneity. We present an alternative method using 
meta-regression residuals that corrects funnel plot asymmetry in the presence 
of no publication bias. 
 
Finally, due to concerns that methodological limitations exaggerated effect 
estimates, we used trial sequential analysis to determine whether sufficient low 
risk of bias evidence exists to reject type I and type II errors in the analyses of 
analgesic adjuncts. We demonstrated there is currently insufficient evidence 
from low risk of bias trials to be confident of the efficacy of the majority of 
analgesic adjuncts. 
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Overview 	
This thesis presents an overview of the peri-operative use of gabapentin and 
other multimodal analgesic adjuncts. Gabapentin has emerged as a versatile 
agent for reducing various negative consequences associated with anaesthesia 
and surgery. A wealth of clinical trials have been published over the last 
decade that demonstrate the benefit of gabapentin. The thesis begins with 
chapter one, which presents a narrative review of the many negative 
consequences of surgery and anaesthesia, justifying the study of these 
outcomes within this thesis. The second part of the chapter discusses 
gabapentin, providing a narrative review of its pharmacology and adverse 
effects. Reference will be made to both animal and human studies conducted 
on gabapentin to help elucidate its biological mechanisms in relation to pain 
management and reductions in the stress responses to endotracheal intubation. 
Following this, current meta-analyses in the area of gabapentin for 
postoperative pain will be discussed and their limitations highlighted. This 
chapter will conclude with a discussion of various meta-analytic techniques 
that aim to investigate heterogeneity between study results, identify potential 
publication bias and reduce type I and type II errors in analysis. 
 
Chapter two presents the first systematic review and meta-analysis conducted 
on gabapentin, which focuses on the core outcomes of acute and chronic 
postoperative pain while addressing the limitations of those published 
previously. Moreover, this chapter will present the novel use of a meta-
regression model to help predict the efficacy of gabapentin under different 
clinical conditions. Chapter three will build on the first meta-analysis by 
evaluating the use of gabapentin for other important peri-operative outcomes 
such as postoperative opioid side effects and gabapentin adverse effects. This 
chapter will also extend the use of the meta-regression model to evaluate 
whether gabapentin adverse effects are dose-dependent.  
 
Chapter four examines whether gabapentin exhibits any pre-emptive analgesic 
effect by including trials that directly compared pre-operative with post-
incision administration. Chapter five examines whether gabapentin has an 
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effect for attenuating the haemodynamic response to endotracheal intubation 
and whether this in turn can reduce postoperative myocardial events and 
mortality in high-risk patients.  
 
Chapter six extends the meta-regression techniques used in chapter two to 
other analgesic adjuncts. It examines the prevalence of statistical heterogeneity 
and if present, uses meta-regression analysis to investigate clinical and 
methodological covariates as sources of heterogeneity. Furthermore, Bayesian 
analysis of baseline risk will be used to reduce the bias present in traditional, 
naive analysis. Ultimately, this chapter will argue the more appropriate use of 
meta-regression to present results from meta-analyses of analgesic adjuncts 
while also outlining other important implications for clinical practice, primary 
and secondary research studies.  
 
Chapter seven examines publication bias in analgesic adjuncts and argues that 
for the outcome of morphine consumption, funnel plots may be an unsuitable 
method for highlighting potential publication bias due to correlation between 
baseline risk and standard errors. Furthermore, we present a novel method to 
overcome this correlation and demonstrate it using simulated meta-analyses 
with no publication bias present. Chapter eight will utilise trial sequential 
analysis, which is a method analogous to sample size calculations for primary 
research studies to help reduce type I and type II errors in meta-analyses. We 
use this analysis to examine whether sufficient low risk of bias evidence exists 
for analgesic adjuncts. The thesis concludes with chapter nine, which will 
summarise and discuss the results of the preceding chapters. 
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Background literature 	
1.1 Postoperative pain 	
Postoperative pain is a common consequence of surgery with an incidence of 
around 80%. In one US survey of 250 patients, 39% of patients with 
postoperative pain experienced severe or extreme pain (Apfelbaum  et al. 
2003). In another European survey of 1490 patients, 41% reported moderate or 
severe pain after surgery (Sommer et al. 2008). Pain is cited as one of the main 
concerns of patients undergoing surgical procedures (59%) (Apfelbaum  et al. 
2003). In patients who do receive analgesia in the postoperative period, 23% of 
patients suffer adverse effects such as drowsiness, nausea and constipation, 
usually as a result of opioid medication (Apfelbaum  et al. 2003). Indeed, 72% 
of patients would choose non-opioid analgesia owing to concerns over adverse 
effects and potential addiction. Despite this, 88% of patients remain satisfied 
with their analgesia postoperatively and the incidence of moderate to severe 
pain has decreased over the last few decades (Dolin et al. 2002). 
 
The use of opioids following surgery is prevalent. In one large European 
survey of medical practitioners involving 1558 respondents (Benhamou et al. 
2008), over half of patients undergoing major surgery were treated with 
intravenous opioids within the first 24-hours postoperatively (52-57%). Patient 
controlled analgesia (PCA) with opioids was used in approximately half of 
patients undergoing abdominal, orthopaedic and gynaecological surgeries. As 
the results of these surveys suggest, postoperative pain is currently often 
inadequately controlled in the postoperative population. Intravenous opioids 
continue to be used in a large proportion of patients, despite patient concerns 
over side effects and addiction. In order to improve postoperative pain 
management, a variety of solutions have been proposed (White and Kehlet 
2010). Amongst these solutions is the use of multimodal analgesia using non-
opioid based medication, which has now become the gold standard. A move 
towards multimodal analgesia is reflected by >75% of respondents reporting its 
use following both minor and major surgery (Benhamou  et al. 2008).  
Multimodal analgesia relies upon the use of various analgesics from a variety 
of drug classes which aims to target multiple mechanisms of pain and therefore 
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provide synergistic analgesic activity, reducing opioid use and associated 
adverse effects (Assouline et al. 2016; Doleman et al. 2015a).  
 
The consequences of postoperative pain are not limited to negative 
psychological effects for the patient. Detrimental physiological sequelae can 
result from postoperative pain, which may lead to negative postoperative 
outcomes. Postoperative pain is associated with increases in postoperative 
delirium (Vaurio et al. 2006), pulmonary complications (Desai 1999) and 
increases in the stress response to surgery (Desborough 2000). Furthermore, 
postoperative pain can negatively affect the patient experience. Pain can 
interfere with general activities such as walking and sleeping while also 
negatively affecting mood (Strassels, Chen and Carr 2002). One large survey 
of 10,000 patients in Australia found moderate or severe postoperative pain 
was associated with patient dissatisfaction (odds ratio (OR) 3.94; 95% 
confidence interval (CI) 3.16 to 4.91) (Myles et al. 2000). However, evidence 
is currently lacking with regards to any form of analgesia reducing 
postoperative mortality or morbidity (Liu and Wu 2007). A previous large 
randomised controlled trial (RCT) has concluded no benefit in terms of 
mortality and major morbidity (beyond respiratory failure) with the use of 
epidural anaesthesia (Rigg et al. 2002). Conversely, previous meta-analyses 
have found the use of epidural analgesia may reduce mortality (Landoni et al. 
2015; Rodgers et al. 2000) and myocardial infarction (Beattie, Badner and 
Choi 2001). 
 
The effects of postoperative pain are not limited to the immediate postoperative 
period. Indeed, acute postoperative pain is associated with the development of 
chronic pain in 10-50% of patients, with incidence dependent on the type of 
surgery (Kehlet, Jensen and Woolf 2006). Of those patients experiencing 
chronic pain, it will be severe in around 10% of patients, with a relationship 
between increased acute postoperative pain levels and subsequent risk of 
chronic pain. This chronic pain may mimic neuropathic pain and therefore, 
damage to nerves during surgery is thought to mediate this process. Similar to 
preventative measures for acute postoperative pain, less invasive surgical 
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techniques and multimodal pre-emptive or preventive analgesia are all thought 
to have a role in reducing the incidence of chronic postoperative pain.  
 
As discussed previously, postoperative pain is prevalent and potentially 
undermanaged. However, pain varies greatly between individuals and therefore 
many previous studies have examined whether particular patient characteristics 
can predict postoperative pain. This may help better target multimodal 
therapies and also explain varying results from previous trials with these 
therapies. A systematic review was conducted to identify independent 
predictors of postoperative pain (Ip et al. 2009). These factors included the 
presence of pre-operative pain, higher levels of pre-operative anxiety and the 
type of surgery performed. In addition, younger patients were found to 
experience higher levels of pain and have higher postoperative analgesic 
requirements. Both existing pain and reduced pain tolerance were found to 
increase postoperative pain. Open abdominal surgery, orthopaedic surgery and 
thoracic surgery were the types of surgery most likely to lead to increased 
postoperative pain. Longer duration of surgery was also cited as a further 
predictive factor. There were conflicting results when focussing on the 
influence of gender on postoperative pain.  
 
These predictors have previously been incorporated into a pre-operative risk 
score to identify patients at high-risk of severe postoperative pain (Kalkman et 
al. 2003). Multivariate logistic regression was used to identify independent 
predictors of severe postoperative pain (defined as numeric rating score of 
>8/10 within the first hour postoperatively, which had an incidence of 26%). 
The factors identified were patients of a younger age, female gender, increased 
severity of pre-operative pain, larger incision size and type of surgery. With 
abdominal procedures causing the most pain, followed by orthopaedic, 
laparoscopy then ophthalmological procedures. Clearly, identification of 
patients at risk of severe postoperative pain could help inform postoperative 
analgesic strategies and target intensive therapies at those at the highest risk.  
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In summary, severe pain is prevalent in the postoperative period and continues 
to be under-managed. Such pain has negative physiological and psychological 
consequences for the patient. Current opioid-based analgesics are associated 
with patient concerns and therefore multimodal analgesia represents a viable 
adjunct to postoperative pain management.  
1.2 Pre-operative anxiety and complications of opioid analgesia 	
1.2.1 Pre-operative anxiety 	
In addition to pain arising as a consequence of surgical injury, surgery itself in 
conjunction with anaesthetic agents and opioid analgesia are associated with 
complications for the patient. Prior to surgery, patients may suffer from 
anxiety. In one study of around 700 patients, the mean score for pre-operative 
anxiety was 30/100mm on a visual analogue scale (VAS). Predictors for 
anxiety included younger patients, female sex and a previous negative 
experience of surgery (Kindler et al. 2000). In addition to the distressing 
psychological nature of this anxiety, such anxiety is associated with 
postoperative pain (Ip et al. 2009) and lower patient satisfaction (Kindler et al. 
2000).  
 
1.2.2 Opioid adverse events 	
As previously discussed, opioid use is widespread in postoperative pain 
management. However, the use of opioids is associated with patient concerns 
over side effects and addiction (Apfelbaum  et al. 2003). Opioid adverse events 
have been associated with increases in postoperative hospital costs and length 
of stay in two observational studies (Oderda et al. 2003; Oderda et al. 2007). 
 
1.2.3 Postoperative nausea and vomiting 	
Postoperative nausea and vomiting (PONV) is common following surgery, 
with an incidence of around 25% for nausea and 20% for vomiting (Cohen et 
al. 1994). Risk factors include female sex, previous history of motion sickness 
or PONV, non-smokers and the use of peri-operative opioids (Koivuranta et al. 
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1997; Roberts et al. 2005). If all four factors were present, this resulted in an 
incidence of 79% for PONV (Apfel et al. 1999). Additional factors may also be 
involved, including age, obesity, anxiety and the type of surgical procedure 
(Watcha and White 1992). Postoperative nausea and vomiting has many 
negative effects including hospital readmission, increased recovery time, 
increased healthcare costs and patient dissatisfaction (Gan et al. 2003). Indeed, 
patients have cited postoperative vomiting as the most undesirable outcome of 
anaesthesia, ranking this above postoperative pain and sedation (Macario et al. 
1999). Despite this, expert guidelines do not advocate the routine use of 
prophylactic anti-emetics for all patients (Gan et al. 2003). Therefore, 
treatment may be best targeted to those at highest risk. 
 
1.2.4 Postoperative delirium 	
Postoperative opioid use can cause more direct adverse events during the 
postoperative period. A particular problem in the elderly population is 
postoperative delirium, which has an incidence of 46% in patients aged over 65 
years (Vaurio et al. 2006). In addition to postoperative pain, the use of 
postoperative oral opioids reduced the odds of postoperative delirium when 
compared with intravenous PCA opioids (OR 0.40; 95% CI 0.20 to 0.70). 
However, one review found that only pethidine was consistently associated 
with postoperative delirium (Fong, Sands and Leung 2006). Postoperative 
delirium can lead to negative outcomes including increased morbidity, delayed 
functional recovery and increases in hospital length of stay (Parikh and Chung 
1995).  
 
1.2.5 Urinary retention 	
Urinary retention is common following surgery and anaesthesia, with an 
incidence ranging between 5 and 70% (Baldini et al. 2009). The use of 
systemic opioids have a direct and dose-dependent effect on the incidence of 
postoperative urinary retention. Furthermore, route of opioid administration is 
a further risk factor, with intravenous PCA opioids increasing the risk above 
intramuscular opioids. Moreover, the use of opioid-sparing analgesics is 
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associated with reductions in the incidence of postoperative urinary retention. 
This has important clinical implications, as urinary retention is associated with 
other postoperative complications such as increased parasympathetic activity 
(bradycardia, hypotension and vomiting), urinary tract infection and chronic 
bladder dysfunction (Baldini et al. 2009).  
 
1.2.6 Respiratory depression 	
Postoperative respiratory depression has an incidence of 1.2% in opioid-treated 
patients (Shapiro et al. 2005). Although less common than other adverse 
events, respiratory depression represents an important challenge in opioid-
treated patients as it may lead to fatal outcomes (Dahan, Aarts and Smith 
2010). Reasons cited for respiratory depression following the use of opioid 
PCA devices includes drug interactions, dose escalation and inappropriate 
patient use (Looi-Lyons et al. 1996). Therefore, any peri-operative agent that 
can reduce postoperative opioid requirements may help reduce the incidence of 
this potentially fatal consequence of opioid treatment.  
 
1.2.7 Pruritus 	
Postoperative pruritus is another common consequence of opioid treatment, 
mediated via histamine release from mast cells (Waxler et al. 2005). Following 
opioid administration, incidence is variable (Kam and Tan 1996) with a 
possible dose-dependent effect. Such symptoms are unpleasant for patients and 
reduction of pruritus postoperatively may improve patient satisfaction (Waxler 
et al. 2005). Pruritus can cause significant distress to the patient and the 
management of established pruritus is challenging (Kam and Tan 1996). 
Therefore, any routine analgesic agent that can reduce the incidence of pruritus 
represents a useful option to the anaesthetist in clinical practice.  	
1.2.8 Constipation 	
Opioid-induced constipation is a consequence of direct effects on opioid 
receptors in the gastro-intestinal tract. It can result in significant discomfort for 
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the patient and cause discontinuation of opioid treatment postoperatively, 
which in turn can negatively affect pain management (Pappagalio 2001). 
Moreover, other complications may result such as faecal impaction, pseudo-
obstruction, decreased drug absorption, increased length of stay, increased 
healthcare costs and increases in pain over that of the surgical injury 
(Pappagalio 2001). During opioid dose escalation, constipation symptoms may 
increase (Klepstad et al. 2000); suggesting reducing the doses of postoperative 
opioids may reduce the incidence of constipation and improve patient 
discomfort. Although treatment for opioid-induced constipation is available 
such as non-pharmacological methods (mobilisation and adequate fluid intake) 
and laxatives, these agents may not effectively target the mechanisms of 
opioid-induced constipation, producing therapy that is sub-optimal (Pappagalio 
2001). Alternatives such as the opioid antagonist methylnaltrexone are 
available (Bates, Foss and Murphy 2004), however costs may limit its use in 
clinical practice. Therefore, other potential treatments for opioid-induced 
constipation that limit opioid dosages would be welcomed. 
 
1.2.9 Opioid-induced hyperalgesia 	
The use of peri-operative opioids have other associated sequelae, which is not 
limited to adverse events. Paradoxically, higher doses of intra-operative 
opioids have been associated with an increase in pain and hyperalgesia during 
the postoperative period. This phenomenon is termed opioid-induced 
hyperalgesia (OIH). A systematic review of clinical trials found evidence of 
increased postoperative opioid consumption in patients who received higher 
doses of intra-operative opioids (Angst and Clarke 2006). In the same review, 
human volunteer studies have provided direct evidence of OIH in pre-existing 
hyperalgesia and cold pressor pain tests. A more recent meta-analysis of 
clinical RCTs has shown higher doses of intra-operative opioids increased 
postoperative pain at one hour on a 100mm VAS (mean difference (MD) 
9.4mm; 95% CI 4.4mm to 14.5mm) and increased 24-hour morphine 
consumption (standardised mean difference (SMD) 0.70; 95% CI 0.37 to 1.02) 
(Fletcher and Martinez 2014). These results suggest opioid use may in fact 
exacerbate postoperative pain through mechanisms of hyperalgesia. 
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1.2.10 Immune function 	
Opioid use may also be associated with immune dysfunction. In healthy 
volunteers, administration of morphine at therapeutic levels can suppress 
natural killer cell cytotoxicity (Yeager et al. 1995). These findings have been 
replicated in clinical studies that enrolled postoperative participants, with 
higher doses of fentanyl causing prolonged suppression of natural killer cell 
cytotoxicity (Beilin et al. 1996). Mechanisms for such immune suppression are 
yet to be fully elucidated; although a direct effect on immune cells via classic 
opioid receptors seems unlikely (Williams et al. 2007). Other mechanisms may 
be implicated, such as neuro-endocrine systems and non-classical opioid 
receptors (Al-Hashimi et al. 2013). Further studies are required to evaluate 
whether such immune suppression translates into increases in postoperative 
infections. Moreover, whether the use of multimodal analgesic agents can 
reduce the incidence of postoperative infections through reductions in opioid 
requirements.  
 
1.2.11 Addiction 	
Addiction is a common concern for patients who are treated with postoperative 
opioids (Apfelbaum et al. 2003). Although continuation of opioid medication 
following surgery should correlate with continuing pain, one cohort study 
contradicted this expectation (Carroll et al. 2012). Using a sample of 134 
postoperative patients, 6% were still using opioids at 150 days (the number of 
these patients in pain was not reported). This study calculated that using these 
figures, postoperative opioid use would contribute 1.1 million new users of 
opioids in the United States (US) each year. Using a multivariate Cox 
regression model, pre-operative opioid use, self-perceived risk of addiction and 
depressive symptoms better predicted the continued use of opioids when 
compared with postoperative pain intensity and duration. However, data is 
limited as to whether this prolonged use translated into longer-term addictive 
opioid use. Future studies may wish to follow participants for a longer duration 
to identify if this continued opioid use increases the number requiring 
treatment for opioid addiction. Despite this, this study does implicate 
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psychological factors as the most important determinants of prolonged opioid 
use when compared to pain-related factors. This further highlights the need to 
reduce peri-operative opioid use and the effects this could have on longer-term 
outcomes.  
 
1.2.12 Summary 	
In summary, the negative consequences of both surgery and anaesthesia are 
diverse. Pain and vomiting are those feared most by patients and represent 
ideal targets to improve the patient experience. However, the continued 
widespread use of opioids may further exacerbate postoperative pain and 
vomiting, as well as having many other negative consequences. Therefore, 
alternative strategies are required for postoperative pain management that aim 
to limit the use of opioid medication and help improve patient outcomes. 
1.3 Pre-emptive analgesia 	
The process of surgical injury can cause secondary changes in the central 
nervous system, which may lead to postoperative hyperalgesia and reductions 
in pain thresholds, so called central sensitisation. It has been postulated that by 
providing adequate analgesia before surgical incision, such central sensitisation 
could be reduced, a concept called pre-emptive analgesia (Woolf and Chong 
1993). This led to development of clinical trials comparing treatments 
administered before surgical incision versus the same treatment given after 
surgical incision. The first review of pre-emptive analgesia (Moiniche, Kehlet 
and Dahl 2002) showed no benefit with NSAIDS, opioids, ketamine or local 
anaesthetic wound infiltration. There was evidence from some trials for pre-
emptive epidural analgesia. A second review of pre-emptive analgesia (Ong et 
al. 2005) found a possible benefit for pre-emptive NSAIDS, epidural analgesia 
and local anaesthetic wound infiltration. However, due to the novel use of 
gabapentin over recent years, neither review examined a potential pre-emptive 
benefit for gabapentin.  
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The concept of pre-emptive analgesia is now outdated and the subject has now 
shifted focus to preventive analgesia, which aims to continue pre-emptive 
interventions longer into the postoperative period in order to target 
sensitisation as it develops throughout this period or initiate interventions 
sooner to treat pre-operative processes (Katz, Clarke and Seltzer 2011). This 
includes nociceptive input from pre-existing pain, surgical incision and 
postoperative inflammation from the injury site. A preventive effect is then 
demonstrated if the effect lasts beyond the therapeutic activity of the drug 
(Katz, Clarke and Seltzer 2011). For this reason, reductions in chronic pain 
remain a major priority for preventive analgesia as it is thought that by 
reducing peri-operative nociceptive input, chronic pain incidence can be 
reduced.  
 
In terms of animal models evaluating the preventive effects of gabapentinoids, 
one study using a rat postoperative pain model concluded that administration of 
pregabalin (which binds to the same site as gabapentin) resulted in a longer 
duration of anti-hyperalgesia compared with post-incision administration (Field 
et al. 1997b). Another study found administration of gabapentin before 
formalin injection reduced pain responses compared to administration after 
injection (Yoon and Yaksh 1999). However, a study in human volunteers 
found gabapentin both prevented development of and treated established 
sensitisation (Dirks et al. 2002). Despite these animal and human volunteer 
studies, clinical data is lacking on whether gabapentin is beneficial as a pre-
emptive analgesic in clinical practice. 
1.4 Stress response to tracheal intubation 	
Tracheal intubation is the gold standard of securing the airway before general 
anaesthesia. However, this procedure is associated with negative sequelae 
including a pronounced stress response. This stress response causes 
haemodynamic changes such as increases in heart rate, blood pressure and 
circulating catecholamines (Derbyshire et al. 1987; Shribman, Smith and 
Achola 1987). Such changes may lead to myocardial ischaemia (Thompson et 
al. 1998) and increases in cardiac complications in high-risk patients, such as 
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those with pre-existing cardiovascular disease (Kovac 1996). Ultimately, such 
episodes of myocardial ischaemia may lead to myocardial infarction in a small 
number of patients (Slogoff and Keats 1985). One study followed untreated 
hypertensive patients and concluded myocardial ischaemia had a peri-operative 
incidence of 28% on analysing ECG recordings (Stone et al. 1998). All 
episodes were precipitated by stimulation such as intubation and emergence 
from anaesthesia. Another study (Roy, Edelist and Gilbert 1979) found rate-
pressure products of greater than 11,000 were associated with myocardial 
ischaemia in 10 out of 11 patients who suffered myocardial ischaemia peri-
operatively.  
 
Stimulation from extubation can also cause rises in heart rate and blood 
pressure. One study (Edwards et al. 1994) included 35% of patients with 
ischaemic heart disease and 27% with cardiac risk factors. This study showed 
both intubation and extubation were associated with increases in rate-pressure 
products (p<0.01). During the study, 12 patients out of 60 developed cardiac 
ischaemia at some point during the peri-operative period. At extubation, 
increases in rate-pressure products were significantly higher in patients who 
suffered myocardial ischaemia. In another study (Fusciardi et al. 1986), a small 
control group of six patients with angina were enrolled in a randomised 
controlled trial. Four patients developed myocardial ischaemia during 
laryngoscopy and intubation. This group also had significant increases in mean 
blood pressure, heart rate and mean pulmonary wedge pressure. Although these 
studies are dated and enrolled a small number of participants, they demonstrate 
the potential for haemodynamic changes to affect myocardial perfusion, 
especially in high-risk patients.  
 
Although conducted in a more invasive procedure, one study followed a cohort 
of patients with cardiovascular co-morbidity undergoing microlaryngoscopy 
and rigid bronchoscopy. Eleven percent of patients in the control group 
suffered myocardial ischaemic episodes on ECG monitoring and 88% had 
features of arrhythmias during the procedure, which were accompanied by 
increases in haemodynamic variables (Matot et al. 2000). These features were 
reduced in an intervention group administered clonidine, an alpha 2-agonist 
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with known efficacy in reducing the haemodynamic responses to intubation. 
Although these procedures are more invasive than direct laryngoscopy and 
endotracheal intubation, they help illustrate that in high-risk patients, changes 
in haemodynamic variables may have consequences for myocardial perfusion 
during the peri-operative period. Indeed, a previous meta-analysis has shown 
clonidine can reduce episodes of myocardial ischaemia in both cardiac and 
non-cardiac surgery (Nishina et al. 2002). 
 
Many agents have been used to attenuate the haemodynamic response to 
intubation. However, while agents such as beta-blockers, clonidine and opioids 
are effective, they may be associated with bradycardia and hypotension 
(Blaudszun et al. 2012; Thompson et al. 1999). Therefore, alternative agents 
may be required that do not induce such adverse effects. Moreover, alternative 
agents that induce other therapeutic benefits may be advantageous. It is hoped 
such agents can reduce episodes of myocardial ischaemia, myocardial 
infarction and in turn reduce peri-operative mortality in high-risk patients. 
1.5 Gabapentin  	
Gabapentin (1-(aminomethyl)cyclohexane acetic acid) is a structural analogue 
of gamma-aminobutyric acid (GABA) with a molecular weight of 171. It exists 
as a zwitterion (a neutral molecule with both positive and negative charges that 
are not adjacent) with pKa1 of 3.7 and pKa2 of 10.7. It is water-soluble with 
properties similar to that of an amino acid. It was originally developed as an 
anti-convulsant medication (Rose and Kam 2002). However, in recent years it 
has found favour in the treatment of a variety of pain conditions, including 
chronic neuropathic pain.  
 
Gabapentin has shown early promise in clinical trials addressing many aspects 
of anaesthetic practice such as reductions in postoperative opioid consumption, 
pre-operative anxiolysis, PONV, attenuation of the haemodynamic response to 
intubation, reductions in chronic pain after surgery and reductions in 
postoperative delirium (Kong and Irwin 2007). Such multimodal effects from a 
single agent would be attractive to practising anaesthetists. However, in recent 
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years, numerous studies have been published on gabapentin in the peri-
operative period and it has now become necessary to summarise and scrutinise 
the current evidence to guide clinical practice recommendations and future 
research focus. 
 
Pharmacodynamics and pharmacokinetics of gabapentin 	
1.6 Pharmacodynamics 	
1.6.1 α2δ subunit of calcium channels 	
The most likely therapeutic target of gabapentin (Kong and Irwin 2007) 
involves binding to the α2δ subunit of voltage-dependent pre-synaptic calcium 
channels (Fink et al. 2002). The history of this discovery started when a 
specific gabapentin-binding site was discovered within the central nervous 
system (Suman-Chauhan et al. 1993). This later proved to be the 
aforementioned calcium channels. Both gabapentin and pregabalin (although 
not the R isomer of pregabalin) bind to the α2δ subunit. Indeed, the R isomer 
of pregabalin exhibits no anti-hyperalgesic effect. Therefore, this finding 
implicated these α2δ subunits as the mechanism of gabapentin activity in pain 
management (Jun and Yaksh 1998).  Furthermore, over-expression of these 
channels in transgenic mice enhanced mechanical and thermal stimulation and 
increased pain-related behaviours (Li et al. 2006). This provides further 
corroborative evidence for the role of these channels in the pain process. 
 
The consequence of binding to the α2δ subunit of calcium channels includes 
effects on pre-synaptic neurons and reductions in excitatory neurotransmitters 
such as glutamate, aspartate (Feng, Cui and Willis 2003) and potassium-
stimulated noradrenaline release (Maneuf, Luo and Lee 2006). Other potential 
substances involved in pre-synaptic calcium channel inhibition include 
calcitonin gene related peptide (CGRP) and substance P (Fehrenbacher, Taylor 
and Vasko 2003; Kukkar et al. 2013).  			
	 31	
1.6.2 GABA receptors 	
Although gabapentin is a structural analogue of GABA and was originally 
developed to exert increased GABA activity for treating epilepsy, it does not 
exert any direct effect on GABA receptors (Bloms-Funke and Loscher 1996) 
and is not converted metabolically into GABA. Although some research has 
indicated selective activation of heterodimeric GABAB receptors (Bertrand et 
al. 2001), elevated levels of GABA and increased synthesis of GABA from 
glutamate, it is unlikely this is the mechanism of action of gabapentin in the 
treatment of pain (Maneuf, Luo and Lee 2006). Indeed, administration of 
GABA antagonists failed to reverse the anti-allodynic effects of gabapentin 
(Cheng et al. 2006; Hwang and Yaksh 1997), which would argue against this 
as a mechanism. However, it remains possible that effects on GABA may 
mediate some of the other therapeutic effects of gabapentin, such as reductions 
in anxiety and increases in sedation.  
 
1.6.3 NMDA receptors 	
Other potential sites of action for gabapentin (in addition to calcium channels) 
include indirect inhibition of NMDA receptors, as previous research has shown 
reversal of gabapentin effects using NMDA agonists (Partridge et al. 1998). 
However, gabapentin has been shown to have no direct binding sites on 
NMDA receptors and antagonism of the NMDA receptor did not reverse the 
anti-allodynic effects of gabapentin (Cheng and Chiou 2006). Therefore, this 
mechanism appears unlikely to be involved in the pain relieving effects of 
gabapentin (Mao and Chen 2000).  
 
1.6.4 Opioid receptors 	
It is clear from the research conducted thus far that gabapentin does not have 
any effect on opioid receptors (Field et al. 1997).  In a rat model, there was no 
cross-tolerance with opioids and the anti-hyperalgesic activity of gabapentin 
was not reversed using the opioid antagonist naloxone. Therefore, it is safe to 
assume this is unlikely to be the mechanism of action of gabapentin in reducing 
postoperative pain. 
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1.6.5 Other mechanisms 	
Gabapentin may affect other chemical targets such as sodium channels, protein 
kinase C, transient receptor potential ion channels and increases in spinal 
noradrenaline (Hayashida et al. 2008a). Spinal noradrenaline release may have 
particular relevance in a postoperative pain model (Hayashida et al. 2008b). 
Other studied targets include AMPA receptors, KATP channels and 
hyperpolarisation-activated cation current channels, although evidence is thus 
far conflicting (Cheng and Chiou 2006). One mechanism proposed was action 
via amino acid transporters on cell surfaces. However, this mechanism is also 
unlikely, as a previous study has shown injection of antagonists of the L-amino 
acid transporter did not reverse the analgesic effects of gabapentin (Cheng, Pan 
and Eisenach 2000).  
 
In terms of gabapentin effects on haemodynamic parameters, an experiment in 
rats has shown that neither intra-thecal nor intra-peritoneal administration of 
gabapentin affects baseline blood pressure or heart rate (Yoon and Choi 2003). 
However, intra-cerebroventricular administration resulted in a rise in 
haemodynamic variables. Although no depressive effect was observed in rats, 
an in vitro study revealed a possible effect of gabapentin on catecholamine 
secretion (Todd et al. 2012). Using cultured bovine adrenal chromaffin cells, 
gabapentin inhibited catecholamine secretion by inhibiting release of secretory 
vesicles. Such work suggests a possible role for gabapentin in reducing stress 
responses to invasive procedures such as endotracheal intubation and surgery. 
 
In conclusion, although a number of targets have been proposed, the exact 
mechanism of gabapentin is yet to be fully elucidated, although it appears that 
the α2δ subunits of calcium channels are the most likely mechanism in pain 
management. Other mechanisms may have relevance to other postoperative 
outcomes such as the role of GABA in anxiety reduction and reduced 
catecholamines in attenuating the stress response to endotracheal intubation. 			
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1.6.6 Adverse events 	
Gabapentin is typically well tolerated, although it is associated with a number 
of adverse events. In a large study of over 2000 outpatients who were taking 
daily gabapentin, around 10% discontinued treatment due to adverse events, 
most commonly due to sedation (2%) and dizziness (2%) (McLean et al. 
1999). However, 80% of patients rated the safety and tolerability as good or 
excellent. The most common side effects included sedation (15%), dizziness 
(11%), asthenia (6%) and headache (5%). Other less common side effects 
included nausea (3%), ataxia (3%), weight gain (3%) and amblyopia (2%). 
There were higher incidences of sedation (23%) and dizziness (24%) in a 
randomised controlled trial in patients with diabetic neuropathy (Backonja et 
al. 1998). With regards to postoperative pain management, a meta-analysis of 
randomised controlled trials revealed that gabapentin increased the risk of 
postoperative sedation (OR 3.86; 95% CI 2.50 to 5.94). There was however no 
significant increase in dizziness (OR 1.34; 95% CI 0.86 to 2.10) (Ho, Gan and 
Habib 2006).  
1.7 Pharmacokinetics 	
Absorption of gabapentin is reliant on a saturable L-amino acid system within 
the intestine (Stewart et al. 1993). Therefore, increasing dosages of gabapentin 
result in a reduction in oral bioavailability as this transport system becomes 
saturated. A dose of 300mg has a bioavailability of around 65% although when 
increased to 1200mg, the bioavailability falls to around 35%. Peak levels 
following oral administration (Tmax) are achieved within 2-3 hours. In terms 
of distribution, gabapentin is well distributed within the human body at 0.6-
0.8L/kg and is not bound to plasma proteins (McLean 1994). Following a 
single 600mg dose, concentrations in cerebrospinal fluid are around 9-14% of 
plasma levels (Ben-Menachem et al. 1992).  
 
Gabapentin does not undergo hepatic metabolism, is not structurally altered by 
the body and does not cause induction or inhibition of hepatic cytochrome 
enzymes. Antacids reduce bioavailability by around 20% (Busch et al. 1992) 
and cimetidine decreases clearance of gabapentin when these are used 
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concurrently (Rose and Kam 2002). Gabapentin is renally excreted; exhibiting 
first order kinetics and plasma clearance is proportional to creatinine clearance 
(Blum et al. 1994). This is thought to be the cause of age-related reductions in 
drug clearance (Boyd et al. 1999). Gabapentin has a half-life of around 6-8 
hours at steady state (Beydoun, Uthman and Sackellares 1995).  
1.8 Gabapentin for postoperative pain 	
1.8.1 Animal models 	
Animal studies have proven gabapentin as an effective agent in reducing 
features of allodynia and hyperalgesia. Interestingly, in rat models of both 
neuropathic and acute nociceptive pain, gabapentin showed efficacy in treating 
allodynic pain with little effect on acute nociceptive pain (Hunter et al. 1997). 
This suggests that gabapentin is more effective is abnormal pain states and has 
little effect on acute pain transmission. Other studies have also demonstrated 
the utility of gabapentin in abnormal pain states. A further study in rats 
demonstrated gabapentin reversed heat-induced thermal injury in rats (Jun and 
Yaksh 1998). However, it again had no effect on response latency in normal 
hind paws, again suggesting effects only in abnormal pain states.  
 
Further studies corroborate these findings of efficacy in abnormal pain states. 
Field et al. (1997b) used a plantaris incision to simulate postoperative pain. 
The administration of subcutaneous gabapentin one hour before the incision 
resulted in a reduction in allodynia and hyperalgesia. The highest dose reduced 
these for 49 and 24 hours respectively. Morphine reduced hyperalgesia 
although had no effect on tactile allodynia. Yoon and Yaksh (1999) studying a 
rat model found intra-thecal gabapentin reduced pain behaviour and 
cardiovascular responses to injury induced by formalin injection, without 
affecting resting cardiovascular responses or acute nociception. 
 
Further evidence of the effect of gabapentin in abnormal pain states comes 
from another in vitro study on rats (Fehrenbacher, Taylor and Vasko 2003). 
This study found that gabapentin attenuated release of spinal sensory 
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neuropeptides in rats pre-treated with Freund’s adjuvant but only in the 
presence of inflamed tissues and not in normal tissues. These results suggest, 
like in other animal models, that gabapentin effects are limited to abnormal 
pain states.  		
1.8.2 Human models 	
Results from animal models have been translated into human models of pain. 
In a human volunteer study (Dirks et al. 2002), a capsaicin sensitisation model 
was used to test the effect of gabapentin on acute nociception and neuronal 
sensitisation in order to mimic postoperative pain. Gabapentin was shown to 
reduce the incidence of and reduce established secondary hyperalgesia. 
However, in agreement with animal models, gabapentin did not affect acute 
nociceptive transmission in normal skin. Another study performed in healthy 
volunteers again showed that gabapentin reduced mechanical pain thresholds 
and secondary hyperalgesia and had no effect in normal skin (Werner et al. 
2001). Another study used intra-dermal capsaicin to induce central 
sensitisation and found gabapentin administered over 15 days reduced the area 
of allodynia when compared with placebo (Gottrup et al. 2004). These models 
provide evidence for the theoretical potential of gabapentin to reduce 
postoperative and neuropathic pain in abnormal tissues only.     
 
Other interesting observations have been noted from human volunteer studies. 
In one study of 12 healthy male volunteers, gabapentin was shown to have both 
a pharmacodynamic and pharmacokinetic interaction with morphine (Eckhardt 
et al. 2000). The co-administration of gabapentin and morphine was found to 
act synergistically to increase analgesic effects when compared to either drug 
alone. Furthermore, the pharmacokinetics of gabapentin were altered when co-
administrated with morphine with absorption increased and renal clearance 
decreased (p<0.05). This suggests when both drugs are used together, they may 
offer improved efficacy in the treatment of pain than either agent alone, which 
has important implications for postoperative pain management, bearing in 
mind the prevalent use of opioids for postoperative pain management 
(Benhamou  et al. 2008). 
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1.8.3 Central sensitisation and postoperative pain 	
Following injury induced by surgical incision, two processes take place that 
can exacerbate postoperative pain, beyond that induced by the injury itself. 
Peripheral sensitisation involves reductions in the threshold of afferent nerve 
fibres and central sensitisation, which increases the excitability of spinal 
neurons (Woolf and Chong 1993). This causes hyperalgesia of the affected 
tissues and increases in pain. Many chemical mediators are involved in 
peripheral sensitisation and are released following tissue damage (surgery). 
The result of this sensitisation is to cause both allodynia (normal sensations 
producing pain) and hyperalgesia (exaggerated pain response to noxious 
stimuli). Peripheral sensitisation allows low intensity stimulus to produce pain 
via Aδ and C nociceptors and central sensitisation allows normal sensory 
inputs from Aβ fibres to produce pain via the spinal cord.   
 
Mechanisms have been postulated for the maintenance of central sensitisation, 
which mainly include NMDA receptors, as administration of NMDA 
antagonists reduced central facilitation induced by mustard oil (Woolf and 
Thompson 1991). Through understanding the mechanisms involved in the 
development and maintenance of postoperative pain, the search started for 
agents that could directly affect central sensitisation as a way of treating 
postoperative pain. NMDA-antagonists have proven efficacy in treating central 
sensitisation (Woolf 2011). However, gabapentin has emerged as an alternative 
agent. These mechanisms have been proven conceptually in the animal and 
human studies mentioned previously. This then led to clinical trials assessing 
the efficacy of gabapentin for postoperative pain. 
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1.9 Methodological limitations of meta-analyses of gabapentin for 
postoperative pain 
1.9.1 Summary of published meta-analyses and findings 	
There have been numerous RCTs conducted on the use of gabapentin for 
postoperative pain, which have been summarised in various meta-analyses 
(Table 1.1). Hurley et al. (2006) published one of three meta-analyses 
published in 2006, which included 12 RCTs with 896 participants. Gabapentin 
reduced pain scores, opioid consumption, reduced anxiety and increased 
sedation. There was significant statistical and clinical heterogeneity in results, 
which was not investigated. There was some attempt to investigate for 
publication bias by calculating the failsafe N, which showed 119 studies would 
be required to observe a null result from their findings.  
 
Seib and Paul (2006) also published a meta-analysis in the same year. This 
review included eight RCTs and found similar results to Hurley et al. (2006). It 
however found no difference in adverse effects. Although again statistical 
heterogeneity was considerable, there was little investigation of this 
heterogeneity and no assessment of publication bias, although the review 
included less studies than the minimum recommended for such analyses. The 
studies included in the review were most likely underpowered for detecting 
differences in adverse events for both gabapentin and opioid-induced adverse 
events.  
 
Ho et al. published the final meta-analysis published in 2006. This review 
included a larger number of RCTs; 16 studies with 1151 participants. This 
review found lower pain scores, opioid consumption and increases in 
gabapentin-induced sedation. However, this was the first meta-analysis to show 
reductions in vomiting and pruritus. Although some attempt was made to 
analyse data in subgroups based on dose, these were not directly compared on 
subgroup analysis. Furthermore, publication bias was not assessed. 
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The following year, Peng, Wijeysundera and Li (2007) published a meta-
analysis. It found similar results to those published previously, although 
contrary to those already published; it did find a significant increase in 
dizziness in the gabapentin group. This review included 18 RCTs, which again 
showed considerable clinical and statistical heterogeneity, which was not 
explored. Although assessment of publication bias involved visual inspection 
of funnel plots, no formal statistical test for publication bias was performed.  
 
Tiippana et al. (2007) published a meta-analysis in the same year, which also 
included pregabalin. This review included 21 RCTs involving gabapentin. 
Results were similar to previous reviews. Meta-regression was undertaken 
using gabapentin dose as a covariate, which had no significant effect on 24-
hour opioid consumption. Publication bias was not assessed. Although some 
attempt was made to analyse pain scores based on type of surgery, there were 
no formal subgroup analyses of 24-hour morphine consumption. 
 
The most recent meta-analysis of gabapentin was published by Mathiesen et al. 
(2007) and included 23 RCTs with 1529 participants. This review attempted to 
analyse patients in specific surgical subgroups based on type of procedure. 
However, there were no formal subgroup comparisons between surgical 
subgroups. Furthermore, there was no other investigation of heterogeneity or 
assessment of publication bias. Results again were broadly in agreement with 
those published previously.  
 
In conclusion, although each of the published meta-analyses has strengths, no 
single review satisfies the gold standard of current systematic review 
methodology. These inherent limitations and the publication of new studies 
since these previous reviews mandates an updated evaluation of the evidence. 
The following sections will discuss the limitations of the previous meta-
analyses on gabapentin. 
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Author Year 
N 
(studies) 
N 
(participants) 
Heterogeneity investigation 
(covariate) 
Publication 
bias 
Risk of 
bias 
Hurley 2006 12 896 No Failsafe N Cochrane 
Seib 2006 8 663 NR No 
Jadad 
scale 
Ho 2006 16 1151 Subgroup analysis (dose) No 
Oxford 
scale 
Peng 2007 18 1181 
Sensitivity analysis 
(methodology and pain 
severity) 
Funnel 
plots 
Yes 
(author 
created) 
Tiippana 2007 21 1614 Meta-regression (dose) No 
Oxford 
scale 
Mathiesen 2007 23 1529 Subgroup analysis (surgery) No 
Oxford 
scale 
 
Table 1.1: Summary of previously published meta-analyses on gabapentin. NR=not reported 
	 40	
1.9.2 Outdated evidence 	
The main limitation of current meta-analyses on gabapentin relate to the 
amount of time lapsed since the last published review. The last three reviews 
were published in 2007. However, the Cochrane Collaboration suggests 
undertaking systematic reviews every two years (Higgins 2008). Although 
more recent procedure-specific meta-analyses have been published (Alayed et 
al. 2014; Yu et al. 2013), none have been recently published evaluating 
gabapentin in all forms of surgery. Over 100 RCTs on gabapentin have since 
been published, which mandates an updated review to help guide clinical 
practice and future clinical trials. 
 
1.9.3 Internal validity 	
An important component of the systematic review process involves evaluating 
the internal validity of the included studies, since poorly conducted RCTs can 
bias the conclusions of a review. Indeed, one review of 122 meta-analyses 
(Juni et al. 2003) found that inadequate or unclear allocation concealment was 
associated with an average 21% (95% CI 11% to 30%; p<0.001) exaggerated 
effect compared to those with adequate allocation concealment. In addition, 
although not statistically significant, inadequate or unclear double blinding was 
associated with an average 12% (95% CI -4% to 25%; p=0.13) beneficial effect 
compared to those with adequate double blinding. These results suggest that 
the inclusion of trials at higher risk of bias can exaggerate the effects of 
interventions, which has important implications for using such reviews to 
inform clinical practice. 
 
Of the current meta-analyses, five used aggregated scoring systems for quality 
assessment. These scoring systems have inherent limitations (Higgins et al. 
2011), including assigning score weightings to different measures of internal 
validity that are not supported by empirical evidence. For example, the Jadad 
score used in some of the meta-analyses gives equal weighting to adequate 
randomisation and double blinding, which may not reflect empirical findings 
on their relative importance (Juni et al. 2003). Some validity scores also 
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confuse aspects of trial reporting (such as the presentation of data) with 
measures of internal validity (Juni et al. 2001). Furthermore, many scoring 
systems attribute a lack of reporting the same score as those whose methods are 
reported, although inadequate. For example, one trial may report randomisation 
according to date of birth (high risk of bias) and another trial may not report 
how randomisation was performed (unclear risk of bias), scoring systems may 
give these trials equal scores, which is inappropriate. Despite an association 
between poorly reported trials and methodological quality, this method causes 
misclassification of those trials that are poorly reported but well conducted. For 
these reasons, the use of component items such as the Cochrane risk of bias 
tool is preferable to composite scoring tools (Higgins et al. 2011). One review 
used the Cochrane risk of bias tool (Hurley et al. 2006), although did not report 
details of the risk of bias given to each study. In the wider anaesthesia 
literature, a recent meta-epidemiological study has shown that in a sample of 
174 systematic reviews, the Jadad scale was still the most popular method used 
to assess internal validity (33%) when compared to the Cochrane risk of bias 
tool (20%) (Detweiler et al. 2016). 
 
Although component item assessment is generally accepted as the method of 
choice for measuring the internal validity of trial findings, how to incorporate 
methodological quality into systematic review results is a subject of continued 
debate (Juni et al. 2001). Approaches include excluding trials of low 
methodological quality. However this method is subjective and may introduce 
bias into the systematic review process. For example, authors may exclude 
studies that contradict their expectations of the results. Effect estimates can 
also be weighted by study quality, although this method lacks any statistical or 
empirical evidence for its use (Juni et al. 2001). Thus, the recommended 
approach is to perform sensitivity analysis to evaluate whether study quality 
affects the conclusion of any given meta-analysis. Only one meta-analysis on 
gabapentin conducted such a sensitivity analysis (Peng, Wijeysundera and Li 
2007). 
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1.9.4 Publication bias 	
In addition to issues of bias from the included trials, systematic reviews may be 
subject to other forms of bias. Publication bias relates to the preferential 
publication of positive trials by journals or preferential reporting of positive 
outcomes within a study (p<0.05). This results in bias in effect estimates in 
favour of the treatment under review. One cohort study of 218 studies (Stern 
and Simes 1997) showed that trials with positive results, defined as a p<0.05, 
were more likely to be published (hazard ratio (HR) 2.32; 95% CI 1.47 to 3.66) 
and published quicker (median time to publication 4.8 versus 8 years) than 
studies with negative outcomes. Another study found similar results 
(Easterbrook et al. 1991), with positive studies more likely to be published 
(adjusted OR 2.32; 95% CI 1.25 to 4.28) than those with negative results. A 
more recent systematic review (Dwan et al. 2008) and Cochrane review 
(Hopewell et al. 2009) were in agreement with the results above and also 
identified evidence of selective outcome reporting bias, the notion that 
statistically significant results within studies are more likely to be reported in 
manuscripts when compared to non-significant results.  
 
Publication bias is thought to affect around 25%-40% of published meta-
analyses (Egger et al. 1997a; Sterne, Gavaghan and Egger 2000). In the 
anaesthesia literature, a recent review has shown that when evaluating reviews 
from 2007-2015 in five anaesthesia journals there was a prevalence of 
publication bias of 50-80% (Hedin et al. 2016). Methods exist to help identify 
and correct for publication bias. Both funnel plots, which are graphical plots of 
effect estimates plotted against their standard error and regression methods, can 
be used to identify potential publication bias (or more appropriately, imprecise 
study effects). Using these methods, publication bias has been identified as 
being responsible for discrepancies in conclusions from meta-analyses that 
were later contradicted by large RCTs (Egger et al. 1997a). Other methods 
such as rank correlation tests are available. The regression method has more 
power to detect differences when compared to rank correlation tests, although 
regression tests have problems of false positives in particular situations; such 
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as treatments with large effects, trials of similar sample sizes or trials with a 
low numbers of events (Sterne, Gavaghan and Egger 2000).  
 
Egger’s regression test is a test for funnel plot asymmetry and tests that the Y 
intercept from a regression line equals zero. It regresses the standard normal 
deviate (effect size divided by standard error) with the precision (reciprocal of 
standard error) as the predictor variable (Illustration 1.1). In the presence of 
funnel plot symmetry, then the intercept should equal zero (the regression line 
should intercept the Y axis at 0). We can observe from the below plot that this 
is not the case, indicating funnel plot asymmetry. This is because smaller 
studies (with less precision) tend to have more extreme results compared to the 
effect estimate and therefore a predominance of ‘positive’ studies (with 
publication bias) will ‘shift’ the intercept away from 0 (as seen in Illustration 
1.1). 
 
 
 
Illustration 1.1: Egger’s linear regression test. Y-axis is standard normal 
deviate (effect size divided by the standard error) and the X-axis is the study 
precision (1 / standard error). The intercept is significantly different from zero 
(p<0.05). 
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Attempts have been made to devise statistical tests to correct for publication 
bias. Trim and fill analysis is one such method (Duval and Tweedie 2000). 
This method involves trimming extreme cases from the funnel plot, re-
estimating the effect estimate and then producing an adjusted effect estimate in 
the presence of a symmetrical plot (Illustration 1.2). However, this analysis can 
underestimate the true effect in the presence of large between-study 
heterogeneity where no publication bias is present. In addition, this method 
relies on the assumption that an asymmetric funnel plot is entirely due to 
publication bias (Peters et al. 2007). Other causes of an asymmetric funnel plot 
exist such as internal validity issues in smaller trials and possible fraud.  
 
Orwin’s failsafe N is another analysis used to determine the likely influence of 
publication bias (Orwin 1983). This test calculates the number of additional 
negative studies needed to change the effect estimate to a pre-determined, 
clinically insignificant level. Although neither calculation is recommended for 
Cochrane reviews, such analysis can serve as sensitivity analyses to assess the 
extent of publication bias in any given review.  
 
 
 
Illustration 1.2: Funnel plot with log risk ratio on the X-axis and the standard 
error (on a reverse scale) on Y-axis. Original studies (white circles) and effect 
estimate (white diamond) show the original studies in the meta-analysis, which 
show clear asymmetry. The new effect estimate (black diamond) and plotted 
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studies (black circles) show the new symmetrical plot following trim and fill 
analysis. 
 
As alluded to previously, it should be noted that publication bias is not the only 
cause of funnel plot asymmetry. Other causes include poor methodological 
design, fraud and differences in the way the intervention was delivered in 
smaller studies (Sterne et al. 2011). Therefore, extensions to traditional funnel 
plots have been developed such as the use of contour enhanced funnel plots 
(Illustration 1.3). These plots add regions of statistical significance for each 
individual study. Studies falling within these regions are statistically significant 
at the level selected (in our example p<0.05 and p<0.01). We can see from the 
illustration overleaf that in plot A, studies are located in shaded areas of 
statistical significance, making publication bias more likely, as the studies in 
the analysis are statistically significant (the mechanism behind publication 
bias). In contrast, plot B shows studies in regions of non-statistical 
significance, suggested other causes for funnel plot asymmetry should be 
considered (Sterne et al. 2011). Authors have previously been found to be poor 
at visually identifying funnel plot asymmetry (Terrin, Schmid and Lau 2005) 
so adding contour lines for statistical significance may aid interpretation 
(Sterne et al. 2011). 
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Illustration 1.3: Contour enhanced funnel plots. Plot A shows the majority of 
studies in regions of statistical significance (grey p<0.01 and dark grey p<0.05) 
suggesting publication bias as a cause. Plot B shows more studies in the region 
of statistical non-significance (p>0.05) suggested another cause for asymmetry.  
 
Only one meta-analysis of gabapentin use in the perioperative period attempted 
to identify publication bias (Hurley et al. 2006) using the failsafe N. Another 
used qualitative assessment of funnel plots, although did not use quantitative 
methods such as Egger’s linear regression test (Peng, Wijeysundera and Li 
2007). Indeed, as already mentioned, previous research has shown that visual 
inspection of funnel plots can lead to false conclusions of whether asymmetry 
is present (Terrin, Schmid and Lau 2005). Lack of investigation of publication 
bias is also true for meta-analyses of acute postoperative pain in general, with 
only 8% assessing for the possibility of publication bias (Espitalier et al. 2013). 
As described previously, such publication bias has the potential to bias effect 
estimates in favour of gabapentin. In order to attempt to reduce publication 
bias, an extensive search for unpublished studies is required via clinical trial 
databases, conference proceedings and grey literature databases (Thornton and 
Lee 2000). None of the previously published meta-analyses have sought 
unpublished studies. 
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1.9.5 Clinical and statistical heterogeneity 	
Another issue with meta-analyses relates to the concept of heterogeneity. 
Clinical heterogeneity can arise due to differences in study inclusion criteria, 
dose of the intervention used, length of follow up and disease severity that may 
cause issues with the pooling of results (Thompson 1994). Statistical 
heterogeneity arises when effect estimates from individual trials differ, which 
may be due to clinical heterogeneity or methodological differences between 
individual trials. If all studies were conducted on the same population of 
participants, we would expect overlap of confidence intervals, as the only 
differences between studies would be due to sampling error. However, 
statistical heterogeneity exists when studies differ by more than would be 
expected from sampling error. Cochran’s Q can quantify this which is the 
weighted sum of squares between individual study results and the overall meta-
analysis results and is chi-squared distributed with k (number of included 
studies) minus one degrees of freedom. Unfortunately, this test has low power 
in the presence of a small number of studies. An alternative measure that uses 
Cochran’s Q in it’s calculation is the I2 statistic, which quantifies the 
percentage of variation between the studies that is due to between-study 
variance compared to sampling variance (Higgins and Thompson 2002). The I2 
statistic is calculated as follows: 
 
I2 = (Q - df) x 100% 
 Q 
 
Q = Cochran’s Q 
df = degrees of freedom (numbers of studies in analysis - 1) 
 
Should heterogeneity be identified, there are methodological issues that can 
address this. The first is to avoid pooling results of trials that are too clinically 
heterogeneous and instead provide a narrative review of results (a decision 
based on clinical judgement rather than observing a high I2 value). However, 
this method may be a lost opportunity to evaluate why results from trials differ, 
which may be useful for generating further hypotheses. If data are to be pooled, 
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then appropriate methods should be used. This involves the use of a random-
effects model, which does not address heterogeneity, although this model 
incorporates a measure of heterogeneity into its calculation and consequently, 
the precision of estimates are reduced in the presence of between-study 
heterogeneity to reflect uncertainties in the data (DerSimonian and Laird 
1983).  
 
1.9.6 Investigation of heterogeneity 	
Probably the most clinically important analysis to conduct in the presence of 
clinical and statistical heterogeneity is a thorough investigation of its causes. 
Such analyses can be used to generate hypotheses for future clinical trials or 
give an indication of where an intervention may be more effective. Both 
subgroup analysis and meta-regression can be used for this purpose. These 
analyses use study-level covariates; such as the dose of an intervention, to 
assess the impact on effect estimates. Meta-regression has advantages over 
subgroup analysis as it allows analyses of multiple covariates, which reduces 
problems of confounding. Also, meta-regression focuses on differences 
between subgroups rather than the effects in each subgroup and makes 
allowances for the residual heterogeneity not explained by the sub-grouping 
(Thompson and Higgins 2002). However, it must be remembered that any 
conclusions are observational in nature and prone to confounding. 
Furthermore, using study-level covariates that are averaged for the trial (such 
as mean pain score or morphine consumption) may not reflect the effects in the 
individual trial participants, which results in aggregation bias (Thompson and 
Higgins 2002). 
 
Heterogeneity is a particular problem in meta-analyses of acute postoperative 
pain trials. Such clinical heterogeneity can arise due to differences in drug 
doses, type of anaesthesia and surgery or how painful the procedure is. 
Espitalier et al. (2013) explored this by examining 61 published meta-analyses 
focusing on treatment of postoperative pain. Although all meta-analyses 
evaluated statistical heterogeneity, only 6% explored this using meta-
regression. Subgroup analysis was performed in 90% of meta-analyses, with 
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around 50% using type of surgery and 70% using the intervention dose. This 
review concluded that clinical heterogeneity induced by pain level is under-
considered, as only 63% of meta-analyses that pooled trials with a wide range 
of pain levels discussed this as a source of clinical heterogeneity. Furthermore, 
within the heterogeneous group of meta-analyses that included surgeries with 
varying levels of pain, only 38% pooled results using a random-effects model. 
In terms of the gabapentin meta-analyses, only one study conducted meta-
regression using gabapentin dose as a covariate (Tiippana et al. 2007). One 
review used sensitivity analyses of trials with higher pain levels to determine if 
this had an influence on effect estimates (Peng, Wijeysundera and Li 2007). 
However, pain severity (>30mm on 100mm VAS) did not affect results. 
 
As discussed previously, type of surgery is often cited as a cause of clinical and 
statistical heterogeneity in meta-analyses of gabapentin and analgesics for 
postoperative pain in general. However, none of the previous meta-analyses 
have thoroughly explored this through appropriate methods using meta-
regression. Type of surgery is often considered as contributing to the efficacy 
of analgesic agents. Indeed, when different surgeries are combined together to 
measure analgesic efficacy; they may produce varying estimates if re-analysed 
for different types of surgery. For example, paracetamol has been found to be 
less effective in orthopaedic compared to dental surgeries (Gray et al. 2005). 
This paper also cites other examples of where analgesic agents are more 
effective in certain procedures when compared to others. However, it remains 
unclear whether the properties of the surgery itself, pain intensity, character of 
pain or type of anaesthesia are responsible for these differences. 
 
1.9.7 Baseline risk 	
Baseline risk is a potentially important effect modifier. For example, in 
postoperative pain trials, the effect of an analgesic in question may be more 
effective in more painful surgeries (Averbuch et al. 2003). Identifying such 
effect modifiers has important implications for more targeted use of analgesic 
adjuncts. Ideally, determining which patients would benefit most from 
treatment would be derived from individual patient data. However, this 
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information is impossible to obtain from patients who only undergo one 
surgery and where analgesia is initiated before the measurement of the 
outcome of interest (24-hour opioid consumption). The traditional method of 
obtaining this data is to use the mean control group morphine consumption as a 
measure of baseline risk (Doleman et al. 2015a). However, this analysis may 
suffer from various forms of bias, which are highlighted below. 
 
Sources of bias in this analysis are varied. Firstly, the use of control group 
morphine consumption as the covariate presents a problem, as this value is 
included in both the covariate value and the effect estimate. This dependence 
causes issues with regression to the mean (regression dilution bias). This can 
cause an association between baseline risk and effect estimate when in fact no 
relationship exists. Secondly, the analysis needs to account for the fact that the 
covariate for baseline risk is measured with error and are estimated from the 
data rather than ‘true’ values (Sharp and Thompson 2000). Because of these 
issues with naïve analyses, alternative analysis methods are recommended that 
implement Bayesian analysis using Gibbs sampling (Sharp and Thompson 
2000). Interestingly, this analysis has been previously shown to improve model 
fit when examining the relationship between baseline risk and reductions in 
morphine consumption with paracetamol and non-steroidal anti-inflammatory 
drugs (NSAIDS) (Achana et al. 2013). 
 
1.9.8 Clinical versus statistical significance 	
A common criticism of both primary and secondary research is an over-
reliance on statistical, rather than clinical significance. Previous meta-analyses 
of gabapentin have failed to express the benefits of gabapentin in terms of 
clinical, rather than statistical significance. To help illustrate the difference 
between these concepts, consider the following hypothetical example. We wish 
to know the efficacy of two different analgesic agents (x and y) for treating 
postoperative pain. We undertake two RCTs with both agents and pre-
determine a clinically significant reduction in pain as 15mm (on a 100mm 
VAS) (Gallagher, Leibman and Bijur 2001). The first RCT with agent x enrols 
a large number of participants and demonstrates a mean difference of -5mm 
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(95% CI -3mm to -7mm; p<0.001). The second study with agent y recruits 
much fewer participants and demonstrates a mean difference of -12mm (95% 
CI 0.1mm to -24.1mm; p=0.06). Although the p value of the first study is very 
low, the results indicate that we can be confident this agent does not produce a 
clinically significant effect and should therefore not be used. The second study, 
although not statistically significant, does not exclude a clinically significant 
effect and requires more studies to be conducted in order to increase power and 
narrow the confidence interval. If we had relied solely on statistical 
significance, widely different and erroneous conclusions would be made.  
 
Previous research has shown that patients regard minimally clinically 
significant average acute pain score reductions to be around 1.3 on a ten-point 
scale (Gallagher, Leibman and Bijur 2001). Another study, using data from 
three other chronic pain studies, cited reductions of 1 point on a 10-point scale 
as minimally important and 2 points as much improved (Dworkin et al. 2008). 
In terms of dichotomous data, the number needed to treat is the most 
appropriate metric to convey benefits as it is easily understood by clinicians 
while being easy for patients to interpret (Cook and Sackett 1995).  
 
1.9.9 Quality of evidence 	
Although the previously discussed limitations with the current meta-analyses 
on gabapentin are not exclusive to this agent, they all negatively affect the 
confidence we can have in their conclusions. These issues can affect the quality 
the evidence derived from systematic reviews, which led to development of the 
GRADE criteria (Guyatt et al. 2008). The level of evidence from RCTs is 
regarded as high quality although can be downgraded to moderate, low or very 
low quality owing to the following concerns, which form the GRADE criteria 
(Higgins 2008):  
 
• ‘Limitations in the design and implementation of available studies 
suggesting high likelihood of bias’= this factor concerns the conduct of 
studies included in the review. This may relate to measures of internal 
validity such as allocation concealment or blinding. Although there are 
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no objective criteria on which to assign a particular group of included 
studies as at risk of bias and is therefore a subjective assessment on the 
part of the review author. 
• ‘Indirectness of evidence’= this measure relates to the population, 
intervention or outcomes measured and whether they are relevant to 
the population on which the evidence is to be used. This would be an 
issue with the external validity of the findings of a review. For 
example, as the evidence for gabapentin efficacy for attenuating the 
haemodynamic response to intubation is derived from mainly 
normotensive participants, this evidence may not be applicable to 
hypertensive patients. 
• ‘Unexplained heterogeneity or inconsistency of results’= this relates to 
the previously discussed clinical and statistical heterogeneity in results. 
For example, if authors fail to explain why results may vary from 
population to population through investigation of heterogeneity, 
evidence is downgraded. 
• ‘Imprecision of results’= as precision is derived from the confidence 
intervals, if a review includes too few participants and/or standard 
deviations are very large, this will result in imprecision and reduced 
confidence we can place in the conclusions. 
• ‘High probability of publication bias’= methods for detecting possible 
publication bias have been discussed previously. Should there be 
evidence of possible publication bias (imprecise study effects), then 
evidence is downgraded. 
 
However, more rarely, observational studies can be upgraded for the following 
reasons (Higgins 2008): 
 
• Well-performed observational studies can be upgraded if they show a 
large magnitude of effects (such as RR>2 or RR<0.5). 
• Biases may exist that underestimate an intervention effect. For 
example, when estimating negative side effects of gabapentin, potential 
publication bias may overestimate the incidence of this adverse effect, 
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as studies that have shown no statistically significant difference 
between groups may not report the result. 
• In observational studies, a dose-response effect may result in 
upgrading. 
 
1.9.10 Type I and type II errors in meta-analysis 	
Meta-analyses in general, and especially those initiated when few trials have 
been published (as with previous meta-analyses on gabapentin), may produce 
erroneous findings due to both type I and type II errors. When few studies have 
been conducted, type I errors are more likely and may produce false positive 
conclusions. Alternatively, meta-analyses need to include an appropriate 
number of participants that can adequately answer the research question, which 
is called the information size (IS) (Borm and Donders 2009; Pogue and Yusuf 
1998; Thorlund et al. 2009). Many of the previous reviews published on 
gabapentin have included a small number of studies and therefore may be 
prone to type I and II errors. Furthermore, the multiple significance tests of 
these reviews may inflate type I errors, analogous to multiple comparisons 
within primary research studies. Indeed, a recent review of the anaesthesia 
literature that included a random sample of 50 meta-analyses concluded that 
only 12% had a power of >80% and only 32% preserved the type I error rate at 
<5% (Imberger et al. 2015). 
 
In primary RCTs, sample size calculations can be conducted to calculate the 
required number of patients required to answer the clinical question. As meta-
analyses are prone to heterogeneity (Espitalier et al. 2013) this must be taken 
into account in these calculations. To deal with these issues, a method called 
trial sequential analysis (TSA) can be performed. Trial sequential analysis may 
yield more reliable results than traditional meta-analytic methods (Thorlund et 
al. 2009). To control type I error rates, monitoring boundaries can be employed 
that require a larger degree of statistical significance when fewer studies are 
included in a review (Illustration 1.4, A) when compared to traditional 
boundaries (Z score of 1.96; Illustration 1.4, B). Another advantage of this 
analysis is the calculation of the IS so the reviewer can be confident a 
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definitive sample size has been reached from all the included studies 
(Illustration 1.4, C). 
  
In addition, TSA can be used to plot boundaries of futility. For example, when 
a meta-analysis result crosses this boundary, then further trials are unlikely to 
achieve the desired, pre-stated clinically significant effect. This can be 
calculated before the required IS is reached. This is essential so that resources 
are not wasted on future RCTs of futile interventions (Illustration 1.4, D). The 
Z curve is plotted as each additional trial is added (Illustration 1.4, E) and if 
this crosses any of these areas, conclusions can be made regarding adjusted 
statistical significance (A), adequate IS (C) or whether the conduct of further 
trials may be futile (D).  
 
In conclusion, current meta-analyses on gabapentin are limited by the inclusion 
of a small number of studies and the publication of multiple meta-analyses may 
inflate the type I error rate. These reviews are also now largely outdated, due to 
the large number of studies published on gabapentin over the last decade. In 
terms of methodology, previous meta-analyses have failed to explore potential 
publication bias, use current recommended methods to assess internal validity, 
are limited in the outcomes assessed, have not searched for unpublished studies 
and failed to fully explore heterogeneity between studies. These flaws mandate 
an updated review on gabapentin that address the above limitations. 
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Illustration 1.4: Trial sequential analysis (TSA) plot. A on the plot indicates 
the monitoring boundaries for adjusted statistical significance for benefit with a 
larger Z score required to reach significance early in the review process. B 
indicates the traditional boundary for statistical significance (p<0.05), which is 
equivalent to a Z score of 1.96. C indicates the required information size (IS) 
for a conclusive review (341 participants). D indicates the area of futility where 
the addition of further trials will unlikely change the conclusions of the review. 
E shows the Z curve with each point indicating the addition of another trial. 
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1.10 Choice of methodology for thesis 	
Many types of methodologies are available in order to assess the effectiveness 
of an intervention. The optimum methodology for primary research studies 
would be the RCT (Higgins 2008). However, over the last decade there have 
been multiple (often small) RCTs published investigating gabapentin for a 
diverse range of outcomes. When focussing on acute postoperative pain, these 
trials often report variable results with regards to reductions in morphine 
consumption, ranging from 20-62% reductions (Tiippana et al. 2008). In 
addition, for other postoperative outcomes and adverse events, a small number 
of participants are studied, which are often limits the power of the analysis. 
Furthermore, other outcomes such as the haemodynamic response to intubation 
have had multiple primary studies published, which have not be analysed 
together in any previous meta-analysis. For the reasons stated above, 
systematic review methodology is a more appropriate methodology than 
undertaking a primary research study of gabapentin. This fact is also true for 
multimodal analgesic agents in general, with a vast number of published 
studies with heterogeneous results, which as yet has not been fully explored.  
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1.11 Aims of this thesis 
 
1) To investigate whether gabapentin is an effective agent in reducing acute 
postoperative pain. 
2) To investigate whether the efficacy of gabapentin is dependent on clinical 
factors such as baseline risk, dose of gabapentin and the type of 
anaesthesia/surgery. 
3) To investigate whether gabapentin is effective at reducing many opioid 
adverse effects. 
4) To evaluate if gabapentin causes any peri-operative adverse effects 
5) To investigate whether gabapentin is an effective pre-emptive analgesic 
agent. 
6) To investigate whether gabapentin is an effective agent in reducing the 
haemodynamic response to intubation. 
7) To investigate whether heterogeneity can be explained in other multimodal 
analgesic agents. 
8) To identify the prevalence of publication bias (imprecise study effects) in 
meta-analyses of other analgesic adjuncts and test whether this is caused by 
heterogeneity rather than true publication bias. 
9) To investigate whether sufficient low risk of bias evidence exists for 
multimodal analgesics to reject type I and II errors. 
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Chapter 2 
Gabapentin for acute and chronic 
postoperative pain: systematic 
review and meta-analysis 
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2.1 Introduction 	
Postoperative pain is common and continues to be undermanaged in clinical 
practice (Apfelbaum  et al. 2003; Sommer et al. 2008). This can negatively 
affect the patient experience and have detrimental physiological consequences. 
Furthermore, acute postoperative pain can lead to chronic pain in up to 50% of 
patients (Kehlet, Jensen and Woolf 2006). Gabapentin has emerged as a 
potential therapy for treating postoperative pain and reduce the need for 
opioids during the postoperative period.  
 
As discussed in chapter one, previous meta-analyses of gabapentin are no 
longer contemporary. Furthermore, they lack investigation for sources of 
heterogeneity, do not fully assess the presence or impact of publication bias 
and do not present adequate information on the internal validity of the included 
studies. Moreover, meta-analyses that include a low number of studies are 
prone to both type I and type II errors (Imberger et al. 2015). Therefore, this 
chapter aims to improve on those published previously by evaluating the 
effects of gabapentin on acute and chronic postoperative pain while utilising 
trial sequential methods to reduce potential errors that earlier reviews may have 
been prone to. Ultimately, this chapter will aim to fully investigate sources of 
heterogeneity and present a meta-regression model, which can be used in 
clinical practice or when planning future research studies in order to identify in 
which clinical situations gabapentin may more effective.   
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2.2 Methods 	
2.2.1 Reporting standards and prospective registration 	
Reporting standards are an important consideration when producing systematic 
reviews of RCTs. If reviews are not adequately reported, readers are unable to 
fully understand how a review was conducted or appreciate the strengths and 
weaknesses of the review (Moher et al. 2009). To help improve the standards 
of reporting, the PRISMA statement was produced which is now a requirement 
in many journals as a condition of publication. Therefore, this review was 
conducted in accordance with the PRISMA statement checklist.  
 
Another consideration for producing an unbiased review is prospective 
registration of the review on a public database. Such registration improves 
accountability, transparency and prevents duplication of reviews addressing the 
same clinical questions (Moher et al. 2009). Moreover, the protocol allows 
outcomes to be pre-specified and help reduce type I errors that may result from 
multiple post hoc subgroup analyses. This review was registered on the 
PROSPERO website, which is a publically accessible database for systematic 
reviews, using the registration number CRD42014015521. Changes from the 
original protocol included changes to the investigation of heterogeneity using 
meta-regression only and the addition of the covariate control group morphine 
consumption or pain score (baseline risk). 
 
2.2.2 Search strategy 	
The literature search was conducted on 8th December 2014. Databases 
searched included MEDLINE (1946-2014), EMBASE (1974-2014), CINAHL 
(1981-2014), AMED (1985-2014) and CENTRAL. These databases provide 
extensive coverage of RCTs and are recommended by the Cochrane Handbook 
(Higgins 2008). The MEDLINE search included the free text search terms 
‘gabapentin’, ‘neurontin’, ‘surgery’ and the medical subject heading (MeSH) 
‘SURGICAL PROCEDURES, OPERATIVE’ which was exploded. We chose 
these search terms in order to maximise the sensitivity of the search.  
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In order to try to reduce the impact of publication bias, we searched 
unpublished clinical trial databases (Thornton and Lee 2000). These included 
Clinicaltrials.gov and the ISRCTN registry. If studies were identified which 
had not been published, authors were contacted by email. To further maximise 
the sensitivity of the search, references of retrieved articles were hand-
searched. Google Scholar was utilised to identify additional articles that had 
cited those retrieved. Google Scholar may be useful in obtaining more obscure 
citations, which may increase the breath of the articles retrieved (Falagas et al. 
2008).   
 
2.2.3 Inclusion criteria and outcomes 	
We followed a PICO (participants, interventions, comparator and outcomes) 
format in order to formulate the clinical question used for including studies in 
the review. The types of studies included were parallel group RCTs, as these 
are widely regarded as the optimum study design to assess the effectiveness of 
an intervention (Higgins 2008). Participants included patients undergoing any 
type of surgery with any type of anaesthesia. Both elective and emergency 
surgeries were included. Studies that evaluated paediatric populations only 
were excluded (for example, excluded patients >15 years old). The intervention 
was gabapentin at any dose administered either pre-operatively or 
postoperatively, with or without additional postoperative doses. We did not 
include studies that used single dose gabapentin for established postoperative 
pain. Comparator treatments included no treatment, placebo tablets or an active 
placebo with no recognised analgesic activity.  
 
The primary outcome was 24-hour morphine consumption. This was chosen as 
the primary outcome as pain scores may be prone to confounding from variable 
morphine consumption between the groups. For example, two groups may 
have similar pain scores although the active drug group may have used less 
morphine, which would still indicate analgesic activity of the drug. However, 
the reverse may also be true, although as patients generally use PCA devices in 
the included studies, the participant can use as much opioid as they require in 
order to remain comfortable. Moreover, as stated in chapter one, morphine may 
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be responsible for many adverse effects during the postoperative period and 
therefore reducing consumption may also reduce these adverse effects.  
 
If other opioids were used in the included studies, these were converted to 
morphine equivalents using the following conversion factors: 
pethidine/meperidine (7.5-10:1), ketobemidone (1:1), tramadol (25:1), fentanyl 
(1:100) and hydromorphone (1:5). Other secondary outcomes included 
postoperative pain assessed at rest at ≤1, 2, 6, 12 and 24-hours postoperatively. 
All scores were converted to a ten-point scale. We also assessed chronic pain at 
1-2, 3, 6 and 12 months as a continuous outcome. Furthermore, due to different 
methods of reporting chronic pain, we included chronic pain as a dichotomous 
outcome, including studies at the earliest time-point in which they recorded the 
presence or absence of chronic pain. We regarded a mean reduction in pain 
score of 1.5 on a ten-point scale (Dworkin et al. 2008; Gallagher, Leibman and 
Bijur 2001) and a 10mg reduction in 24-hour morphine consumption as 
clinically significant. We could not find any studies regarding the clinical 
significance of morphine consumption so we chose one standard dose of 
morphine for this purpose. For chronic pain reported as a dichotomous 
outcome, we regarded a relative risk reduction (RRR) of 20% as clinically 
significant. Inclusion of studies was assessed independently by two authors and 
agreement reached by consensus. 
 
2.2.4 Data extraction 	
Two study authors independently extracted data onto an electronic database. 
We collected data on the following as reported in the study: study name, year 
of publication, mean age of participants, sex of participants (% female), sample 
size, gabapentin dose and regimen, comparison, country in which the study 
was conducted, type of anaesthesia used and type of surgery. There was no 
language restriction for inclusion in the review. If studies were published in a 
non-English language, we used Google Translate to translate them. This helps 
maximise the breadth of the search and limits bias, as authors are more likely 
to publish statistically significant results in English language journals 
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compared with other language journals (English language bias) (Egger et al. 
1997b). 
 
Where data were not reported, authors were contacted to provide additional 
data. If we received no response, graphs were used to estimate data. If standard 
deviations were not reported, these were estimated from other, similar studies 
in the analysis (Higgins 2008). We chose this method due to the potential for 
negative results to not be fully reported (including standard deviations) 
increasing the potential for selective outcome reporting bias. In order to 
minimise any impact of these estimates, we subsequently removed these 
estimated standard deviations on sensitivity analysis. 
 
2.2.5 Risk of bias in included studies 	
We assessed the internal validity of the included studies using the Cochrane 
tool for assessing risk of bias (Higgins et al. 2011). As discussed previously, 
this tool is preferable to composite scoring systems that were previously used 
in many of the previous reviews on gabapentin. This tool assigns one of three 
outcomes to each domain of internal validity. The tool includes randomisation, 
allocation concealment, blinding of participants and study personnel, blinding 
of outcome assessors, selective outcome reporting and other factors which may 
cause bias (such as imbalances in baseline characteristics). Each domain scores 
either low, high or unclear risk of bias dependent on the methods reported. 
 
2.2.6 Statistical analysis 	
Continuous outcomes are presented as mean differences (MD) and aggregated 
using the inverse variance method. The MD was chosen as readers can easily 
interpret it as it retains results in the original format in which they were 
reported. For example, presenting a MD in milligrams of morphine allows 
readers to evaluate the clinical efficacy of gabapentin while also allowing 
direct comparison with other multimodal analgesic agents from previous 
reviews. Due to the different scales used to report chronic pain as a continuous 
outcome, these results are reported as standardised mean differences (SMD). 
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Dichotomous data are presented as risk ratios (RR) and numbers needed to 
treat (NNT) if results were statistically significant. These are both preferable to 
odds ratios as clinicians find them easier to interpret (Carlisle 2007; Cook and 
Sackett 1995).  
 
All effect estimates are presented with an estimate of precision using 95% 
confidence intervals (CI). Confidence intervals are an important measure as 
they move away from considering whether results are statistically significant, 
and instead focus on the uncertainty that surrounds an estimate. In clinical 
practice, it is more important to identify whether an intervention is clinically 
effective rather than reaching an arbitrary level of statistical significance 
(Gardner and Altman 1986). Therefore, this thesis will highlight effect 
estimates that may not reach the traditional level of statistical significance 
(equivalent to a 95% CI traversing the null portion of the effect estimate), as 
having a possible effect if suggested by both the estimate and the degree of CI 
overlap. As calculations of p values are determined by sample size, large 
studies may show small statistically but not clinically important differences, 
which may be misinterpreted by the reader as clinically important when p 
values are taken at face value (Gardner and Altman 1986). Although we accept 
that sample size also determines precision, CIs can be interpreted as stated 
above rather than p values being either statistically or not statistically 
significant. 
 
Due to the expected clinical heterogeneity between studies, the random-effects 
model was used. As previously discussed, the random-effects model 
incorporates the degree of statistical heterogeneity into its calculation, resulting 
in less precise estimates in the presence of large between-study heterogeneity. 
In addition, the random-effects model assumes that there is no one underlying 
effect to be estimated, rather studies are selected representing a normal 
distribution of different underlying effects. Heterogeneity was assessed using 
the I2 statistic and the p value derived from the chi-squared statistic. Statistical 
heterogeneity was considered with I2 values of >50% or p<0.10 (Higgins and 
Thompson 2002). We conducted all analyses using Comprehensive Meta-
analysis Version 3, STATA Version 14 and Review Manager Version 5.3. 
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2.2.7 Publication bias 	
We assessed for possible publication bias (imprecise study effects) 
qualitatively from funnel plots and quantitatively using Egger’s linear 
regression test due to the increased power of this test compared to alternative 
tests (Higgins and Green 2008). We regarded p<0.1 (one-tailed) as evidence of 
imprecise study effects and thus possible publication bias (Egger et al. 1997a). 
If possible publication bias was found, we conducted sensitivity analysis using 
trim and fill analysis (Duval and Tweedie 2000) and Orwin’s failsafe N (Orwin 
1983). For failsafe N analysis, we used the most negative study in the analysis 
and regarded a null effect as a MD of zero or RR of one. For trim and fill 
analysis, we used a random-effects model. Although these methods have there 
limitations, especially in the presence of large between-study heterogeneity 
(Higgins and Green 2008), we felt it important to quantify the influence of 
possible publication bias, as this can vary depending on the number of studies 
at the base of the funnel plot.  
 
2.2.8 Meta-regression 	
We undertook meta-regression analysis to investigate for possible sources of 
heterogeneity from clinical parameters, which included the covariates 
gabapentin dose, type of surgery, type of anaesthesia and control group 
morphine consumption or pain score (baseline risk). We used control group 
morphine consumption as an estimate of the degree of pain a participant would 
have experienced had they not received gabapentin. Using this surrogate 
measure allows exploration of whether gabapentin is more effective if 
participants experience more pain postoperatively. This may be product of both 
how painful the procedure is and the degree of concurrent analgesia used. 
Previous studies have shown that the efficacy of analgesic agents may be 
determined by the pain experienced by the participant and therefore this may 
be an important factor responsible for the heterogeneous results obtained from 
studies with gabapentin thus far (Averbuch and Katzper 2003; Bjune et al. 
1996).  
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Meta-regression was performed using a method of moments, random-effects 
model. This method does not rely on the underlying assumption that the 
distribution of studies conforms to a normal distribution. In order to facilitate 
differences in the dose covariate, studies that reported multiple treatment 
groups based on dose were treated as separate studies for analysis and numbers 
in the control group re-distributed so that they were not analysed twice 
(Higgins and Green 2008). For categorical covariates, we created dummy 
variables for each comparison. We used hierarchical entry and used the model 
that explained the largest amount of heterogeneity between the studies. We 
report the R2 analogue with a corresponding p value for the model. We used 
predicted and studentised residual plots to assess for heteroscedasticity and 
linearity. Studentised residuals were also used to assess outliers. Outliers have 
the potential to bias the regression model and may be identified from 
studentised residual values that exceed two or three. Heteroscedasticity refers 
to the residuals within the regression model. If present, this means that the 
variability of the residual changes as the independent variable increases. Visual 
inspection of the studentised residual versus predicted plots, if 
heteroscedasticity is present, will show a cone-shaped pattern rather than a 
random scatter of plots. Residuals were also tested for a normal distribution 
using histograms. Violations to normality include skew (positive and negative), 
leptokurtosis (higher peak as data points clustered around the mean) and 
platykurtosis (data points dispersed away from the mean resulting in a flatter 
peak). 
 
We used Cook’s distance to assess the model for influential cases and the 
variance inflation factor (VIF) to assess for collinearity. Influential cases can 
also bias the outcomes of a regression analysis. Influential cases may include 
outliers, although an outlier would only be influential if it significantly 
changed the regression slope if deleted. Cook’s distance assesses the impact of 
deleting a value from the regression model to check its influence on the model. 
Values that exceed one have been cited as a cause for concern (Cook and 
Weisburg 1982). The VIF is used to assess if any independent predictors within 
a model are highly correlated. Such high correlations can bias a model, as the 
influence of each of these independent variables cannot be separated. Values of 
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more than ten (Besley, Kuh and Welsch 1980) or values that average more than 
one have been suggested as a cause for concern. 
 
From the multivariate model, we constructed a formula in order to predict the 
likely reduction in morphine consumption from gabapentin under different 
clinical scenarios. Using the model that explained the largest proportion of 
heterogeneity, the following formula was used: 
 
Y = β0 + β1X1 + β2X2 + β3X3 
Y=reduction in morphine consumption with gabapentin 
β0=intercept 
βi=coefficient of independent variables 
Xi=value of independent variable 
 
The aim of this formula is to help clinicians in clinical practice estimate the 
likely effects of gabapentin in their particular patient. In addition, the model 
could help guide future clinical trials, utilising gabapentin under conditions 
where it is expected to have the largest clinical effects. 
 
2.2.9 Sensitivity analysis 	
Sensitivity analysis involved removing studies where standard deviations were 
estimated. One study removed sensitivity analysis was conducted to assess for 
any influential studies in the analysis. Finally, studies that received high risk of 
bias for any domain on the Cochrane risk of bias tool were excluded. 
Sensitivity analysis is important to identify whether changing decisions 
regarding study inclusion change the conclusions of the review. For example, if 
excluding studies that were at high risk of bias caused the positive conclusions 
of the review to change, this may suggest that such positive conclusions are a 
product of the underlying bias rather than a true effect.  
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2.2.10 Trial sequential analysis 	
As discussed previously, TSA can provide control of the false discovery rate 
(type I errors) and provide an IS to indicate whether definitive participant 
numbers have been enrolled in the studies published thus far (reduce type II 
errors). Furthermore, boundaries of futility can indicate when further trials are 
unlikely to change the findings of a meta-analysis. We performed a TSA for all 
outcomes where possible. We estimated control group incidences from both 
published literature and incidences from the studies included in each analysis. 
References for these are provided where used. For continuous outcomes, we 
used both clinically important differences (from subjective clinical experience) 
and those derived from the effect estimates obtained. 
 
We used estimates of variance and heterogeneity corrections from the studies 
included in the meta-analysis. Heterogeneity corrections are calculated from 
statistical heterogeneity from the meta-analysis (D2). These corrections 
incorporate the uncertainty from the included studies to increase a required IS 
in the presence of large between-study heterogeneity. For dichotomous 
outcomes, we regarded RRR of 20% as clinically significant if incidence was 
above 10% and for low incidence events (≤10%) we used a 50% RRR as 
clinically significant. We conducted sensitivity analyses around these estimates 
by changing various assumptions regarding heterogeneity corrections, 
measures of variance or changing the assumptions of the effect estimates. We 
constructed alpha spending monitoring boundaries using the O’Brien-Fleming 
method with a significance level of p<0.05. We used the DerSimonian and 
Laird method for calculating random-effects estimates. We also constructing 
futility boundaries using a 1-β=0.80. For handling zero events, we used a 
constant value of 0.5. We conducted all analyses using TSA software from the 
Copenhagen Trial Unit (Version 0.9.5.5 beta). 
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2.2.11 Quality of evidence 	
As discussed previously, although meta-analyses can increase precision and 
power of results, they can be prone to problems that affect the quality of the 
evidence. The GRADE criteria can be used, which can assess the quality of the 
evidence provided. Evidence is downgraded owing to concerns over 
unexplained heterogeneity, imprecise effect estimates, high likelihood of 
publication bias, the risk of bias in the included studies and any indirectness of 
evidence (Section 1.9.9). We present the quality of the evidence for each 
outcome when two or more studies are included. With regards to risk of bias, 
high quality evidence could only be derived from studies scoring low risk for 
randomisation, allocation concealment, blinding of participants and outcome 
assessors and low attrition bias, with no high risk elements. 
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2.3 Results 	
2.3.1 Characteristics of included studies 	
Overall, 133 studies were included in the final review (Figure 2.1). The 
characteristics of the included studies are included in Table 2.1. All studies 
were parallel group RCTs. There was clinical heterogeneity in the participants 
studied, type of surgery, dose of gabapentin, administration regimen and type 
of anaesthesia. The risk of bias assessment for the included studies is presented 
in Figure 2.2.  
 
 
 
Figure 2.1: PRISMA flowchart of the included studies. 
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Figure 2.2: Risk of bias assessments for the included studies. Red indicates 
high risk, yellow unclear risk and green low risk. Any study scoring high risk 
for any element on quality assessment was later excluded on sensitivity 
analysis.
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Study 
Mean 
age Sex N Intervention Comparison Country Type of anaesthesia Type of surgery 
JOINT ARTHROSCOPY         
Adam et al. 2006  45 32% 53 
800mg 2hrs before 
surgery Placebo France 
General anaesthesia 
with intra-scalene 
brachial plexus block 
Arthroscopic shoulder 
surgery 
Bang et al. 2010  57.9 63% 46 
300mg 2hrs before 
surgery Placebo South Korea General anaesthesia 
Arthroscopic rotator cuff 
repair 
Mardani-Kivi et al. 2013  31 12% 114 
600mg 2hrs before 
surgery Placebo Iran General anaesthesia 
Arthroscopic anterior 
cruciate ligament repair 
Menigaux et al. 2005  31 32% 40 
1200mg 1-2hrs 
before surgery Placebo France General anaesthesia 
Arthroscopic anterior 
cruciate ligament repair 
Montazeri et al. 2007  34.6 23% 70 
300mg 2hrs prior to 
surgery Placebo Iran General anaesthesia Knee arthroscopy 
Spence et al. 2011  31.6 16% 57 
300mg within 1hr 
surgery, 300mg night 
after surgery then 
300mg BD for 48hrs Placebo USA 
General anaesthesia 
with intra-scalene 
brachial plexus block Shoulder arthroscopy 
JOINT ARTHROPLASTY        
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Clarke et al. 2009a 60.2 39% 114 
600mg 2hrs before 
operation or 2hrs 
after Placebo Canada Spinal anaesthesia Total hip arthroplasty 
Clarke et al. 2009b 62.4 61% 36 
600mg 2hrs before 
operation and 4 
groups different 
postoperative doses Placebo Canada Spinal anaesthesia Total knee arthroplasty 
Clarke et al. 2010a  NR 28% 82 
600mg 2hrs before 
operation or 2hrs 
after Placebo Canada Spinal anaesthesia Total hip arthroplasty 
Clarke et al. 2010b  43.5 NR 70 
600mg 2hrs before 
operation Placebo Canada Spinal anaesthesia Total hip arthroplasty 
Clarke et al. 2014  62.8 50% 179 
600mg 2hrs before 
surgery and 200mg 
TDS for 4 days Placebo Canada 
Spinal anaesthesia 
with sciatic and 
femoral nerve block Total knee arthroplasty 
Nantha-Aree et al. 2011 
[unpublished] 60.7 43% 102 
600mg preoperatively 
and 200mg 
postoperatively then 
200mg TDS for 2 Placebo Canada Spinal anaesthesia Total hip arthroplasty 
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days 
Paul et al. 2013 62.8 63% 101 
600mg preoperatively 
and 600mg per day 
first 2 days after 
operation Placebo Canada Spinal anaesthesia Total knee arthroplasty 
HYSTERECTOMY         
Ajori et al. 2012 48.7 100% 138 
600mg 1hr before 
induction Placebo Iran General anaesthesia Abdominal hysterectomy 
Behdad et al. 2012  47 100% 61 
100mg night before 
and 300mg 2hrs 
before surgery Multivitamin Iran General anaesthesia Abdominal hysterectomy 
Dierking et al. 2004 46.9 100% 71 
1200mg 1hr before 
surgery and 600mg 
TDS for one day Placebo Denmark General anaesthesia 
Abdominal hysterectomy 
with/without salpingo-
oophorectomy 
Durmus et al. 2007 48 100% 50 
1200mg 1hr before 
induction Placebo Turkey General anaesthesia Abdominal hysterectomy 
Fassoulaki et al. 2006a 42 100% 53 
400mg QDS day 
before surgery and 5 
days postoperatively Placebo Greece General anaesthesia Abdominal hysterectomy 
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Frouzanfard et al. 2013 44.2 100% 50 
1200mg 2hrs before 
operation Placebo Iran General anaesthesia Abdominal hysterectomy 
Ghafari et al. 2009 44.6 100% 66 
300mg night before 
and 1hr before 
surgery Placebo Iran General anaesthesia 
Abdominal hysterectomy 
with salpingo-
oophorectomy 
Ghai et al. 2011 and 2012 44.5 100% 60 
900mg 1-2hrs before 
operation Placebo India General anaesthesia Abdominal hysterectomy 
Gilron et al. 2005 44.5 100% 103 
600mg 1hr before 
induction then TDS 
for 2 days after 
surgery and rofecoxib 
Placebo and 
rofecoxib Canada General anaesthesia Abdominal hysterectomy 
Khan et al. 2013 44 100% 69 
1200mg 2hrs before 
operation Placebo Pakistan General anaesthesia Abdominal hysterectomy 
Rorarius et al. 2004 46 100% 75 
1200mg 2.5hrs before 
induction Oxazepam Finland General anaesthesia Vaginal hysterectomy 
Sekhavat et al. 2009 42.7 100% 98 
600mg 1hr before 
surgery and 100mg 
TDS for one day Placebo Iran General anaesthesia Abdominal hysterectomy 
Sen et al. 2009a 46.5 100% 40 1200mg 1hr before Placebo Turkey General anaesthesia Abdominal hysterectomy 
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surgery with salpingo-
oophorectomy 
Turan et al. 2004b 51.4 100% 50 
1200mg 1hr before 
surgery Placebo Turkey General anaesthesia 
Abdominal hysterectomy 
with salpingo-
oophorectomy 
Turan et al. 2006a 50.8 100% 100 
1200mg 1hr before 
surgery and OD for 2 
days and rofecoxib 
Placebo and 
rofecoxib Turkey General anaesthesia 
Abdominal hysterectomy 
with salpingo-
oophorectomy 
Verma et al. 2008 50.8 100% 50 
300mg 2hr before 
surgery Placebo India 
Spinal and epidural 
anaesthesia Abdominal hysterectomy 
CARDIOTHORACIC SURGERY        
Grosen et al. 2014 64.5 50% 67 
1200mg 2hrs before 
surgery then 300mg 
BD for one day, 
300mg TDS for one 
day and 300mg QDS 
for 3 further days Placebo Denmark 
General anaesthesia 
and epidural 
Thoracotomy for lung 
malignancy 
Huot et al. 2008 60 45% 51 
1200mg 2hrs before 
surgery Placebo Canada 
General anaesthesia 
and epidural Thoracotomy 
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Kinney et al. 2012 64.3 48% 120 
600mg 2hrs before 
surgery 
Diphenhydra
-mine USA 
General anaesthesia 
and epidural Thoracotomy 
Koşucu et al. 2014 54.8 52% 60 
1200mg 1hr before 
surgery Placebo Turkey General anaesthesia 
Thoracotomy for 
segmentectomy 
Menda et al. 2010 51 0% 60 
600mg 2hrs before 
surgery Placebo Turkey General anaesthesia CABG 
Rapchuk et al. 2010 60.2 11% 54 
1200mg 2hrs before 
surgery and 600mg 
BD for 2 days Placebo Canada General anaesthesia 
Cardiac surgery with 
median sternotomy 
Soltanzadeh et al. 2011 56.8 0% 60 
800mg 2hrs before 
surgery and 400mg 
2hrs after extubation Placebo Iran General anaesthesia CABG 
Ucak et al. 2011 61.1 40% 40 
1200mg 1hr before 
surgery and following 
2 days Placebo Turkey General anaesthesia CABG 
CHOLECYSTECTOMY         
Bashir et al. 2009 NR 75% 100 
600mg 2hrs before 
surgery Vitamin B India General anaesthesia 
Laparoscopic 
cholecystectomy 
Bhandari et al. 2014a 42.7 65% 40 600mg 2hrs before Placebo India General anaesthesia Laparoscopic 
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surgery and 12hrs 
after first dose 
cholecystectomy 
Gilron et al. 2009 NR 76% 60 
1200mg 1hr before 
surgery and 400mg 
the night of surgery 
then TDS for 2 days 
and meloxicam 15mg 
for 3 days 
Meloxicam 
15mg for 3 
days Canada General anaesthesia 
Laparoscopic 
cholecystectomy 
Khademi et al. 2010 51.7 92% 87 
600mg 2hrs before 
surgery Placebo Iran General anaesthesia Open cholecystectomy 
Kotsovolis et al. 2014 50.8 73% 48 
600mg 4hrs before 
and 24hrs after 
surgery Placebo Greece General anaesthesia 
Laparoscopic 
cholecystectomy 
Maleh et al. 2013 40.3 100% 80 
600mg 1hr before 
surgery Placebo Iran General anaesthesia 
Laparoscopic 
cholecystectomy 
Neogi et al. 2012 40.4 63% 60 
900mg 2hrs before 
induction Vitamin B India General anaesthesia 
Laparoscopic 
cholecystectomy 
Pandey et al. 2004b 42.6 65% 306 
300mg 2hrs before 
surgery Placebo India General anaesthesia 
Laparoscopic 
cholecystectomy 
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Pandey et al. 2006 42.3 83% 250 
600mg 2hrs before 
surgery Placebo India General anaesthesia 
Laparoscopic 
cholecystectomy 
Pandey et al. 2012 43.4 51% 70 
600mg 2hrs before 
surgery Placebo India General anaesthesia 
Laparoscopic 
cholecystectomy 
Pathak and Chaturvedi 
2013 39.5 86% 80 
1200mg 2hrs before 
surgery Placebo Nepal General anaesthesia Open cholecystectomy 
Saeed et al. 2013 40.1 83% 100 
600mg 2hrs before 
surgery Vitamin B Iraq General anaesthesia 
Laparoscopic 
cholecystectomy 
Semira et al. 2013 40.9 72% 60 
600mg 2hrs before 
surgery Placebo India General anaesthesia 
Laparoscopic 
cholecystectomy 
Soroush et al. 2012 47.2 83% 92 
600mg 2hrs before 
surgery and 6hrs after Placebo Iran General anaesthesia 
Laparoscopic 
cholecystectomy 
Sousa and Alves Neto 2009 NR NR 40 
1200mg 2hrs before 
induction Placebo Brazil General anaesthesia Cholecystectomy 
Srivastava et al. 2010 43.8 68% 120 
600mg 2hrs before 
surgery Placebo India General anaesthesia 
Minilap open 
cholecystectomy 
Syal et al. 2010 39.7 76% 120 
1200mg 2hrs before 
induction and 
paracetamol 
Placebo and 
paracetamol India General anaesthesia Open cholecystectomy 
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BREAST SURGERY         
Amr and Yousef 2010 43.5 100% 100 
300mg a day the 
night before surgery 
for 10 days Placebo Egypt General anaesthesia 
Partial or radical 
mastectomy with axillary 
dissection 
Azemati et al. 2013 47.2 100% 100 
600mg 30mins before 
induction Placebo Iran General anaesthesia 
Modified radical 
mastectomy or 
quadrantectomy with 
axillary node dissection 
Bharti et al. 2013 46.5 100% 40 
600mg 2hrs before 
surgery Placebo India General anaesthesia 
Total mastectomy with 
axillary node clearance 
Butt et al. 2011 NR 100% 100 
1200mg 1hr before 
surgery Placebo India General anaesthesia Mastectomy 
Dirks et al. 2002 60 100% 65 
1200mg 1hr before 
surgery Placebo Denmark General anaesthesia 
Radical mastectomy with 
axillary dissection 
Fassoulaki et al. 2002 43.6 100% 46 
400mg TDS the 
evening before 
surgery for 10 days Placebo Greece General anaesthesia 
Modified radical 
mastectomy or 
lumpectomy with 
axillary node dissection 
Grover et al. 2009 45.8 100% 46 600mg 1hr before Vitamin B India General anaesthesia Total mastectomy with 
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surgery axillary node dissection 
Metry et al. 2008 57.8 100% 101 
1200mg 2 hours 
before or 1200mg 
postoperatively Placebo Egypt General anaesthesia Mastectomy 
ENT/DENTAL         
Abdelmageed et al. 2010 30.6 42% 60 
1200mg 2hrs before 
induction Placebo Saudi Arabia General anaesthesia Tonsillectomy 
Al-Mujadi et al. 2006 47 74% 72 
1200mg 2hrs before 
surgery Placebo Kuwait/India General anaesthesia Thyroidectomy 
Brogly et al. 2008 49 86% 43 
1200mg 2hrs before 
surgery Placebo France General anaesthesia 
Total or partial 
thyroidectomy 
Debaecker et al. 2014 NR NR 83 
1200mg 2hrs before 
surgery Placebo France General anaesthesia Thyroid surgery 
Işik et al. 2014  34.3 73% 60 
600mg 30mins before 
endodontic treatment Placebo Turkey Local anaesthesia Endodontic treatments 
Jahromi et al. 2013 31.8 35% 60 
300mg 1hr before 
surgery Placebo Iran General anaesthesia 
Open reduction and 
internal fixation 
maxillofacial trauma 
Jeon et al. 2009 26.1 53% 58 600mg night before Placebo South Korea General anaesthesia Tonsillectomy 
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and 1hr before 
surgery 
Kazak et al. 2010 34 42% 60 
600mg 1hr before 
surgery Placebo Turkey 
Local anaesthesia and 
sedation 
Nasal septal or nasal 
sinus surgery 
Kilic et al. 2014 37 48% 60 
1200mg 1hr before 
surgery Placebo Turkey General anaesthesia 
Functional endoscopic 
sinus surgery 
Lee et al. 2013 48.7 76% 71 
600mg 1hr before 
induction Placebo Korea General anaesthesia 
Total or partial 
thyroidectomy 
Marashi 2012 38.3 82% 44 
900mg 2hrs before 
surgery Placebo Iran General anaesthesia Total thyroidectomy 
Mikkelsen et al. 2006 NR 69% 49 
1200mg 1hr before 
induction and 600mg 
BD then 600mg TDS 
for 5 days Placebo Denmark General anaesthesia Tonsillectomy 
Mogadam et al. 2012 14.5 38% 60 
20mg/kg 1hr before 
surgery Placebo Iran General anaesthesia Tonsillectomy 
Mohammed et al. 2012 32.1 NR 80 
1200mg 1hr before 
surgery Placebo Egypt General anaesthesia 
Functional endoscopic 
sinus surgery 
Nesioonpour 2014 28.6 45% 62 800mg 1hr before Placebo Iran General anaesthesia Repair of deviated nasal 
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surgery septum 
Turan et al. 2004c 28.5 NR 50 
1200mg 1hr before 
surgery Placebo Turkey 
Local anaesthesia and 
sedation 
Nasal septal or nasal 
sinus surgery 
SPINAL SURGERY         
Erten et al. 2010 44.1 46% 59 
900mg or 1200mg 
1hr preoperatively Vitamin C Turkey General anaesthesia Elective laminectomy 
Khan et al. 2011 41.8 35% 175 
600mg, 900mg or 
1200mg 2hrs pre or 
immediately post-
incision via NG tube Placebo Iran General anaesthesia 
Single level lumbar 
laminectomy 
Khurana et al. 2014 48 27% 60 
300mg 1hr 
preoperatively and 
TDS Placebo India General anaesthesia Lumbar discectomy 
Kiskira et al. 2006 NR NR 40 
1200mg 1hr before 
surgery Placebo Greece NR Lumbar discectomy 
Leung et al. 2006 59.6 48% 21 
900mg 1-2hrs 
preoperatively Placebo USA General anaesthesia Spinal surgery 
Ozgencil et al. 2011 49.6 53% 60 
600mg 2hrs before 
operation and 10 and Placebo Turkey General anaesthesia 
Elective decompressive 
lumbar laminectomy and 
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22hrs after operation discectomy 
Pandey et al. 2004a 38.8 32% 56 
300mg 2hrs before 
surgery Placebo India General anaesthesia Single-level disc surgery 
Pandey et al. 2005a 41.2 33% 100 
Four groups receiving 
doses of gabapentin 
2hrs before surgery 
(300-1200mg) Placebo India General anaesthesia Single-level disc surgery 
Radhakrishnan et al. 2005 40.6 33% 60 
400mg (one dose 
night before surgery 
and one dose 2hrs 
prior to induction) Placebo India General anaesthesia 
Elective lumbar 
laminectomy and 
discectomy 
Turan et al. 2004a 46.5 44% 50 
1200mg 1hr before 
operation Placebo Turkey General anaesthesia 
Lumbar discectomy or 
spinal fusion 
Vahedi et al. 2011 44.4 42% 76 
300mg 2hrs before 
operation Placebo Iran General anaesthesia 
Single level lumbar 
laminectomy and 
discectomy 
CAESAREAN SECTION         
Moore et al. 2011 34 100% 44 
600mg 1hr before 
surgery Placebo Canada Spinal anaesthesia Caesarean section 
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Short et al. 2012 35.1 100% 126 
300mg or 600mg 1hr 
before surgery Placebo Canada Spinal anaesthesia Caesarean section 
GENERAL SURGERY         
Jadeja et al. 2014 38.4 64% 50 
1200mg 2hrs before 
surgery Placebo India General anaesthesia Upper abdominal surgery 
Mahoori et al. 2014 47.2 0% 50 
400mg 2hrs before 
surgery Placebo Iran Spinal anaesthesia Inguinal herniorrhaphy 
Mohammadi and Seyedi 
2008 40 NR 80 
300mg 1hr before 
surgery Placebo Iran General anaesthesia 
Abdominal surgery 
(general and 
gynaecological) 
Parikh et al. 2010 39.6 60% 60 
600mg 1hr before 
surgery Placebo India General anaesthesia Abdominal surgery 
Radwan et al. 2010 38.1 54% 50 
600mg 1hr before 
surgery Placebo Egypt General anaesthesia Abdominal surgery 
Sava and Rusu 2009 62.5 40% 50 
800mg 2 hrs before 
surgery Placebo Romania General anaesthesia Colorectal surgery 
Sen et al. 2009b 24 0% 60 
1200mg 1hr before 
surgery Placebo Turkey Spinal anaesthesia Inguinal herniorrhaphy 
Siddiqui et al. 2014 37.6 NR 72 600mg 1hr before Placebo Canada General anaesthesia Laparotomy for IBD 
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surgery 
Zaldivar Ramirez 2011 48.1 47% 34 
300mg 1hr before 
surgery and 300mg 
BD after surgery Placebo Mexico General anaesthesia 
Laparoscopic Nissen 
fundoplication 
GYNAECOLOGICAL SURGERY        
Bafna et al. 2014 42 100% 60 
600mg 1hr before 
surgery Placebo India Spinal anaesthesia 
Gynaecological surgery 
(total abdominal 
hysterectomy and 
laparotomy for ovarian 
cyst) 
Bartholdy et al. 2006 37 100% 80 
1200mg 30mins 
before surgery Placebo Denmark General anaesthesia Laparoscopic sterilisation 
Chowdhury et al. 2010 40.5 100% 200 
300mg 2hrs before 
surgery Placebo India General anaesthesia 
Internal ligation, pelvic 
floor repair, Bartholian 
cyst marsupialisation and 
Gartner’s duct cyst 
excision 
Kang et al. 2009 45.3 100% 100 
300mg, 600mg or 
1200mg 2hrs before Placebo Korea General anaesthesia 
Laparotomy for 
gynaecological surgery 
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surgery 
Mohammadi and Seyedi 
2008b 31.6 100% 70 
300mg 1hr before 
surgery Placebo Iran General anaesthesia 
Laparoscopic surgery for 
assisted reproductive 
technologies 
Said-Ahmed 2007 37 100% 80 
300mg, 600mg or 
1200mg 2hrs before 
surgery Placebo Egypt General anaesthesia Myomectomy 
PLASTIC SURGERY         
Rimaz et al. 2012 49.4 70% 50 
1200mg 2hrs before 
surgery Placebo Iran General anaesthesia 
Debridement of burn 
wounds 
Turan et al. 2006b 52 NR 40 
1200mg 1hr before 
surgery and OD for 2 
days Placebo Turkey 
General and epidural 
anaesthesia 
Scar revision and/or skin 
graft 
ORTHOPAEDIC SURGERY        
Panah Khahi et al. 2011 32.5 17% 64 
300mg 2hrs before 
surgery Placebo Iran Spinal anaesthesia Internal fixation of tibia 
Panah Khahi et al. 2012 32.5 27% 64 
300mg immediately 
after surgery Placebo Iran Spinal anaesthesia Internal fixation of tibia 
Raghove et al. 2010 30.6 0% 90 200mg or 600mg 1hr Placebo India Spinal anaesthesia Lower limb orthopaedic 
	 92	
before operation 
Sheen et al. 2008 27.5 4% 80 
1200mg 2hrs before 
operation Placebo Taiwan Spinal anaesthesia 
Cruciate ligament 
reconstruction, open 
reduction, removal of 
implant and arthroscopy 
Tuncer et al. 2005 37.3 NR 45 
800mg or 1200mg 
1hr before operation Placebo Turkey General anaesthesia 
Major orthopaedic 
surgery 
Waikakul 2011 49.6 46% 99 
400mg 1-2hrs before 
operation and 300mg 
12hrs and 24hrs after 
operation and 
celecoxib 
Placebo and 
celecoxib Thailand General anaesthesia 
Major orthopaedic 
surgery 
OPTHALMOLOGY         
Bakry and Marey 2012 62.3 28% 60 
1200mg 2 hours 
before anaesthesia Placebo Egypt Peribulbar nerve block Cataract surgery 
Khezri et al. 2013 74.2 41% 80 
600mg 1.5hrs before 
surgery Placebo Iran 
Retrobulbar nerve 
block Cataract surgery 
Kuhnle et al. 2011 31.8 11% 82 
300mg TDS for 7 
days started 2 days Placebo USA NR 
Photorefractive 
keratectomy 
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before surgery 
Lichtinger et al. 2011 26.7 62% 40 
300mg night before 
surgery, BD on day 
of surgery and TDS 3 
days postoperatively Placebo Mexico Local anaesthesia 
Photorefractive 
keratectomy 
Pakravan et al. 2012 26.6 55% 100 
300mg TDS for 3 
days starting 2 hours 
after surgery Placebo Iran Local anaesthesia 
Photorefractive 
keratectomy 
NEUROSURGERY         
Misra et al. 2013 44 45% 73 
600mg 2hrs before 
induction 
Vitamin B 
complex India General anaesthesia 
Craniotomy for 
supratentorial tumour 
Özcan et al. 2012 52.8 40% 40 
600mg 1hr before 
surgery Placebo Turkey General anaesthesia 
Craniotomy for 
supratentorial tumour 
Ture et al. 2009 47 52% 75 
1200mg for 7 days 
before surgery Phenytoin Turkey General anaesthesia 
Craniotomy for 
supratentorial tumour 
MIXED         
Adam et al. 2012 37.5 39% 64 
1200mg 2-3hrs 
before surgery Placebo France 
General and regional 
anaesthesia 
Orthopaedic or open 
inguinal hernia repair 
Arora et al. 2009 41 37% 60 1200mg 1hr before Multivitamin India Spinal anaesthesia Infra-umbilical surgery 
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anaesthesia 
Clarke et al. 2013 41.7 100% 44 
1200mg 2 hrs before 
surgery Placebo Canada NR 
General, gynaecological, 
plastics and ENT surgery 
Prabhakar et al. 2007 29.2 5% 20 
800mg 2hrs before 
surgery Placebo India General anaesthesia 
Surgery for brachial 
plexus injury 
Rajendran et al. 2014 42.2 35% 60 
900mg 1hr before 
surgery Placebo India Spinal anaesthesia 
General, urological, 
vascular and plastic 
surgery 
Tirault et al. 2010 45 64% 135 
1200mg 2hrs before 
surgery Placebo France General anaesthesia 
Orthopaedic, ENT, 
spinal, general, 
gynaecological and 
endoscopic procedures 
UROLOGY         
Agarwal et al. 2007 39 18% 108 
600mg 1hr before 
surgery Placebo India General anaesthesia 
Percutaneous 
nephrolithotomy 
Bala et al. 2012 53.3 21% 100 
600mg or 1200mg 
1hr before surgery Placebo India Spinal anaesthesia 
Transurethral resection 
of bladder tumour 
Koç, Memis and Sut 2007 38.5 0% 80 
800mg 1hr before 
surgery and 
Placebo and 
dexamethaso Turkey General anaesthesia Varicocele surgery 
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dexamethasone -ne 
Pandey et al. 2005b 43.6 68% 60 
600mg 2hrs before or 
600mg post-incision Placebo India General anaesthesia Open donor nephrectomy 
 
 
Table 2.1: Characteristics of the included studies. NR=not reported; OD=once daily, BD=twice daily; TDS=three times daily; QDS=four times 
daily; CABG=coronary artery bypass graft; ENT=ear, nose and throat; IBD=inflammatory bowel disease. Sex is reported as the % female. Ghai 
2011 and 2012 are duplicates of the same study.
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2.3.2 24 hour morphine consumption 	
Overall, 66 studies with 5257 participants were included in the analysis. 
Gabapentin resulted in lower consumption of morphine in the first 24 hours 
after surgery (MD -8.44mg; 95% CI -9.62mg to -7.26mg; Figure 2.3). There 
was evidence of considerable statistical heterogeneity (I2=98%; p<0.001). The 
quality of evidence was regarded as low according to GRADE (downgraded 
due risk of bias and potential publication bias). 
 
 
 
Figure 2.3: Forest plot of gabapentin effect on 24-hour morphine consumption 
(mg). 
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In addition, there was evidence of imprecise study effects with an asymmetric 
funnel plot (Figure 2.4) and a statistically significant Egger’s regression test 
(p<0.001). Trim and fill analysis found only three missing studies to the right 
of the mean, which did not significantly change the effect estimates (MD -
7.97mg; 95% CI -9.16mg to -6.78mg) and Orwin’s failsafe N calculated an 
additional 211 negative studies would be required to observe a negative result. 
 
 
 
Figure 2.4 Funnel plot of gabapentin effects on 24-hour morphine 
consumption. X-axis shows the mean difference and the Y-axis shows the 
standard error. 
 
Meta-regression analysis revealed that the heterogeneity between the studies 
was largely predicted by the 24-hour morphine consumption in the control 
group (R2=81%; p<0.001) (Figure 2.5). The addition of type of anaesthesia and 
gabapentin dose significantly improved this (R2=90%; p<0.001). The addition 
of type of surgery did not improve the model. Using the meta-regression 
equation, the following reductions in morphine consumption would be 
expected in the following clinical examples:  
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Firstly, for a patient undergoing a procedure with an expected morphine 
consumption of 30mg, using a gabapentin dose of 1200mg and undergoing 
general anaesthesia, the expected reduction in morphine consumption would 
be: 
 
3.73 + (-0.378 x 30) + (-0.0023 x 1200) + (-1.917 x 1) = 12.29mg 
 
Conversely, a patient undergoing a procedure with an expected morphine 
consumption of 10mg, using a gabapentin dose of 600mg and undergoing 
spinal anaesthesia, the expected reduction in morphine consumption would be: 
 
3.73 + (-0.378 x 10) + (-0.0023 x 600) + (-1.917 x 0) = 1.43mg 
 
 
 
Figure 2.5 Meta-regression plot. X-axis shows the control group morphine 
consumption in mg and the Y-axis the mean difference in morphine 
consumption with gabapentin in mg. 
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In terms of regression diagnostics, predicted versus studentised residual plots 
revealed no violations of the assumptions of linearity and homoscedasticity. 
Histograms showed residuals to be approximately normally distributed. 
Although 13 studies had studentised residuals of more than two, Cook’s 
distance revealed there were no influential cases in the model. The final model 
had no VIF values above 10. However, the model that included type of surgery 
showed evidence of multicollinearity with spinal anaesthesia and orthopaedic 
surgery (VIF 14.4 and 11.8 respectively).  
 
On sensitivity analysis, removal of studies that estimated standard deviations 
did not significantly affect the results. In addition, removal of each study from 
the analysis did not identify any influential studies. Finally, removing studies 
that were at high risk of bias did not change the results. 
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Figure 2.6: Trial sequential analysis of 24-hour morphine consumption (mg). 
Performed assuming a mean difference of 8.44mg, variance of 7.8, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 98. Blue line indicates 
cumulative Z score with values more than zero indicating benefit with 
gabapentin.  
 
Trial sequential analysis could not be performed for a 10mg reduction, as there 
was not enough information for analysis. Using an empirical -8.44mg 
morphine reduction, gabapentin crossed the O’Brien-Fleming boundary for 
benefit (adjusted CI -9.62mg to -7.26mg) (Figure 2.6). In addition, gabapentin 
reached the required IS for a definitive answer (242 participants). On 
sensitivity analysis, increasing the variance to 14 did not affect the results 
obtained with an IS of 424 participants. We did not perform any further 
sensitivity analysis with heterogeneity corrections due to high value already 
used in the analysis.  
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2.3.3 Pain scores one hour 	
Overall, 43 studies with 2874 participants were included in the analysis. 
Gabapentin resulted in a clinically significant reduction in pain scores at one 
hour on a ten-point scale (MD -1.69; 95% CI -2.01 to -1.35; Figure 2.7). There 
was evidence of considerable statistical heterogeneity (I2=93%; p<0.001). The 
quality of evidence was regarded as moderate according to GRADE 
(downgraded due to risk of bias).  
 
 
 
Figure 2.7 Forest plot of pain scores at one hour postoperatively. 
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Although there was little asymmetry on visual inspection of the funnel plot 
(Figure 2.8), Egger’s regression test suggested statistically significant evidence 
of imprecise study effects (p=0.06). However, trim and fill analysis showed the 
two missing studies were to the left of the plot resulting in a larger adjusted 
effect estimate (MD -1.75; 95% CI -2.08 to -1.42). Orwin’s failsafe N 
estimated 211 studies were needed to observe a negative effect. 
 
 
 
Figure 2.8 Funnel plot of gabapentin effects on pain scores at one hour. X-axis 
shows the mean difference and the Y-axis shows the standard error. 
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Figure 2.9 Meta-regression plot. X-axis shows the control group pain score 
and the Y-axis the mean difference in pain score with gabapentin. 
 
On meta-regression analysis, control group pain score explained a large 
proportion of the heterogeneity between the studies (R2=43%; p<0.001) 
(Figure 2.9). The addition of type of surgery improved the proportion of the 
heterogeneity explained by the model (R2=57%; p<0.001). Diagnostics showed 
only three studies had a studentised residual of more than two and no study had 
a Cook’s distance of more than one. Residuals were normally distributed on 
histograms. Predicted versus studentised residual plots demonstrated 
homoscedasticity and linearity. There were no covariates with a VIF of more 
than ten. 
 
On sensitivity analysis, removing studies at high risk of bias and those where 
standard deviations were estimated did not significantly affect the results. One 
study removed sensitivity analysis did not reveal any influential studies in the 
analysis.  
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Figure 2.10: Trial sequential analysis of pain score at one hour. Performed 
assuming a mean difference of 1.5 in pain score, variance of 1.11, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 95. Blue line indicates 
cumulative Z score with values more than zero indicating benefit with 
gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for statistical significance (Figure 2.10). The results reached the 
required IS for a definitive answer (299 participants). On sensitivity analysis, 
similar results were obtained using a mean difference of 1.68 (IS 243 
participants) or increasing the variance to 2.5 (IS 654 participants). We did not 
perform any further sensitivity analysis with heterogeneity corrections due to 
high value already used in the analysis.   
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2.3.4 Pain scores two hours 	
Overall, 40 studies with 2666 participants were included in the final analysis. 
Gabapentin resulted in a reduction in pain scores at two hours (MD -1.21; 95% 
CI -1.55 to -0.88; Figure 2.11). However, this reduction was not clinically 
significant. There was evidence of considerable statistical heterogeneity 
(I2=91%; p<0.001). The quality of evidence was moderate according to 
GRADE (downgraded owing to concerns over risk of bias in the included 
studies). 
 
  
 
Figure 2.11 Forest plot of pain scores at two hours postoperatively. 
 
 
 
 
 
 
 
	 106	
There was no evidence of an asymmetric funnel plot on visual inspection 
(Figure 2.12). Egger’s regression test showed no statistical evidence of 
imprecise study effects (p=0.41). Therefore, trim and fill analysis and failsafe 
N analyses were not conducted. 
 
 
 
Figure 2.12 Funnel plot of gabapentin effects on pain scores at two hours. X-
axis shows the mean difference and the Y-axis shows the standard error. 
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Figure 2.13 Meta-regression plot. X-axis shows the control group pain score 
and the Y-axis the mean difference in pain score with gabapentin. 
 
On meta-regression analysis, the majority of the heterogeneity between studies 
was explained by the mean pain score in the control group (R2=54%; p<0.001) 
(Figure 2.13). This was improved by the addition of the covariate gabapentin 
dose (R2=59%; p<0.001). Regression diagnostics revealed four studies had a 
studentised residual of more than two, although no study had a Cook’s distance 
of more than one. Histograms showed residuals were approximately normally 
distributed. Predicted versus studentised residual plots did not violate the 
assumptions of homoscedasticity or linearity. No covariate had a VIF value of 
more than ten.  
 
Sensitivity analysis showed no change in the results if studies where standard 
deviations were estimated were removed or removing studies at high risk of 
bias. One study removed sensitivity analysis revealed no influential studies in 
the analysis. 
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Figure 2.14: Trial sequential analysis of pain scores at two hours 
postoperatively. Performed assuming a mean difference of 1.5 in pain score, 
variance of 1.68, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 
91. Blue line indicates cumulative Z score with values more than zero 
indicating benefit with gabapentin.  
 
Trial sequential analysis showed gabapentin crossed the O’Brien-Fleming 
boundary for benefit (adjusted CI -1.62 to -0.86) (Figure 2.14). The effect of 
gabapentin on pain scores at two hours passed the IS required for a definitive 
answer (279 participants). On sensitivity analysis, assuming a variance of 3 
increased the required IS, which was still reached with gabapentin (488 
participants). Assuming a mean difference of 1.21 did not change the results 
(IS 407 participants). We did not perform any further sensitivity analysis with 
heterogeneity corrections due to high value already used in the analysis. 
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2.3.5 Pain scores six hours 	
Overall, there were 40 studies with 2914 participants included in the analysis. 
Gabapentin reduced pain scores at six hours (MD -1.28; 95% CI -1.57 to -0.98; 
Figure 2.15). However, this reduction was not clinically significant. There was 
evidence of considerable statistical heterogeneity (I2=93%; p<0.001). The 
quality of evidence was low according to GRADE (downgraded owing to 
concerns over risk of bias and possible publication bias). 
 
 
 
Figure 2.15 Forest plot of pain scores at six hours postoperatively. 
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Funnel plots revealed no gross asymmetry on visual inspection (Figure 2.16). 
However, Egger’s regression test was statistically significant (p=0.004). Trim 
and fill analysis showed no missing studies either side of the plot and failsafe 
N showed 25 negative studies would be required to observe a negative effect of 
the intervention. 
 
 
 
Figure 2.16 Funnel plot of gabapentin effects on pain scores at six hours. X-
axis shows the mean difference and the Y-axis shows the standard error. 
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Figure 2.17 Meta-regression plot. X-axis shows the control group pain score 
and the Y-axis the mean difference in pain score with gabapentin. 
 
On meta-regression analysis, mean pain score in the control group explained a 
large proportion of the between-study heterogeneity (R2=37%; p<0.001) 
(Figure 2.17). The addition of the covariates gabapentin dose and type of 
surgery improved the model (R2=65%; p<0.001). Diagnostics revealed three 
studies had studentised residuals of more than two although no study had a 
Cook’s distance of more than one. Histograms of residuals showed some 
positive skew. Residual plots showed no violation of the assumption of 
linearity and homoscedasticity. No covariate had a VIF of more than ten. 
 
Sensitivity analysis showed results did not change when studies where standard 
deviations were estimated were removed or removing studies that were at high 
risk of bias. One study removed sensitivity analysis showed there were no 
influential studies in the analysis. 
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Figure 2.18: Trial sequential analysis of pain score at six hours 
postoperatively. Performed assuming a mean difference of 1.5 in pain score, 
variance of 0.94, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 
94. Blue line indicates cumulative Z score with values more than zero 
indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 2.18). The results reached the required IS for a 
definitive answer (248 participants). On sensitivity analysis, increasing the 
variance to 2 increased the IS, which gabapentin reached (496 participants). 
Assuming a mean difference of -1.28 increased the required IS (336 
participants). Neither analysis changed the results obtained. We did not 
perform any further sensitivity analysis with heterogeneity corrections due to 
high value already used in the analysis. 
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2.3.6 Pain scores 12 hours 	
Overall, 60 studies with 4266 participants were included in the analysis. 
Gabapentin reduced pain scores at 12 hours (MD -1.12; 95% CI -1.33 to -0.91; 
Figure 2.19). However, this reduction was not clinically significant. There was 
evidence of considerable statistical heterogeneity (I2=86%; p<0.001). The 
quality of evidence was low according to GRADE (downgraded owing to 
concerns over risk of bias and possible publication bias). 
 
 
 
Figure 2.19 Forest plot of pain scores at 12 hours postoperatively. 
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Funnel plots showed no obvious asymmetry (Figure 2.20). However, Egger’s 
linear regression test showed statistically significant imprecise study effects 
(p=0.01). Trim and fill analysis showed 13 studies were missing from the right 
of the mean, which reduced the effect estimates (MD -0.87; 95% CI -1.07 to -
0.66). Failsafe N stated 83 negative studies would be required to observe a 
negative effect with gabapentin.  
 
 
Figure 2.20 Funnel plot of gabapentin effects on pain scores at 12 hours. X-
axis shows the mean difference and the Y-axis shows the standard error. 
 
On meta-regression analysis, the majority of the between-study heterogeneity 
was explained by type of surgery and mean control group pain score (R2=61%; 
p<0.001). Only one value had a studentised residual of more than two and no 
study had a Cook’s distance of more than one. Histograms showed residuals 
were normally distributed. Studentised residual versus predicted plots did not 
violate the assumptions of homoscedasticity or linearity. Sensitivity analysis 
showed no change in results if studies where standard deviations were 
estimated were removed or excluding studies at high risk of bias. One study 
removed sensitivity analysis showed no studies to be influential in the analysis. 
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Figure 2.21: Trial sequential analysis of pain scores at 12 hours 
postoperatively. Performed assuming a mean difference of 1.12 in pain score, 
variance of 1.46, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 
89. Blue line indicates cumulative Z score with values more than zero 
indicating benefit with gabapentin.  
 
Trial sequential analysis for a MD of 1.5 showed that inner boundaries for 
benefit and futility boundaries could not be constructed. Therefore, analysis 
was conducted for an empirical MD of 1.12 (Figure 2.21). Gabapentin crossed 
the O’Brien-Fleming boundary for benefit. In addition, the IS for a definitive 
answer was reached (323 participants). On sensitivity analysis, increasing the 
variance to 3 increased the IS, which gabapentin still reached (664 
participants). We did not perform any further sensitivity analysis with 
heterogeneity corrections due to high value already used in the analysis. 
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2.3.7 Pain scores 24 hours 	
Overall, 73 studies with 5195 participants were included in the analysis. 
Gabapentin reduced pain scores at 24 hours (MD -0.71; 95% CI -0.87 to -0.56; 
Figure 2.22). However, this reduction was not clinically significant. There was 
evidence of considerable statistical heterogeneity (I2=85%; p<0.001). The 
quality of evidence was moderate according to GRADE (downgraded owing to 
concerns over risk of bias). 
 
 
 
Figure 2.22 Forest plot of pain scores at 24 hours postoperatively. 
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There was no obvious asymmetry on visual inspection of the funnel plot 
(Figure 2.23). However, Egger’s linear regression test showed evidence of 
statistically significant imprecise study effects (p=0.05). Trim and fill analysis 
showed four studies were missing from the left of the mean, suggesting bias 
against the effect of gabapentin (adjusted MD -0.77; 95% CI -0.93 to -0.61). 
Failsafe N showed 62 studies would be required to observe a negative effect 
with gabapentin. 
 
 
 
Figure 2.23 Funnel plot of gabapentin effects on pain scores at 24 hours. X-
axis shows the mean difference and the Y-axis shows the standard error. 
 
On meta-regression analysis, a smaller proportion of the between study 
heterogeneity was explained by mean control group pain score and type of 
surgery (R2=23%; p<0.001). Only four studies had studentised residuals of 
more than two and no study had a Cook’s distance of more than one. 
Histograms of residuals showed they were approximately normally distributed. 
Residual plots did not violate the assumptions of linearity or homoscedasticity. 
No VIF value for any of the covariates exceeded ten. 
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On sensitivity analysis, removing studies where standard deviations were 
estimated or studies at high risk of bias did not change results. One study 
removed analysis showed there were no influential studies in the meta-analysis. 
 
 
Figure 2.24: Trial sequential analysis of pain scores at 24 hours 
postoperatively. Performed assuming a mean difference of 0.71, variance of 1, 
adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 88. Blue line 
indicates cumulative Z score with values more than zero indicating benefit with 
gabapentin.  
 
Trial sequential analysis could not be performed for a mean difference of 1.5. 
Using a mean difference of 0.71, gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 2.24) and reached the required IS for a definitive 
answer (530 participants). On sensitivity analysis, assuming an increased 
variance of 2 increased the IS, which gabapentin reached (1036 participants). 
We did not perform any further sensitivity analysis with heterogeneity 
corrections due to high value already used in the analysis. 
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2.3.8 Chronic pain (dichotomous) 	
Overall, nine studies with 539 participants were included in the analysis. 
Gabapentin did not affect the incidence of chronic pain, although a clinically 
significant effect could not be excluded (RR 0.85; 95% CI 0.68 to 1.06; Figure 
2.25). There was a significant reduction in one study, which reported chronic 
pain at two months (Kosucu et al. 2014). There was no evidence of statistical 
heterogeneity (I2=0%; p=0.49). The quality of evidence was moderate 
according to GRADE (downgraded owing to concerns over risk of bias). 
 
 
 
Figure 2.25 Forest plot of the incidence of chronic pain at various follow up 
times. 
 
Due to the low number of studies, tests for publication bias were not 
undertaken. Due to the lack of statistical heterogeneity and low number of 
studies, meta-regression was not undertaken. On sensitivity analysis, one 
study-removed analysis did not reveal any influential studies. Excluding 
studies at high risk of bias did not change results.   
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Figure 2.26: Trial sequential analysis of chronic post-surgical pain 
(dichotomous). Performed assuming an incidence of 35% in the control group 
(Kehlet, Jensen and Woolf 2006), RRR of 20%, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 0. Blue line indicates cumulative Z score with 
values more than zero indicating benefit with gabapentin.  
 
Trial sequential analysis showed that the effects of gabapentin on chronic pain 
did not cross any boundary for benefit (Figure 2.26) and did not reach the 
required IS for a definitive answer (1383 participants). There was too few data 
to construct boundaries for futility. On sensitivity analysis, assuming an 
incidence as low as 10% (Kehlet, Jensen and Woolf 2006), increased the 
required IS (6429 participants). Assuming a RRR of 50%, gabapentin crossed 
the boundary of futility and then reached the required IS of no benefit. 
Assuming a heterogeneity correction of 25 required a larger IS (1844 
participants). 
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2.3.9 Chronic pain one to two months 	
Overall, six studies with 405 participants were included in the analysis. 
Gabapentin did not reduce pain scores at one to two months (SMD -0.72; 95% 
CI -1.57 to 0.14; Figure 2.27), although a clinically significant effect could not 
be excluded. There was evidence of considerable statistical heterogeneity 
(I2=93%; p<0.001). The quality of evidence was moderate according to 
GRADE (downgraded owing to concerns over risk of bias). 
 
 
 
Figure 2.27: Forest plot of chronic pain scores at one to two months. 
 
Tests for publication bias were not performed due to the low numbers of 
included studies. On meta-regression analysis, between-study heterogeneity 
was not explained by gabapentin dose or type of anaesthesia. After deleting the 
one study that used an alternative pain score (Clarke et al. 2014), baseline pain 
score predicted the majority of the heterogeneity between studies (R2=84%; 
p<0.001). No study had a studentised residual of more than two. However, one 
study (Sen et al. 2009b) had a Cook’s distance of 2.8 and was therefore 
deemed to be highly influential on the model. Residual plots were not 
performed due to the low number of studies.  
 
Sensitivity analysis removing high risk of bias studies did not change results. 
One study-removed analysis did not change results. Due to the use of 
standardised mean differences to report the effect estimate, trial sequential 
analysis was not performed. 
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2.3.10 Chronic pain three months 	
Overall, eight studies with 528 participants were included in the analysis. 
Gabapentin reduced chronic pain scores at three months (SMD -0.37; 95% CI -
0.75 to 0; Figure 2.28). There was evidence of considerable statistical 
heterogeneity (I2=76%; p<0.001). The quality of evidence was low according 
to GRADE (downgraded owing to concerns over risk of bias and unexplained 
heterogeneity).  
 
 
 
Figure 2.28: Forest plot of chronic pain scores at three months 
 
Due to the low number of studies, tests for publication bias were not 
undertaken. On meta-regression analysis, after deleting the study that used a 
different pain scale (Clarke et al. 2014), no covariates were significant 
predictors of between-study heterogeneity. On sensitivity analysis, removing 
the study where standard deviations were estimated resulted in confidence 
intervals that overlapped the null effect. Removing studies at high risk of bias 
improved effect estimates in favour of gabapentin (SMD -0.56; 95% CI -0.97 
to -0.16). One study-removed analysis showed two studies to be influential 
(Sen et al. 2009a and 2009b). Due to the use of standardised mean difference 
to report the effect estimate, trial sequential analysis was not performed. 
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2.3.11 Chronic pain six and 12 months 	
Overall, three studies with 131 participants were included in the analysis of 
chronic pain at six months. No studies reported chronic pain scores at 12 
months. Gabapentin did not reduce chronic pain scores at 6 months (SMD -
0.55; 95% CI -1.21 to 0.11; Figure 2.29). There was evidence of substantial 
statistical heterogeneity (I2=70%; p=0.04). The quality of evidence was low 
according to GRADE (downgraded owing to concerns over risk of bias and 
unexplained heterogeneity). 
 
 
 
Figure 2.29: Forest plot of chronic pain scores at six months. 
 
Due to the small number of studies, exploration of publication bias and 
investigation of heterogeneity were not undertaken. Sensitivity analysis 
showed removing the one study at high risk of bias (Grosen et al. 2014), 
resulted in a significant reduction in pain scores (SMD -0.88; 95% CI -1.30 to -
0.47). Due to the use of standardised mean difference to report the effect 
estimate, trial sequential analysis was not performed. 
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2.4 Discussion 	
2.4.1 Summary of results 	
We found that gabapentin reduced opioid consumption and pain scores during 
the first 24 hours after surgery. However, the results from clinical trials thus far 
have been highly heterogeneous with morphine reductions ranging from 0-
63mg in the first 24 hours postoperatively. The efficacy of gabapentin was 
found to be largely dependent on the degree of pain and the amount of opioid 
consumed without gabapentin (baseline risk). When, on average, participants 
experienced more pain or had higher opioid consumption for the procedure 
under study, the absolute effects of gabapentin were improved. General 
anaesthesia and increases in dose also improved the efficacy of gabapentin. 
There was some evidence that type of surgery contributed to heterogeneity 
between studies, although this was less convincing than for other covariates. 
However, with regards to pain scores, only early postoperative pain scores (one 
hour) were clinically significant. For acute postoperative pain and morphine 
consumption, trial sequential analysis showed that gabapentin demonstrated 
benefit adjusted for multiple comparisons (false discovery rate) while also 
reaching the required IS for a definitive answer. 
 
There was little evidence for the effects of gabapentin on chronic pain. We 
found limited evidence of reduced chronic pain at three months when measured 
on a continuous scale and only one study found reductions in the incidence of 
chronic pain at two months. However, there was no evidence of any reductions 
at any other time point. Trial sequential analysis showed that the results 
obtained for the incidence of chronic pain (dichotomous) did not show any 
benefit, although this analysis did not reach the required IS. Therefore, further 
research is likely required for these outcomes. 
 
Imprecise study effects were evident for many outcomes, raising the possibility 
of publication bias. However, on sensitivity analysis, adjusted effect estimates 
assuming a symmetric funnel plot did not change results to a large degree, 
suggesting any potential missing studies would not substantially alter our 
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conclusions. In addition to potential publication bias, uncertainty over risk of 
bias for many studies (unclear risk on Cochrane risk of bias tool) reduced the 
quality of evidence for many outcomes.  
 
2.4.2 Links with previous research 	
Our meta-regression analysis demonstrated the main determinant of gabapentin 
efficacy related to the degree of pain experienced by the participant and not the 
type of surgery the participant underwent. For example, imagine two patients 
undergoing abdominal hysterectomy and two undergoing spinal surgery, with 
one patient undergoing one form of surgery experiencing severe postoperative 
pain and requiring large doses of morphine in the postoperative period and the 
other patient having lower pain scores and morphine requirements. The 
expected effect of gabapentin on opioid consumption would be determined by 
the patient’s pain and not by the type of surgery they had undergone. Indeed, 
despite greater reductions in opioid consumption in certain procedures, type of 
surgery was not in itself independently associated with heterogeneity between 
studies in relation to 24-hour morphine consumption. However, caution is 
advised with this example above owing to concerns over aggregation bias. 
 
This finding is consistent with previous research studies, which have shown 
larger absolute reductions in pain with higher postoperative pain scores 
(Averbuch and Katzper 2003; Bjune et al. 1996). The first study (Averbuch 
and Katzper 2003) included previous studies that had used ibuprofen in a 
dental extraction model and included 527 participants. These participants were 
divided into those with moderate (2/3) and severe pain (3/3). Pain scores were 
then taken after administration of 400mg ibuprofen. After two hours, the group 
with severe pain had greater absolute reductions in pain scores, which 
converged with the moderate group after two hours. Similar findings were 
found in the other study, which used paracetamol and codeine following 
Caesarean section (Bjune et al. 1996). Study medication was only effective in 
participants who had severe baseline pain scores (>6/10) compared to those 
with moderate pain (4-6/10). These primary studies help strengthen the 
biological basis on which we base our meta-regression model.  
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Previous groups have advocated the use of procedure-specific evidence as a 
way of limiting heterogeneity between postoperative pain trials, largely based 
on the observed differences in analgesic efficacy between different procedures 
(Espitalier et al. 2013; Gray et al. 2005). Our results suggest this difference 
may largely be due to different levels of pain/opioid consumption within 
surgical subtypes rather than the type of surgery itself. Indeed, even within 
surgical subgroups statistical heterogeneity was still considerable (data not 
shown), most of which was accounted for by the mean control group morphine 
consumption. As procedure specific meta-analyses emerge, heterogeneity still 
remains an issue (Alayed et al. 2014).  
 
Such differences in morphine consumption within certain surgical subtypes 
may be due to different procedures within a trial (Waikakul 2011), for instance 
open versus laparoscopic surgery, different procedures within surgical 
subgroups (ENT for example), variation in concurrent analgesic drugs and 
techniques, genetic variations in participants and variations in the prescribing 
practices of attending doctors and the administration practices of nursing staff. 
The lack of an association between type of surgery and 24-hour morphine 
consumption is in agreement with a recent meta-analysis of pregabalin 
(Mishriky, Waldron and Habib 2014). Similar to our review, this review 
performed meta-regression analysis on 24-hour morphine consumption and 
found the proportion of between-study heterogeneity was explained by 
pregabalin dose (R2=14%) and type of anaesthesia (R2=3%). However, type of 
surgery was not a significant predictor of pregabalin effect.  
  
The dose of gabapentin altered the analgesic effect less than the amount of 
pain. The effect of gabapentin dose was inconsistent for all outcomes, with 
dose only explaining a small proportion of the heterogeneity between studies 
(Mishriky, Waldron and Habib 2014). Some RCTs have suggested that the 
maximum effective analgesic dose of gabapentin is 600 mg or 900 mg (Khan et 
al. 2011; Pandey et al. 2005a). One dose ranging study suggested larger doses 
(Van Elstraete et al. 2008). This study used an up-and-down sequential 
allocation technique in 67 participants. They concluded that the median 
effective dose of gabapentin was 21.7mg/kg (95% CI 19.9mg/kg to 
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23.5mg/kg). This would translate into approximately 1500mg for a 70kg 
patient. Based on these studies and our meta-regression analysis, future studies 
should aim to use doses of between 600-1200mg. However, it is as yet 
unknown whether these increased dosages will translate into an increase in 
gabapentin adverse effects. This will be the subject of the meta-regression 
analysis in the next chapter.                                         
 
The statistically significant imprecise study effects indicate possible 
publication bias in favour of the analgesic effect of gabapentin (Hopewell et al. 
2009), although some analyses contradicted this expectation. The conclusions 
of meta-analyses uninformed by analyses of possible publication bias may 
overstate the effects of gabapentin. Publication bias is one reason why the 
results of meta-analyses and subsequent large RCTs disagree (Egger et al. 
1997a). However, other causes of an asymmetrical funnel plot include larger 
effects or methodological differences in smaller studies, sampling variation and 
possible fraud. Furthermore, some of our results for imprecise study effects 
showed missing studies to the left of the mean (for one and 24 hour pain 
scores), which would suggest bias against gabapentin. 
 
With regards to chronic pain, there was limited evidence of reductions at three 
months and one study, which showed a significant reduction at two months 
(Kosucu et al. 2014). There was no evidence of reductions at any other time 
points or any reductions in the overall incidence. However, TSA indicates 
further research is required before definitive conclusions can be made, 
although further analysis revealed that gabapentin is unlikely to be able to 
achieve RRR in chronic pain of 50%, as this crossed the boundary for futility. 
Our results contradict those in a previous review of gabapentin, which found 
gabapentin reduced the incidence of chronic pain (OR 0.52; 95% CI 0.27 to 
0.98) (Clarke et al. 2012). However, our results included a more contemporary 
sample of studies and did not include one study that showed a large positive 
result as it measured chronic pain at one month, which is outside of 
contemporary definitions of chronic post-surgical pain (Fassoulaki et al. 
2006a). 
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2.4.3 Limitations 	
There are several limitations with this review. Firstly, the use of meta-
regression, the analysis from which we derived our conclusions, should be 
regarded as observational in nature and is therefore prone to bias and 
confounding. Examples of bias include aggregation bias, where pain scores and 
morphine consumption averaged for a group may not represent differences at 
the participant level. This means the data we used as a surrogate for pain 
experienced by the participant may not be applicable. Despite this, there is no 
other method that can be used to estimate how much pain individual 
participants would have had if they had not been given gabapentin using 
reported measures from the included studies. Indeed, even with access to 
individual participant data, there is no way of obtaining baseline scores for 
outcomes which are measured after an intervention is administered.  
 
Examples of confounding were evident when type of surgery and type of 
anaesthesia were analysed together as we found evidence of multi-collinearity 
with VIF values exceeding ten. This makes it difficult to separate the effects of 
these covariates. Within this model, we found that gabapentin was less 
effective after spinal anaesthesia, but the cause might be the type of surgery 
(orthopaedic, caesarean section and joint arthroplasty) with which spinal 
anaesthesia was used more often. In addition, our regression model may have 
been biased as the covariate used in the analysis is also used in the calculation 
of the effect estimate (Thompson and Higgins 2002).  
 
Secondly, methodological weaknesses in the some of the included studies may 
have been responsible for statistical heterogeneity between the studies. As we 
only included clinical covariates in the model, we cannot exclude the 
possibility that such methodological deficiencies may have been responsible 
for heterogeneity. For example, smaller studies at higher risk of bias may be a 
marker for poor study conduct, which may have included less intensive 
analgesic protocols resulting in higher levels of postoperative pain. Such 
studies could have lower mean differences in morphine consumption due to 
bias in the conduct of the study rather than the higher control group morphine 
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consumption per se. Therefore, the association between mean control group 
morphine consumption would be confounded by high risk of bias in the study 
conduct. This possible confounding will be the subject of chapter six. 
 
Thirdly, we found evidence of statistically significant imprecise study effects, 
which may indicate possible publication bias. As discussed previously, such 
bias is the reason why large RCTs and meta-analyses may disagree (Egger et 
al. 1997a). Therefore, results from our analysis should be interpreted with 
caution. Finally, the risk of bias was unclear for many domains of internal 
validity in the included trials, particularly for allocation concealment, which 
may distort effect estimates in favour of gabapentin (Schulz and Grimes 
2002a). Indeed, both of these limitations reduce the strength of the evidence 
derived from our meta-analyses according to GRADE criteria (Guyatt et al. 
2008). Although we were able to explain a large proportion of the between-
study heterogeneity found in previous reviews, the limitations above limit the 
validity of the data on which our regression models are based and therefore 
should be interpreted with further caution. 
 
The design of future clinical trials should attempt to use our regression model 
to ensure the targeted use of gabapentin in clinical situations in which it will 
derive the most benefit, such as using higher doses in more painful procedures 
performed under general anaesthesia. However, such increases in doses are 
unknown in relation to increases in adverse events. With regards to clinical 
practice, although the evidence has limitations, if anaesthetists are to use 
gabapentin to reduce postoperative pain, use of our regression model could 
help more effectively target its use. Information on expected postoperative 
morphine consumption could be derived from small audit data and inform 
gabapentin use in more beneficial clinical contexts (although the limitations of 
our analyses should be considered). 
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2.4.4 Conclusion 	
In conclusion, gabapentin was an effective acute analgesic agent, with the 
absolute effect being proportionate to the mean opioid requirement or pain 
score in the control group, gabapentin dose and type of anaesthesia. However, 
the quality of the evidence was of moderate to low quality owing to concerns 
over risk of bias and possible publication bias. Further research should focus 
on chronic pain and aim to use gabapentin in situations expected to derive the 
most benefit. 
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Chapter 3 
Gabapentin adverse events and other 
postoperative effects 
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3.1 Introduction 	
In addition to pain, surgery and anaesthesia have many adverse effects. Some 
of these such as PONV are common (Cohen et al. 1994) and lead to other 
consequences such as increased costs, length of stay and patient dissatisfaction 
(Gan et al. 2003). Indeed, patients rank PONV above pain as the most feared 
outcome of surgery and anaesthesia (Macario et al. 1999). Other adverse 
events such as pruritus and urinary retention similarly can increase length of 
stay and reduces patient satisfaction, and therefore any agent capable of 
reducing these may help improve the patient experience. This chapter will 
therefore use the studies identified from the second chapter to extract data on 
the effects of gabapentin on various postoperative outcomes. Furthermore, we 
will present in this chapter use of meta-regression to investigate whether 
increases in gabapentin dose, as suggested in the conclusions of the second 
chapter, result in an increase in adverse events or whether larger doses help 
further reduce opioid side effects. We also aim to investigate whether 
reductions in opioid adverse events were dependent on the degree of morphine 
reduction achieved in the study. 
3.2 Methods 	
The methods used for the data collection in this chapter are identical to those 
used in chapter two (Section 2.2). We did not consider data from observational 
studies, which may be a more appropriate methodology to assess adverse 
events. Changes for this chapter of the thesis include limiting meta-regression 
analysis to gabapentin dose in order to identify any dose-response reductions in 
opioid adverse events or increases in gabapentin side effects. Furthermore, for 
opioid side effects where more than twenty studies were included, we used 
opioid reduction as a covariate to test if reductions in opioid adverse events 
were dependent on the degree of opioid reduction in the individual study. For 
pre-operative anxiety, baseline anxiety (mean anxiety level in the placebo 
group) was used as a covariate (baseline risk). We regarded clinically 
significant reductions in events as a RRR of 20%. 
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3.3 Results 	
3.3.1 Characteristics of included studies 	
The characteristics of the included studies are listed in Table 2.1. We included 
only studies that reported the outcomes described. There was clinical 
heterogeneity in the time point at which outcomes were measured. 
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3.3.2 Nausea 	
Overall, 58 studies with 4062 participants were included in the analysis. 
Gabapentin resulted in clinically significant reductions in the risk of 
postoperative nausea (RR 0.78; 95% CI 0.69 to 0.87; Figure 3.1). There was 
evidence of moderate statistical heterogeneity (I2=27%; p=0.03). The NNT to 
prevent one episode of nausea was 11 (95% CI 8.1 to 15). The quality of 
evidence was very low according to GRADE (downgraded owing to concerns 
over risk of bias, unexplained heterogeneity and possible publication bias).   
 
 
 
Figure 3.1: Forest plot for the risk of postoperative nausea. 
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Figure 3.2: Funnel plot of gabapentin effects on postoperative nausea. X-axis 
shows the log risk ratio and the Y-axis shows the standard error of the log risk 
ratio. 
 
Visual inspection of the funnel plot demonstrated little asymmetry (Figure 3.2). 
Egger’s linear regression test was statistically significant indicating possible 
publication bias (p=0.05). Trim and fill analysis revealed no studies were 
missing from either side of the mean. Failsafe N showed eight negative studies 
would be required to observe a negative effect with gabapentin. On meta-
regression analysis, neither dose (R2=0%; p=0.82) nor degree of morphine 
reduction (R2=0%; p=0.90) accounted for any of the between-study 
heterogeneity. On sensitivity analysis, excluding high risk of bias studies gave 
similar results. One study-removed analysis identified no influential studies. 
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Figure 3.3: Trial sequential analysis of postoperative nausea. Performed 
assuming an incidence of 30% in the control group, RRR of 20%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 43. Blue line indicates 
cumulative Z score with values more than zero indicating benefit with 
gabapentin.  
 
Trial sequential analysis showed that the analysis for nausea reached the 
required IS (3009 participants) for a definitive answer (Figure 3.3). The 
cumulative Z score also passed the O’Brien-Fleming monitoring boundaries 
(adjusted CI 0.69 to 0.87) and avoided the area of futility. Assuming an 
incidence as low as 10%, gabapentin crossed the boundary for benefit although 
did not meet the required IS of 11256 participants. Gabapentin did not pass the 
boundary for a 50% RRR. Assuming a heterogeneity correction of 75, the 
results did not reach the required IS. 
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3.3.3 Vomiting 	
Overall, there were 57 studies with 3880 participants included in the analysis. 
Gabapentin resulted in a clinically significant reduction in the risk of 
postoperative vomiting (RR 0.67; 95% CI 0.59 to 0.76; Figure 3.4). There was 
no evidence of statistical heterogeneity (I2=3%; p=0.42). The NNT to prevent 
one episode of vomiting was 10 (95% 7.5 to 12.1). The quality of the evidence 
was low according to GRADE (downgraded owing to concerns over risk of 
bias and possible publication bias). 
 
 
 
Figure 3.4: Forest plot for the risk of postoperative vomiting. 
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Figure 3.5: Funnel plot of gabapentin effects on postoperative vomiting. X-
axis shows the log risk ratio and the Y-axis shows the standard error of the log 
risk ratio. 
 
Visual inspection of funnel plots revealed some asymmetry (Figure 3.5). 
Indeed, this reflected in a statistically significant Egger’s linear regression test 
(p=0.05). Trim and fill analysis indicated five studies were missing from the 
right of the plot although the addition of these studies did not affect results (RR 
0.68; 95% CI 0.59 to 0.78). Failsafe N showed 21 negative studies would be 
required to observe a negative effect with gabapentin. On meta-regression 
analysis, neither dose (R2=0%; p=0.32) nor morphine reduction (R2=0%; 
p=0.81) explained the heterogeneity between studies. On sensitivity analysis, 
excluding high risk of bias trials did not affect results. One study-removed 
analysis revealed no influential studies. 
 
	 139	
 
Figure 3.6: Trial sequential analysis of postoperative vomiting. Performed 
assuming an incidence of 25% in the control group (Cohen et al. 1994), RRR 
of 20%, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 3.6. Blue 
line indicates cumulative Z score with values more than zero indicating benefit 
with gabapentin.  
 
Trial sequential analysis showed that the included trials passed both the 
O’Brien-Fleming monitoring boundaries (adjusted CI 0.58 to 0.77; p<0.001) 
and passed the required IS for a definitive answer (2273 participants) while 
avoiding the boundaries of futility (Figure 3.6). However, the results did not 
cross the boundary for benefit when assuming a 50% RRR. Assuming an 
incidence of vomiting as low as 10%, gabapentin passed the monitoring 
boundary but did not reach the required IS. Assuming a heterogeneity 
correction of 25, this did not change the results.    
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3.3.4 Pruritus 	
Overall, 29 studies with 2248 participants were included in the meta-analysis. 
Gabapentin resulted in clinically significant reductions in the incidence of 
postoperative pruritus (RR 0.64; 95% CI 0.51 to 0.80; Figure 3.7). There was 
evidence of moderate statistical heterogeneity (I2=51%; p=0.001). The NNT to 
prevent one episode of pruritus was 12 (95% CI 8.2 to 19.4). The quality of 
evidence was very low according to GRADE (downgraded owing to concerns 
over risk of bias, unexplained heterogeneity and possible publication bias). 
 
 
 
Figure 3.7: Forest plot for the risk of postoperative pruritus. 
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Figure 3.8: Funnel plot of gabapentin effects on postoperative pruritus. X-axis 
shows the log risk ratio and the Y-axis shows the standard error of the log risk 
ratio. 
 
The funnel plot showed some evidence of asymmetry and the result from 
Egger’s linear regression test was statistically significant (Figure 3.8; p=0.002). 
Trim and fill analysis showed 11 studies were missing from the right of the 
plot. Including these missing studies reduced the efficacy of gabapentin on 
postoperative pruritus, although the result remained clinically significant (RR 
0.80; 95% CI 0.63 to 1.03). Failsafe N stated 10 negative studies would be 
required to observe a negative effect with gabapentin. On meta-regression 
analysis, neither dose (R2=0%; p=0.75) nor morphine reduction (R2=4%; 
p=0.28) explained between-study heterogeneity. On sensitivity analysis, 
removing studies at high risk of bias did not affect results. One study-removed 
analysis revealed no influential studies. 
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Figure 3.9: Trial sequential analysis of postoperative pruritus. Performed 
assuming an incidence of 30% in the control group, RRR of 20%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 77. Blue line indicates 
cumulative Z score with values more than zero indicating benefit with 
gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
monitoring boundary (adjusted 95% CI 0.42 to 0.88) and did not cross the 
boundary for futility (Figure 3.9). However, gabapentin failed to reach the 
required IS for a definitive answer (7436 participants). Assuming an incidence 
of 10%, gabapentin did not reach either the boundary for benefit or the 
required IS. Gabapentin did not reach the boundary for benefit assuming a 
RRR of 50%. 
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3.3.5 Pre-operative anxiety  	
For pre-operative anxiety, eight studies with 527 participants were included in 
the analysis. As different scales were used, this outcome was analysed using 
SMD. Gabapentin reduced pre-operative anxiety (SMD -0.84; 95% CI -1.2 to -
0.48; Figure 3.10). There was evidence of substantial statistical heterogeneity 
(I2=74%; p<0.001). The quality of evidence was moderate (downgraded owing 
to concerns over risk of bias). 
 
 
 
Figure 3.10: Forest plot of gabapentin effects on pre-operative anxiety. 
Reported as SMD due to the different scales used in the studies. 
 
Tests for publication bias were not conducted due to the low number of 
included studies. On meta-regression analysis, baseline anxiety score in the 
control group predicted a large proportion of the between-study heterogeneity 
(R2=35%; p=0.02) (Figure 3.11). Dose was not a significant predictor of pre-
operative anxiety (R2=0%; p=0.52). In terms of diagnostics, histograms 
showed residuals within the model were normally distributed. One studentised 
residual was more than two (Menigaux et al. 2005). Due to the small number 
of studies, homoscedasticity and linearity were not assessed. No data point had 
a Cook’s distance of more than one. We were unable to perform trial sequential 
analysis, as SMD was used for the effect estimate. On sensitivity analysis, 
excluding the one high risk of bias trial (Tirault et al. 2010) did not affect 
results. One study-removed analysis did not identify any influential studies. 
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Figure 3.11: Meta-regression plot. X-axis shows the mean control group 
anxiety score and the Y-axis the standardised mean difference in anxiety with 
gabapentin. 
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3.3.6 Sedation 	
Overall, 52 studies with 4112 participants were included in the analysis. 
Gabapentin increased the risk of postoperative sedation (RR 1.18; 95% CI 1.09 
to 1.28; Figure 3.12). There was evidence of some statistical heterogeneity 
(I2=28%; p=0.03). The NNH for one episode of sedation was 13 (95% CI 9 to 
18.2). The quality of evidence was very low according to GRADE 
(downgraded owing to concerns over risk of bias, possible publication bias and 
unexplained heterogeneity).  
 
 
 
Figure 3.12: Forest plot of gabapentin effects on the incidence of 
postoperative sedation. 
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Figure 3.13: Funnel plot of gabapentin effects on postoperative sedation. X-
axis shows the log risk ratio (with data points to the right indicating an increase 
in sedation) and the Y-axis shows the standard error of log risk ratio. 
 
Visual inspection of the funnel plot showed asymmetry, with more studies on 
the right of the plot (Figure 3.13). Egger’s linear regression test was 
statistically significant (p<0.001). Trim and fill analysis showed there were 19 
studies missing from the left of the plot, which adjusted the risk closer to the 
null effect (RR 1.12; 95% CI 1.01 to 1.25). Failsafe N indicated five negative 
studies would be required to observe no effect with gabapentin on sedation. On 
meta-regression analysis, dose did not predict the incidence of postoperative 
sedation (R2=0%; p=0.94). On sensitivity analysis, removing studies at high 
risk of bias did not affect results. One study-removed analysis revealed no 
influential studies. 
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Figure 3.14: Trial sequential analysis of postoperative sedation. Performed 
assuming an incidence of 25% in the control group, relative risk increase of 
20%, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 74. Blue 
line indicates cumulative Z score with values less than 0 indicating harm with 
gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
monitoring boundary for harm and avoided the area for futility (adjusted 95% 
CI 1.04 to 1.32) (Figure 3.14). However, gabapentin did not reach the required 
IS for a definitive answer (9704 participants). Gabapentin did not cross any 
boundary for harm assuming an incidence as low as 10%. Furthermore, 
gabapentin did not pass the boundary for a relative increase in sedation of 50%. 
We did not perform sensitivity analysis around the heterogeneity correction 
due to the high number already included in the analysis. 
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3.3.7 Confusion 	
Overall, three studies with 184 participants were included in the analysis. 
Confidence intervals suggested a possible reduction in the incidence of 
postoperative confusion with gabapentin, however this was not statistically 
significant (RR 0.50; 95% CI 0.19 to 1.34; Figure 3.15). There was no 
evidence of statistical heterogeneity (I2=0%; p=0.52). There were too few 
studies in the analysis to assess publication bias or perform meta-regression 
analysis. The quality of evidence was low according to GRADE (downgraded 
owing to concerns over risk of bias and imprecision of effect estimates). On 
sensitivity analysis, only one study remained when excluding high risk of bias 
trials (Siddiqui et al. 2014), which also resulted in no reduction in 
postoperative confusion. One study-removed analysis revealed no influential 
studies in the analysis.  
 
 
 
Figure 3.15: Forest plot of gabapentin effects on the incidence of 
postoperative sedation. 
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Figure 3.16: Trial sequential analysis of postoperative confusion. Performed 
assuming an incidence of 10% in the control group, RRR of 50%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin failed to reach the boundary 
for benefit and did not reach the required IS (872 participants) (Figure 3.16). 
Following publication of the first study with a small number of participants 
(21) (Leung et al. 2006), meta-analyses would have falsely concluded that 
gabapentin was effective. However, subsequent publications have concluded 
that overall results demonstrate no clear benefit.  
 
 
 
 
 
 
 
	 150	
3.3.8 Constipation 	
Overall, 10 studies with 565 participants were included in the analysis. There 
was no significant reduction in the incidence of postoperative constipation with 
gabapentin (RR 0.80; 95% CI 0.44 to 1.44; Figure 3.17). There was no 
evidence of statistical heterogeneity (I2=0%; p=0.81). The quality of the 
evidence was moderate according to GRADE (downgraded owing to concerns 
over risk of bias).  
 
 
Figure 3.17: Forest plot of gabapentin on the incidence of postoperative 
constipation. 
 
There was no evidence of publication bias on either visual inspection of the 
funnel plot (Figure 3.18) or on Egger’s linear regression test (p=0.18). On 
meta-regression, dose did not predict the incidence of constipation (R2=0%; 
p=0.84). On sensitivity analysis, removing studies at high risk of bias did not 
affect results. One study-removed analysis showed no influential studies in the 
analysis. 
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Figure 3.18: Funnel plot of gabapentin effects on postoperative constipation. 
X-axis shows the log risk ratio and the Y-axis shows the standard error of log 
risk ratio. 
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Figure 3.19: Trial sequential analysis of postoperative constipation. Performed 
assuming an incidence of 10% in the control group, RRR of 50%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin did not pass any boundary for 
benefit assuming an incidence of 10% and a RRR of 20%. However, assuming 
an incidence of 10% and a RRR of 50%, gabapentin crossed the boundary for 
futility (Figure 3.19). None of the analyses reached the required IS for a 
definitive answer.  
 
 
 
 
 
 
 
 
	 153	
3.3.9 Dizziness 	
Overall, 51 studies with 3746 participants were included in the analysis. 
Gabapentin did not increase the risk of postoperative dizziness (RR 1.04; 95% 
CI 0.94 to 1.15; Figure 3.20). There was no evidence of statistical 
heterogeneity (I2=0%; p=0.91). The quality of evidence was moderate 
according to GRADE (downgraded owing to concerns over risk of bias). 
 
 
 
Figure 3.20: Forest plot of gabapentin on the incidence of postoperative 
dizziness. 
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Figure 3.21: Funnel plot of gabapentin on the incidence of postoperative 
dizziness. X-axis shows the log risk ratio and the Y-axis shows the standard 
error of log risk ratio. 
 
There was evidence of funnel plot asymmetry (Figure 3.21) and Egger’s linear 
regression test was statistically significant (p<0.001). Trim and fill analysis 
showed 11 missing studies were to the left of the mean, which demonstrated a 
bias against gabapentin for this outcome (adjusted RR 1.00; 95% CI 0.91 to 
1.11). Failsafe N was not conducted, as the original results were not 
statistically significant. On meta-regression analysis, gabapentin dose did not 
predict the incidence of postoperative dizziness (R2=0%; p=0.16). On 
sensitivity analysis, removing studies at high risk of bias did not affect results. 
One study-removed analysis showed there were no influential studies. 
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Figure 3.22: Trial sequential analysis of postoperative dizziness. Performed 
assuming an incidence of 20% in the control group, relative risk increase of 
20%, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line 
indicates cumulative Z score with values less than 0 indicating harm with 
gabapentin.  
 
Trial sequential analysis showed that gabapentin reached the required IS for a 
definitive answer (3368 participants) (Figure 3.22). Gabapentin entered the 
area of futility and subsequently did not reach the monitoring boundary for 
harm. Following the publication of one study (Gilron et al. 2009), the effects of 
gabapentin crossed the conventional boundary for harm (unadjusted p<0.05). 
However, this effect subsequently returned to no harm. On sensitivity analysis, 
assuming a heterogeneity correction of 25, gabapentin did not reach the 
required IS. Gabapentin did not cross the boundary for a 50% increase in 
dizziness. Assuming an incidence as low as 10%, gabapentin crossed the 
boundary of futility without reaching the required IS. 
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3.3.10 Headache 	
Overall, 24 studies with 1710 participants were included in the analysis. There 
was no difference in the incidence of headache between the groups (RR 1.05; 
95% CI 0.82 to 1.33; Figure 3.23). There was no evidence of statistical 
heterogeneity (I2=8%; p=0.35). The quality of evidence was moderate 
according to GRADE (downgraded owing to concerns over risk of bias). 
 
  
 
Figure 3.23: Forest plot of gabapentin effects on the incidence of 
postoperative headache. 
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There was no evidence of an asymmetric funnel plot (Figure 3.24) and Egger’s 
linear regression test was not statistically significant (p=0.38). On meta-
regression analysis, dose did not predict the incidence of postoperative 
headache (R2=0%; p=0.84). On sensitivity analysis, removing studies at high 
risk of bias did not affect the results. One study-removed analysis showed there 
were no influential studies in the analysis. 
 
 
 
Figure 3.24: Funnel plot of gabapentin effects on postoperative headache. X-
axis shows the log risk ratio and the Y-axis shows the standard error of log risk 
ratio. 
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Figure 3.25: Trial sequential analysis of postoperative headache. Performed 
assuming an incidence of 15% in the control group, relative risk increase of 
20%, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 4. Blue line 
indicates cumulative Z score with values less than 0 indicating harm with 
gabapentin.  
 
Trial sequential analysis shows that gabapentin crossed the boundary of futility 
for harm (Figure 3.25). Gabapentin did not reach the required IS for a 
definitive answer (5022 participants). On sensitivity analysis, assuming an 
incidence of 10% and a relative risk increase of 20%, no futility boundaries 
could be constructed, although the results did not pass any boundary for harm. 
For an incidence of 15% and relative risk increase of 50%, gabapentin did not 
reach the boundary for harm. Assuming a heterogeneity correction of 25 
increased the required IS (5432 participants). 
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3.3.11 Patient satisfaction 	
Overall, eight studies with 454 participants were included in the analysis. 
Gabapentin resulted in an increase in patient satisfaction (SMD 0.59; 95% CI 
0.18 to 1.00; Figure 3.26). Results are reported as SMD due to different scales 
used. There was evidence of considerable statistical heterogeneity (I2=77%; 
p<0.001). The quality of evidence was moderate according to GRADE 
(downgraded owing to concerns over risk of bias). Due to the low number of 
studies, tests for publication bias were not undertaken. 
 
 
 
Figure 3.26: Forest plot of gabapentin effects on patient satisfaction. 
 
On meta-regression analysis, there was some evidence that increases in dose 
predicted increases in patient satisfaction (R2=19%; p=0.07) (Figure 3.27). On 
diagnostics, there were no studentised residuals with a value of more than two 
and no study had a Cook’s distance of more than one. Histograms showed 
residuals to be normally distributed. Homoscedasticity and linearity were 
difficult to assess due to the low number of data points. Due to the use of SMD 
for this outcome, TSA could not be performed. Sensitivity analysis showed that 
removing studies at high risk of bias or those where standard deviations were 
estimated did not affect results. One study-removed analysis showed there 
were no influential studies in the analysis. 
	 160	
 
 
Figure 3.27: Meta-regression plot. X-axis shows gabapentin dose (mg) and the 
Y-axis the standardised mean difference in patient satisfaction scores. 
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3.3.12 Respiratory depression 	
Overall, there were seven studies with 801 participants included in the analysis. 
There was no difference in the incidence of postoperative respiratory 
depression with gabapentin (RR 1.08; 95% CI 0.51 to 2.29; Figure 3.28). There 
was no evidence of statistical heterogeneity (I2=0%; p=0.71). The quality of 
the evidence was moderate according to GRADE (downgraded owing to 
concerns with risk of bias). 
 
 
 
Figure 3.28: Forest plot of gabapentin effect on respiratory depression. 
 
Due to the low number of studies, tests for publication bias were not 
conducted. On meta-regression analysis, dose did not predict the effect of 
gabapentin on respiratory depression (R2=0%; p=0.28). On sensitivity analysis, 
excluding studies at high risk of bias did not affect results. One study-removed 
analysis showed there were no influential studies. 
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Figure 3.29: Trial sequential analysis of postoperative respiratory depression. 
Performed assuming an incidence of 3% in the control group, relative risk 
increase of 50%, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 
0. Blue line indicates cumulative Z score with values less than 0 indicating 
harm with gabapentin.  
 
Trial sequential analysis showed that the effects of gabapentin on respiratory 
depression crossed the boundary for futility (Figure 3.29). However, this effect 
did not reach the required IS (1500 participants). There was too few 
information to perform sensitivity analysis using a relative risk difference of 
20% or an incidence as low as 1% with a 50% relative risk difference. 
Assuming a heterogeneity correction of 25, this increased the required IS (4092 
participants). 
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3.3.13 Urinary retention 	
Overall, 14 studies with 888 participants were included in the analysis. 
Gabapentin did not reduce the incidence of postoperative urinary retention, 
although confidence intervals suggested a possible effect (RR 0.64; 95% CI 
0.40 to 1.04; Figure 3.30). There was no evidence of statistical heterogeneity 
(I2=0%; p=0.60). The quality of the evidence was low according to GRADE 
(downgraded owing to concerns over risk of bias and imprecision in results). 
 
 
 
Figure 3.30: Forest plot of the effects of gabapentin on the incidence of 
urinary retention. 
 
Visual inspection of the funnel plot revealed no asymmetry (Figure 3.31) and 
Egger’s linear regression test was not significant (p=0.21). On meta-regression 
analysis, dose did not predict the incidence of postoperative urinary retention 
(R2=0%; p=0.37). On sensitivity analysis, removing studies at high risk of bias 
resulted in a reduction in the incidence of urinary retention (RR 0.60; 95% CI 
0.36 to 1.00). One study-removed analysis showed there were two influential 
studies in the analysis (Radhakrishnan et al. 2005; Waikakul 2011), which 
when removed resulted in reductions in urinary retention. 
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Figure 3.31: Funnel plot of gabapentin effects on the incidence of 
postoperative urinary retention. X-axis shows the log risk ratio and the Y-axis 
shows the standard error of log risk ratio. 
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Figure 3.32: Trial sequential analysis of postoperative urinary retention. 
Performed assuming an incidence of 10% in the control group, RRR of 50%, 
adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line 
indicates cumulative Z score with values more than 0 indicating benefit with 
gabapentin.  
 
Trial sequential analysis showed gabapentin demonstrated benefit using 
conventional boundaries following the publication of one trial (Turan et al. 
2004a). However, publication of subsequent trials reduced this effect (Figure 
3.32). Gabapentin results reached the required IS for a 50% RRR (872 
participants) and did not cross the boundary for benefit. On sensitivity analysis, 
assuming a 20% RRR, the effects of gabapentin did not reach the required IS 
(6429 participants) or cross any boundary for benefit or futility. Assuming a 
heterogeneity correction of 25 or an incidence as low as 5%, gabapentin did 
not reach the required IS or area of futility.  
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3.3.14 Visual disturbance 	
Overall, four studies with 348 participants were included in the analysis. 
Gabapentin did not increase the incidence of postoperative visual disturbance 
(RR 1.36; 95% CI 0.77 to 2.40; Figure 3.33). There was no evidence of 
statistical heterogeneity (I2=0%; p=0.89). Due to the low number of studies, 
tests for publication bias or investigation of heterogeneity were not undertaken. 
The quality of the evidence was low according to GRADE (downgraded owing 
to concerns over risk of bias and imprecision of results). On sensitivity 
analysis, removing studies at high risk of bias did not affect results. One study-
removed analysis showed there were no influential studies. 
 
 
 
Figure 3.33: Forest plot of the effects of gabapentin on the incidence of visual 
disturbance. 
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Figure 3.34: Trial sequential analysis of postoperative visual disturbance. 
Performed assuming an incidence of 10% in the control group, relative risk 
increase of 50%, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 
0. Blue line indicates cumulative Z score with values less than 0 indicating 
harm with gabapentin.  
 
Trial sequential analysis showed gabapentin did not cross any boundary for 
harm assuming a 50% increase in visual disturbance (Figure 3.34). Gabapentin 
did not reach the required IS for a definitive answer (1374 participants). On 
sensitivity analysis, assuming a relative risk increase of 20%, a heterogeneity 
correction of 25 or an incidence as low as 5% did not change the results.   
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3.3.15 Ataxia 	
Only one study reported the incidence of postoperative ataxia (Adam et al. 
2006). There was no difference between the groups (RR 1.08; 95% CI 0.74 to 
1.56). As only one study was identified, no analyses for publication bias, 
investigation of heterogeneity or TSA were performed. 
 
3.3.16 Fatigue 	
Overall, eight studies with 527 participants were included in the analysis. 
There was no difference in the incidence of postoperative fatigue between the 
groups (RR 0.88; 95% CI 0.65 to 1.19; Figure 3.35). There was evidence of 
moderate statistical heterogeneity (I2=46%; p=0.08). The quality of evidence 
was low according to GRADE (downgraded owing to concerns over risk of 
bias and unexplained heterogeneity).   
 
 
 
Figure 3.35: Forest plot of the effects of gabapentin on the incidence of 
postoperative fatigue. 
 
Due to the low number of studies, tests for publication bias were not 
undertaken. On meta-regression analysis, gabapentin dose did not predict the 
incidence of postoperative fatigue (R2=0%; p=0.61). On sensitivity analysis, 
removing studies at high risk of bias did not affect results. One study-removed 
analysis showed there were no influential studies. 
 
 
 
	 169	
 
Figure 3.36: Trial sequential analysis of postoperative fatigue. Performed 
assuming an incidence of 35% in the control group, RRR of 20%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 84. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed the results for gabapentin on the incidence of 
fatigue did not cross any boundary for benefit or harm (Figure 3.36). 
Gabapentin did not reach the required IS for a definitive answer (8752 
participants). On sensitivity analysis, similar results were obtained assuming a 
RRR of 50% and an incidence as low as 10%. Sensitivity analysis around 
estimates of heterogeneity corrections were not performed due to the high 
value already used in the analysis. 
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3.3.17 Catheter-related bladder discomfort 	
Overall, two studies with 208 participants were included in the analysis. 
Although there was no statistically significant reduction with gabapentin, the 
confidence intervals suggested a possible decrease in the incidence of catheter-
related bladder discomfort (RR 0.22; 95% CI 0.02 to 1.96; Figure 3.37). 
Furthermore, individually, each study showed a significant reduction. There 
was evidence of considerable statistical heterogeneity (I2=93%; p<0.001). Due 
to the low number of studies, analyses for publication bias or investigation of 
heterogeneity were not conducted. The quality of the evidence was very low 
according to GRADE (downgraded owing to concerns over risk of bias, 
unexplained heterogeneity and imprecision of results). No studies were 
removed on sensitivity analysis of high risk of bias studies. Removal of each 
study resulted in significant reductions on both analyses.  
 
 
 
Figure 3.37: Forest plot of the effects of gabapentin on the incidence of 
catheter-related bladder discomfort. 
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Figure 3.38: Trial sequential analysis of the effects of gabapentin on 
postoperative catheter-related bladder discomfort. Performed assuming an 
incidence of 75% in the control group, RRR of 50%, adjusted α=0.05, 1-
β=0.80 and a heterogeneity correction of 98. Blue line indicates cumulative Z 
score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential could not be performed for a RRR of 20% due to too little 
information. When analysing using a RRR of 50% (Figure 3.38), the effects of 
gabapentin crossed the conventional boundary for significance following the 
publication of the first trial (Agarwal et al. 2007), which subsequently returned 
to the area of no effect on the publication of the second trial. The analysis for 
gabapentin did not reach the required IS (3147 participants). On sensitivity 
analysis, similar results were obtained assuming an incidence as low as 50%. 
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3.3.18 Anti-emetic requirement 	
Overall, there were 22 studies with 1863 participants included in the analysis. 
Gabapentin reduced the number of participants requiring anti-emetics (RR 
0.64; 95% CI 0.53 to 0.76; Figure 3.39). There was evidence of moderate 
statistical heterogeneity (I2=36%; p=0.05). The NNT to prevent one patient 
requiring an anti-emetic was 7 (95% CI 4.9 to 8.4). The quality of evidence 
was moderate according to GRADE (downgraded owing to concerns over risk 
of bias).  
 
 
 
Figure 3.39: Forest plot of the effect of gabapentin on the incidence of patients 
requiring anti-emetics. 
 
There was evidence of funnel plot asymmetry (Figure 3.40). However, Egger’s 
linear regression test was not significant (p=0.15). Therefore, further analyses 
for publication bias were not performed.  
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Figure 3.40: Funnel plot of gabapentin effects on the incidence of patients 
requiring anti-emetics. X-axis shows the log risk ratio and the Y-axis shows the 
standard error of log risk ratio. 
 
Paradoxically, on meta-regression analysis, increasing gabapentin doses 
predicted more patients requiring anti-emetic treatment (R2=66%; p=0.008) 
(Figure 3.41). On regression diagnostics, only one study had a studentised 
residual of more than two and no study had a Cook’s distance of more than 
one. Residuals were normally distributed on histograms and plots for 
homoscedasticity and linearity showed no violations of these assumptions. On 
sensitivity analysis, removing studies at high risk of bias did not affect the 
results. One study-removed analysis showed there were no influential studies. 
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Figure 3.41: Meta-regression plot. X-axis shows gabapentin dose (mg) and the 
Y-axis the log risk ratio of patients requiring anti-emetic treatment. 
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Figure 3.42: Trial sequential analysis of postoperative patients requiring anti-
emetics. Performed assuming an incidence of 40% in the control group, RRR 
of 20%, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 44. Blue 
line indicates cumulative Z score with values more than 0 indicating benefit 
with gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the monitoring 
boundary for benefit (adjusted CI 0.52 to 0.76) (Figure 3.42). However, 
gabapentin did not reach the required IS for a definitive answer (2002 
participants). On sensitivity analysis, similar results were found assuming an 
incidence as low as 20%. Gabapentin did not cross the boundary for benefit 
assuming a 50% RRR.  
 
 
 
 
 
 
	 176	
3.3.19 Emergence agitation 	
One study reported emergence agitation (Azemati et al. 2013). It found a 
reduction with gabapentin (RR 0.33; 95% CI 0.13 to 0.85).  
 
3.3.20 Postoperative shivering 	
Overall, three studies with 174 participants were included in the analysis. 
Gabapentin reduced the incidence of postoperative shivering (RR 0.38; 95% CI 
0.17 to 0.86; Figure 3.43). The NNT to prevent one episode of postoperative 
shivering was 8 (95% CI 4.1 to 29.4). There was no evidence of statistical 
heterogeneity (I2=0%; p=0.70). Due to the low number of studies no 
investigations for publication bias or heterogeneity were undertaken. The 
quality of evidence was moderate according to GRADE (downgraded owing to 
concerns over risk of bias). On sensitivity analysis, removing studies at high 
risk of bias resulted in the confidence interval crossing the line of null effect. 
One study-removed analysis showed that two studies (Ozgencil et al. 2011; 
Rapchuk et al. 2010) were influential and their removal caused the confidence 
interval to cross the line of no effect. 
 
 
 
Figure 3.43: Forest plot of the effects of gabapentin on the incidence of 
postoperative shivering. 
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Figure 3.44: Trial sequential analysis of postoperative shivering. Performed 
assuming an incidence of 20% in the control group, RRR of 20%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that although gabapentin crossed the 
conventional boundary for statistical significance (Figure 3.44), it did not cross 
the adjusted O’Brien-Fleming boundary. Furthermore, the results for 
gabapentin did not reach the required IS for a definitive answer (2897 
participants). On sensitivity analysis, similar results were obtained assuming an 
incidence of 10%, a heterogeneity correction of 25 and a RRR of 50%.  
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3.3.21 Vertigo 	
Overall, three studies with 566 participants reported the incidence of 
postoperative vertigo. There was no difference between the groups (RR 0.69; 
95% CI 0.13 to 3.74; Figure 3.45). There was evidence of substantial statistical 
heterogeneity (I2=62%; p=0.07). Due to the low number of included studies, 
analyses for publication bias or heterogeneity were not undertaken. The quality 
of evidence was very low according to GRADE (downgraded owing to 
concerns over risk of bias, unexplained heterogeneity and imprecision of 
results). On sensitivity analysis, no studies were at high risk of bias. One study-
removed analysis showed no influential studies. 
 
 
 
Figure 3.45: Forest plot of the effects of gabapentin on the incidence of 
postoperative vertigo. 
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Figure 3.46: Trial sequential analysis of postoperative vertigo. Performed 
assuming an incidence of 5% in the control group, RRR of 50%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 70. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that after the publication of the first trial 
(Pandey et al. 2004b), gabapentin crossed the conventional boundary for 
benefit (p<0.05). However, subsequent trials resulted in no benefit with 
gabapentin (Figure 3.46). Gabapentin did not reach the required IS for a 
definitive answer (5950 participants). On sensitivity analysis, similar results 
were obtained assuming a 20% RRR or an incidence as low as 1%. Sensitivity 
analysis around heterogeneity corrections was not performed due to the high 
value already in the analysis. 
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3.3.22 Time to mobilise (hours) 	
Overall, four studies with 174 participants were included in the analysis. 
Gabapentin reduced the time to first mobilisation (MD -5.02 hours; 95% CI -
10.02 hours to -0.02 hours; Figure 3.47). There was evidence of considerable 
statistical heterogeneity (I2=95%; p<0.001). Due to the low number of studies, 
further analyses for publication bias or heterogeneity were not undertaken. The 
quality of evidence was low according to GRADE (downgraded owing to 
concerns over risk of bias and unexplained heterogeneity). On sensitivity 
analysis, there were no high risk of bias trials. One study-removed analysis 
showed that removing three studies resulted in the confidence interval crossing 
the line of null effect (Frouzanfard et al. 2013; Sen et al. 2009a; Turan et al. 
2006a). However, removing one study (Zaldivar Ramirez 2011) resulted in 
more precise confidence intervals (MD -2.38 hours; 95% CI -3.56 hours to -
1.21 hours). 
 
 
 
Figure 3.47: Forest plot of the effects of gabapentin on the time to mobilise 
(hours). 
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Figure 3.48: Trial sequential analysis of time to mobilise (hours). Performed 
assuming a clinically significant reduction of 6 hours, variance of 12.8, 
adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 95. Blue line 
indicates cumulative Z score with values more than 0 indicating benefit with 
gabapentin.  
 
Trial sequential analysis showed that gabapentin resulted in a significant 
decrease in time to mobilise using conventional boundaries (Figure 3.48). 
However, gabapentin did not cross the O’Brien-Fleming boundary or reach the 
required IS (266 participants). On sensitivity analysis, using the reported mean 
difference did not change results (IS 355 participants). Doubling the variance 
(to 25 hours) resulted in an increased IS requirement (488 participants).  
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3.3.23 Dry mouth 	
Overall, nine studies with 561 participants were included in the analysis. There 
was no difference between the groups in the incidence of dry mouth (RR 1.00; 
95% CI 0.95 to 1.06; Figure 3.49). There was no evidence of statistical 
heterogeneity (I2=0%; p=0.58). The quality of the evidence was moderate 
according to GRADE (downgraded owing to concerns over risk of bias). 
 
 
 
Figure 3.49: Forest plot of the effects of gabapentin on the incidence of 
postoperative dry mouth. 
 
Due to the low number of studies, tests for publication bias were not 
conducted. On meta-regression analysis, dose did not predict the incidence of 
dry mouth (R2=0%; p=0.66). On sensitivity analysis, removing studies at high 
risk of bias did not affect results. One study-removed analysis revealed no 
influential studies. 
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Figure 3.50: Trial sequential analysis of postoperative dry mouth. Performed 
assuming an incidence of 35%, a relative risk increase of 20%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line indicates 
cumulative Z score with values less than 0 indicating harm with gabapentin.  
 
Trial sequential analysis found that the effects of gabapentin on postoperative 
dry mouth did not cross any boundary for harm or reach the required IS (1518 
participants) (Figure 3.50). On sensitivity analysis, assuming a relative risk 
increase of 50%, gabapentin crossed the boundary for futility then reached the 
required IS. Similar results from the main results were obtained for an 
incidence as low as 10%. Assuming a heterogeneity correction of 25, the IS 
increased to 2024 participants. 
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3.3.24 Re-admission 	
One study reported the number of patients re-admitted (Grosen et al. 2014). 
Although fewer patients in the gabapentin group were readmitted, this 
difference was not statistically significant. However, the confidence intervals 
suggested a possible decrease with gabapentin (RR 0.09; 95% CI 0.01 to 1.60).  
 
3.3.25 Postoperative arrhythmia  	
Overall, three studies with 198 participants were included in the analysis. All 
were conducted in patients undergoing cardiac surgery. Although gabapentin 
reduced the incidence of postoperative arrhythmia, this was not statistically 
significant (RR 0.55; 95% CI 0.28 to 1.08; Figure 3.51). There was no 
evidence of statistical heterogeneity (I2=0%; p=0.98). Due to the low number 
of studies, analyses for publication bias or heterogeneity were not undertaken. 
The quality of evidence was low according to GRADE (downgrading owing to 
concerns over risk of bias and imprecision of results). On sensitivity analysis, 
removing studies at high risk of bias left only one study (Ucak et al. 2011), 
which gave similar results. One study-removed analysis identified no 
influential studies. 
 
  
 
Figure 3.51: Forest plot of the effects of gabapentin on the incidence of 
postoperative arrhythmia. 
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Figure 3.52: Trial sequential analysis of postoperative arrhythmia. Performed 
assuming an incidence of 20%, a RRR of 50%, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 0. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin did not cross any of the 
boundaries for benefit for a RRR of 20%. In addition, gabapentin did not reach 
the required IS (2897 participants). However, for a 50% RRR (Figure 3.52) as 
suggested by the data, gabapentin avoided the boundary of futility although did 
not reach the required IS (401 participants) or conventional boundary for 
benefit. On sensitivity analysis, assuming an incidence of 10% required an IS 
of 6429 participants and assuming a heterogeneity correction of 25, 3862 
participants would be required for a definitive answer. 
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3.3.26 Hallucinations 	
Overall, two studies with 131 participants were included in the analysis. There 
was no difference in the incidence of hallucinations between the two groups 
(RR 1.15; 95% 0.07 to 19.91; Figure 3.53). There was evidence of substantial 
statistical heterogeneity (I2=72%; p=0.06). Analyses of heterogeneity and 
publication bias were not undertaken due to the low number of included 
studies. There was too few information to perform TSA. The quality of 
evidence was very low according to GRADE (downgraded owing to concerns 
over risk of bias, unexplained heterogeneity and imprecision of results). On 
sensitivity analysis, removing high risk of bias studies left only one study 
(Turan et al. 2006b), which gave similar results. One study-removed analysis 
showed no influential studies. 
 
 
 
Figure 3.53: Forest plot of the effects of gabapentin on the incidence of 
hallucinations. 
 
3.3.27 Postoperative sore throat 	
One study reported the incidence of postoperative sore throat (Lee et al. 2013). 
This study showed the incidence of postoperative sore throat was reduced with 
the administration of gabapentin (RR 0.66; 95% 0.44 to 0.99). The NNT to 
prevent one episode of sore throat was 5 (95% CI 2.2 to 48.3). However, this 
study was at high risk of bias. 
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3.3.28 Lack of concentration 	
Overall, four studies with 502 participants were included in the analysis. There 
was no difference between the groups in the incidence of lack of concentration 
(RR 1.31; 95% CI 0.79 to 2.17; Figure 3.54). There was no evidence of 
statistical heterogeneity (I2=0%; p=0.85). The quality of evidence was 
moderate according to GRADE (downgraded owing to concerns over risk of 
bias). None of the included studies were at high risk of bias. One study- 
removed analysis showed no influential studies were included in the analysis. 
 
 
 
Figure 3.54: Forest plot of gabapentin effect on the incidence of lack of 
concentration. 
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Figure 3.55: Trial sequential analysis of postoperative lack of concentration. 
Performed assuming an incidence of 10%, a relative risk increase of 50%, 
adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line 
indicates cumulative Z score with values less than 0 indicating harm with 
gabapentin.  
 
Trial sequential analysis showed that the effects of gabapentin on lack of 
concentration did not cross the boundary for harm or reach the required IS (872 
participants). However, the results were close to the boundary for futility 
(Figure 3.55). On sensitivity analysis, similar results were found assuming a 
relative risk increase of 20%, although the IS increased (6429 participants). 
Assuming a heterogeneity correction of 25 increased the IS to 1162 
participants. 
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3.3.29 Fasciculations 	
Only one study reported the incidence of postoperative fasciculations (Pandey 
et al. 2012). There was no significant reduction with gabapentin, although the 
confidence intervals suggested an effect (RR 0.67; 95% CI 0.41 to 1.09). As 
only one study was included, no further analyses were conducted. 
 
3.3.30 Euphoria 	
Overall, three studies with 430 participants were included in the analysis. 
Although the incidence of euphoria was not statistically significantly different 
with gabapentin, the confidence intervals suggested an increase (RR 2.48; 95% 
CI 0.44 to 14.03; Figure 3.56). There was no evidence of statistical 
heterogeneity (I2=0%; p=0.90). As only three studies were included, tests for 
publication bias or investigation of heterogeneity were not performed. There 
was too few information from the included studies to perform TSA. The 
quality of evidence was low according to GRADE (downgraded owing to 
concerns over risk of bias and imprecision of results). On sensitivity analysis, 
there were no studies at high risk of bias. One study-removed analysis showed 
there were no influential studies. 
 
 
 
Figure 3.56: Forest plot of gabapentin effect on the incidence of euphoria. 
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3.3.31 Myalgia 	
Overall, two studies with 145 participants reported the incidence of 
postoperative myalgia. Although the reduction with gabapentin was not 
statistically significant, the confidence intervals suggested an effect (RR 0.45; 
95% CI 0.17 to 1.22; Figure 3.57). There was no evidence of statistical 
heterogeneity (I2=0%; p=0.53). As only two studies were included, tests for 
publication bias or investigation of heterogeneity were not performed. There 
was too few information from the included studies to perform TSA. The 
quality of evidence was low according to GRADE (downgraded owing to 
concerns over risk of bias and imprecision of results). On sensitivity analysis, 
removing high risk of bias studies and one study-removed analysis did not 
affect results. 
 
 
 
Figure 3.57: Forest plot of the effects of gabapentin on the incidence of 
myalgia. 
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3.3.32 Time to first flatus (hours) 	
Overall, three studies with 130 participants were included in the analysis. 
Although the difference was not statistically significant, the confidence 
intervals suggested a decrease in time to first flatus with gabapentin (MD -6.85 
hours; 95% CI -14.27 hours to 0.57 hours; Figure 3.58). There was evidence of 
considerable statistical heterogeneity (I2=86%; p<0.001). As only three studies 
were included, tests for publication bias or investigation of heterogeneity were 
not performed. The quality of the evidence was low according to GRADE 
(downgraded owing to concerns over risk of bias and unexplained 
heterogeneity). On sensitivity analysis, no trials were at high risk of bias. One 
study-removed analysis did not identify any influential studies. 
 
 
 
Figure 3.58: Forest plot of the effects of gabapentin on time to first flatus 
(hours). 
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Figure 3.59: Trial sequential analysis of time to first flatus (hours). Performed 
assuming a MD of 6 hours, a variance of 64, adjusted α=0.05, 1-β=0.80 and a 
heterogeneity correction of 86. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the conventional 
boundary for statistical significance, although this reversed on publication of 
subsequent studies (Figure 3.59). Gabapentin did not cross the O’Brien-
Fleming boundary for benefit or reach the required IS for a definitive answer 
(404 participants). On sensitivity analysis, assuming a mean difference of 12 
hours did not affect the results. Assuming a doubling of the variance increased 
the IS required (794 participants). Sensitivity analysis around heterogeneity 
corrections was not undertaken as the value in the analysis was already high. 
 
 
 
 
 
	 193	
3.3.33 Time to return of bowel function (hours) 	
Overall, four studies with 202 participants were included in the analysis. 
Although the confidence intervals suggested gabapentin reduced the time to 
return of bowel function, this difference was not statistically significant (MD -
2.87 hours; 95% CI -6.45 hours to 0.71 hours; Figure 3.60). There was 
evidence of substantial statistical heterogeneity (I2=74%; p=0.01). The quality 
of evidence was low according to GRADE (downgrading owing to concerns 
over risk of bias and unexplained heterogeneity). On sensitivity analysis, there 
were no studies at high risk of bias. One study-removed analysis identified no 
influential studies. 
 
  
 
Figure 3.60: Forest plot of the effects of gabapentin on time to return of bowel 
function (hours). 
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Figure 3.61: Trial sequential analysis of time to return of bowel function 
(hours). Performed assuming a MD of 6 hours, a variance of 12.5, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 93. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis of gabapentin on time to return of bowel function 
showed that gabapentin initially crossed the boundary for conventional 
statistical significance (p<0.05) although after the publication of the second 
trial this benefit was lost (Figure 3.61). Gabapentin crossed the boundary for 
futility and then reached the required IS (148 participants). On sensitivity 
analysis, assuming an empirical MD of 2.87 hours, this increased the required 
IS (648 participants). Assuming a variance as high as 25 also increased the IS 
(297 participants). Sensitivity analysis around heterogeneity corrections was 
not undertaken as the value in the analysis was high. 
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3.3.34 Dysphagia 	
One study reported the incidence of postoperative dysphagia following Nissen 
fundoplication (Zaldivar Ramirez 2011). Gabapentin reduced the incidence of 
postoperative dysphagia (RR 0.24; 95% CI 0.08 to 0.72). The NNT to prevent 
one episode of dysphagia was 2 (95% CI 1.2 to 4.2). 
 
3.3.35 Hospital length of stay (days) 	
Overall, nine studies with 526 participants were included in the analysis. There 
was no reduction in the length of hospital stay with gabapentin (MD -0.30 
days; 95% CI -0.76 days to 0.15 days; Figure 3.62). There was evidence of 
considerable statistical heterogeneity (I2=97%; p<0.001). The quality of the 
evidence was low according to GRADE (downgraded owing to concerns over 
risk of bias and unexplained heterogeneity). On sensitivity analysis, there were 
no studies at high risk of bias. One study-removed analysis identified no 
influential studies. 
 
  
 
Figure 3.62: Forest plot of gabapentin effect on length of stay (days). 
 
Due to the low number of studies, tests for publication bias were not 
undertaken. On meta-regression analysis, dose did not predict reductions in 
length of stay on statistical testing, although the R2 analogue was above zero 
(R2=21%; p=0.92). Trial sequential analysis could not be performed due to a 
lack of information. 
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3.4 Discussion 	
3.4.1 Summary of results 	
In summary, there was consistent evidence from multiple RCTs that 
gabapentin reduced nausea, vomiting, anti-emetic requirement, pruritus, pre-
operative anxiety and increased patient satisfaction (possibly via reducing 
opioid usage). However, the quality of the evidence derived from these 
outcomes was very low to moderate due to concerns over possible publication 
bias and risk of bias in the original studies. There was some evidence that 
higher gabapentin doses increased patient satisfaction and paradoxically, 
increased the number of patients requiring anti-emetics. In terms of pre-
operative anxiety, higher baseline risk predicted larger reductions in pre-
operative anxiety. Other outcomes where results suggest gabapentin is unlikely 
to have an effect include constipation and respiratory depression, where TSA 
showed either no effect where the required IS was reached or the results passed 
the boundary for futility. 
 
In terms of gabapentin adverse events, there was evidence that gabapentin 
increased the risk of postoperative sedation, although this effect may be 
overestimated by imprecise study effects (possible publication bias). Indeed, 
following correction for publication bias, results for sedation were close to the 
line of no effect. We found no evidence of increases in dizziness or headache 
with gabapentin. On meta-regression analysis, there was no evidence that 
increases in dose caused increases in adverse events. However, this analysis 
may be limited by lower levels of underlying statistical heterogeneity. 
 
Other outcomes that require further studies, where results have suggested a 
possible benefit with gabapentin include postoperative confusion, bladder-
related discomfort, urinary retention, postoperative arrhythmia (in cardiac 
surgery patients) and time to first flatus or bowel function. Gabapentin may 
also increase the risk of lack of concentration, euphoria and visual disturbance. 
However, further studies are required to confirm these findings. Gabapentin 
was also found to decrease the time to mobilisation, although caution should be 
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advised as this finding failed to reach the monitoring boundary for benefit or 
reach the required IS and we suggest future studies are required to confirm 
these findings.  
 
3.4.2 Links with previous research 	
We found evidence that peri-operative use of gabapentin reduced nausea, 
vomiting and reduced the number of patients requiring anti-emetics. Previous 
meta-analyses of gabapentin have demonstrated gabapentin is effective at 
reducing PONV, the most recent of which was undertaken in patients 
undergoing abdominal surgeries (Achuthan et al. 2015). With regards to a non-
postoperative population of patients, an open-label study has found benefit 
when gabapentin was used in patients with chemotherapy-induced nausea 
(Gattuso, Roscoe and Griggs 2003). Possible mechanisms for this reduction in 
PONV include decreases in tachykinin neurotransmission and effects on the 
area postrema (Achuthan et al. 2015).  
 
Intuitively, as gabapentin is known to reduce opioid consumption and opioids 
are commonly associated with PONV, this may be a mechanism that could lead 
to reductions in PONV observed in our meta-analysis. However, on our meta-
regression analysis, reductions in opioid consumption did not predict the effect 
of gabapentin in reducing PONV. Therefore, other direct mechanisms may be 
involved, particularly bearing in mind its efficacy on chemotherapy-induced 
emesis. The reductions in PONV with gabapentin compare well with 
traditional anti-emetics such as metoclopramide, ondansetron and cyclizine 
(RR 0.60-0.80) (Carlisle and Stevenson 2006). Therefore, gabapentin may be a 
suitable alternative to these agents in routine anaesthetic practice although 
impracticalities with oral dosing may limit its use. Indeed, since the publication 
of this chapter (Doleman 2015b), one RCT has compared gabapentin to the 
5HT3 antagonist granisetron in reducing PONV. It found that both agents 
produced similar reductions in the incidence and severity of PONV in patients 
undergoing middle ear surgery (Heidari et al. 2015). Future similar studies may 
allow comparisons with other anti-emetics and given the multitude of other 
benefits from gabapentin (postoperative pain and opioid reduction), if 
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equivalent benefit can be demonstrated this may lead to more routine use of 
gabapentin as a pre-operative anti-emetic. 
 
With regards to pruritus, similar to our results with PONV, morphine 
reductions did not predict the efficacy of gabapentin for treating pruritus; again 
suggesting other mechanisms may be involved. Previous studies have 
demonstrated the efficacy of gabapentin for treating a number of conditions 
that cause itching such as uraemia (Gunal et al. 2004) and burns (Goutos et al. 
2010). The mechanism of which is uncertain. As pruritus causes patient 
distress and is challenging to manage, gabapentin prophylaxis may represent a 
useful option to prevent this condition in clinical practice, particularly due to 
its other beneficial effects.  
 
Gabapentin was also found to reduce pre-operative anxiety, with mean control 
group anxiety score predicting larger reductions in anxiety scores (baseline 
risk) as demonstrated on our meta-regression analysis. Gabapentin has been 
shown to increase GABA levels within the central nervous system (Maneuf, 
Luo and Lee 2006) and decrease excitatory neurotransmitters, which may exert 
an anxiolytic effect prior to surgery. In other areas of clinical practice, 
gabapentin may have efficacy in anxiety-related conditions such as panic 
disorder (Pande et al. 2000), social phobia (Pande et al. 1999) and anxiety 
from public speaking in healthy volunteers (Quevedo et al. 2003). Moreover, 
as anxiety is a risk factor for postoperative pain (Ip et al. 2009), reductions in 
anxiety may contribute to the effect of gabapentin on pain scores and opioid 
consumption. Such reductions in anxiety may also help contribute to improved 
patient experience observed in this chapter. Again, if gabapentin is to be 
considered as a standard agent in the treatment of pre-operative anxiety, further 
studies are required comparing gabapentin to the gold standard of 
benzodiazepines. Indeed, one study within our review (Rorarius et al. 2004) 
compared gabapentin with oxazepam 15mg and found gabapentin was inferior 
at reducing pre-operative anxiety (median VAS 10 versus 20; p=0.02). 
 
We also found limited evidence that gabapentin reduced the time to 
mobilisation (MD -5.02 hours; 95% CI -10.02 hours to -0.02 hours), although 
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this finding did not result in a significant reduction in hospital length of stay. 
However, caution is advised with this result as it was dependent on results 
from one unpublished study (Zaldivar Ramirez 2011) and did not reach any 
boundary for benefit on TSA. Moreover, our results may not be clinically 
significant. Although this result may be intuitive owing to the effects of 
gabapentin on reducing pain scores and adverse events such as PONV and 
pruritus, other effects such as increases in sedation may impair postoperative 
mobility. Gabapentin is often used in enhanced recovery protocols, which 
encourage early mobilisation, and future studies may focus on its use in this 
context. 
 
There was some evidence gabapentin reduced the incidence of postoperative 
shivering and sore throat. Although again, caution is advised due to possibility 
of type I errors in these analyses. Postoperative sore throat is a common 
complication related to endotracheal intubation with an incidence of around 
14-50% (McHardy and Chung 1999). As such symptoms can contribute to 
patient discomfort postoperatively, the reduction of this may help improve 
patient experience. Postoperative shivering is another common occurrence and 
may cause associated problems such as patient discomfort, increased oxygen 
consumption, increases in vascular resistance and increased intracranial 
pressure (Kranke et al. 2002). Therefore, future trials should aim to study these 
outcomes in order reduce the possibility of type I errors in our results. 
 
Gabapentin was found to increase the risk of postoperative sedation with a 
NNH of 13. However, our analysis of publication bias suggests the effect may 
be overestimated by the presence of imprecise study effects (possible 
publication bias) and adjusted analysis for this shows a relative risk increase of 
13% (18% unadjusted). Gabapentin is known to cause sedation in an outpatient 
population (McLean et al. 1999), however in the context of differential 
postoperative opioid use between active and placebo groups, this relationship 
becomes more complex, as opioids are also known to cause sedation. 
Anecdotally, gabapentin use is associated with patient sedation, which may 
limit its appeal to practising anaesthetists. Our results suggest this increase in 
risk is small and as many other beneficial effects have been found, such a trade 
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off may be acceptable to patients undergoing surgery. However, over-sedation 
may be a risk factor for serious adverse effects such as respiratory depression. 
A recent healthy volunteer study has found that a combination of pregabalin 
and remifentanil may increase respiratory depression as measured by 
increasing end-tidal CO2 (Myhre, Diep and Stubhaug 2016). However, we 
found no evidence of increasing postoperative respiratory depression with 
gabapentin from the RCTs published thus far. This again may due to the 
differential opioid consumption during the postoperative period. 
 
In order to resolve the issues surrounding the positive and negative effects of 
gabapentin, patient satisfaction can be used to estimate whether the use of 
gabapentin improves the patient experience. However, only eight studies 
reported this outcome and although the use of gabapentin was associated with a 
moderately clinically significant increase in patient satisfaction, there was 
evidence of possible publication bias. This result suggests the patient may, on 
average, be willing to accept a degree of sedation if gabapentin has other 
beneficial effects. Indeed, in a previous study (Macario et al. 1999) of 101 
patients found events such as vomiting (first), pain (third), shivering and sore 
throat were all more feared than sedation (last of ten) when patients were asked 
to rank what were the most undesirable outcomes of anaesthesia. As 
gabapentin reduces vomiting and pain, these effects may be responsible for the 
higher satisfaction scores in the gabapentin group. Furthermore, the results of 
this study suggest that fears of over-sedating patients from anaesthetists may be 
unfounded and potentially should not discourage the peri-operative use of 
gabapentin, particularly in clinical situations where patients may derive 
maximum benefit (high postoperative opioid consumption). 
 
The results from our meta-regression analysis in chapter two demonstrated that 
some of the pain relieving effects of gabapentin might be dose-dependent. 
However, such increases in dose may be offset by theoretical increases in 
adverse events. Within the limitations of meta-regression analysis, we found no 
evidence that increases in dose increase the adverse effects of gabapentin. 
Moreover, such increases in dose were also found to improve patient 
satisfaction as well as previous improvements in postoperative pain and opioid 
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consumption. These analyses suggest future studies should use higher doses to 
improve the beneficial effects of gabapentin without any clear increase in 
adverse events. However, large dose-ranging studies would allow for more 
accurate assessment of the gabapentin dose-response relationship, which 
should aim to measure pain scores and opioid consumption concurrently with 
adverse/opioid adverse events on a continuous scale in order to retain power.  
  
3.4.3 Limitations 	
There are several limitations with this review. Firstly, the number of studies 
included in some outcomes was small. Trial sequential analysis showed many 
of these failed to reach the required IS and therefore type II errors cannot be 
excluded. Some of these outcomes, such as sedation, did cross the monitoring 
boundary meaning we can conclude a likely effect. However, many outcomes 
did not cross any boundary for benefit/harm, futility or reach the required IS. 
These outcomes require further study, especially those where a possible effect 
may be present including postoperative arrhythmia in cardiac patients, 
postoperative confusion and emergence agitation. Our TSA has provided the 
likely number of participants required and for the dichotomous outcomes we 
studied, definitive answers may require thousands of participants in order to 
retain adequate power. Studies of this size are currently not present in the 
anaesthesia postoperative pain literature. Nevertheless, observational studies 
may be a more appropriate methodology to assess adverse events and may also 
have provided adequate numbers compared with the small sample size RCTs 
included in this chapter.  
 
Secondly, there was evidence of imprecise study effects for many outcomes, 
which raises the possibility of publication bias. This may overestimate benefits 
where gabapentin reduced incidence, while also possibly overestimating 
negative effects such as sedation. Indeed, we found evidence of publication 
bias against adverse effects such as sedation and dizziness. Although it has to 
be remembered that other causes of imprecise study effects exist, such as 
methodological limitations and possible clinical differences in smaller studies 
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such as higher doses. The only way to truly overcome concerns over possible 
publication bias is to conduct large RCTs. 
 
Thirdly, many studies were at high or unclear risk of bias for many domains, 
especially for allocation concealment, which may also overestimate the 
benefits observed with gabapentin (Schulz and Grimes 2002a). Issues with risk 
of bias, possible publication bias and unexplained heterogeneity reduce the 
quality of the evidence and therefore limit the confidence we can have in the 
conclusions of this review. Although, meta-analyses have advantages over 
smaller primary research studies such as increasing power and precision, this 
may be offset by the issues of possible publication bias. Again, this requires 
further conduct of RCTs which are conducted using low risk of bias methods. 
Finally, meta-regression has many limitations, which were discussed in the 
limitations section of chapter two (Section 2.4.3). 
 
3.4.4 Conclusions 	
Gabapentin reduced the incidence of many postoperative outcomes such as 
PONV, pruritus and pre-operative anxiety. However, gabapentin increased the 
risk of sedation. Despite this, as sedation is regarded by patients as the least 
undesirable outcome from anaesthesia and other outcomes such as vomiting 
and pain are rated as more undesirable, patients may be willing to accept a 
degree of sedation if offset by these benefits. Indeed, the use of gabapentin was 
associated with an increase in patient satisfaction suggesting its benefit for 
patients undergoing surgery. 
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Chapter 4 
Pre-emptive and preventive effects of 
gabapentin on acute postoperative 
pain 
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4.1 Introduction 	
Pre-emptive analgesia involves administration of analgesia prior to surgical 
incision. This has been proposed as an additional strategy to help improve 
postoperative pain (Dahl and Kehlet 1993) and reduce opioid consumption 
during the postoperative period. Preventive analgesia emerged from pre-
emptive analgesia and extends the definition of pre-emptive analgesia by 
continuing analgesia further into the postoperative period to further reduce 
peri-operative sensitisation (Dahl and Kehlet 2011). Such timing of 
administration has the potential to reduce intra-operative nociception and 
central sensitisation (Woolf and Chong 1993) that results from surgical 
incision, leading to improved postoperative pain control. Previous meta-
analyses have demonstrated conflicting results on the clinical efficacy of pre-
emptive analgesia (Møiniche, Kehlet and Dahl 2002; Ong et al. 2005). 
However, the results of these reviews are nearly a decade old and new 
evidence is emerging on the potential of other analgesic agents that are able to 
induce a pre-emptive analgesic effect in clinical trials. As yet, it is unknown 
whether gabapentin is capable of such pre-emptive or preventive analgesic 
activity. Therefore, the aim of this chapter was to evaluate the effects of pre-
emptive or preventive gabapentin compared to post-incision gabapentin for 
postoperative pain management. 
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4.2 Methods 	
The methods used for the data collection in this chapter are identical to those 
used in chapter two (Section 2.2). We included data from RCTs that evaluated 
pre-emptive gabapentin administration (defined as administered before surgical 
incision) or preventive gabapentin (defined as administered before surgical 
incision and continued postoperatively) versus post-incision gabapentin 
(defined as administered after surgical incision). The outcomes were 24-hour 
morphine consumption and pain scores at rest at one, two, six, 12 and 24 hours 
after surgery. For inclusion, each study needed to give identical dosages in 
order to be comparable. We aimed to conduct meta-regression and tests for 
publication bias. However, the low number of identified studies precluded 
these analyses. We conducted TSA for each pain outcome as described in 
chapter two. The quality of the evidence was assessed according to GRADE 
and rated as high, moderate, low or very low quality. 
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4.3 Results 	
4.3.1 Characteristics of the included studies 	
The characteristics of the included studies are listed in Table 4.1. Overall, only 
four RCTs compared pre-emptive gabapentin with post-incision gabapentin 
(Figure 4.1) (Clarke et al. 2009a; Khan et al. 2011; Metry et al. 2008; Pandey 
et al. 2005b). No studies evaluated preventive gabapentin. Dosages ranged 
from 600-1200mg and all trials were performed in a different type of surgery. 
One study used spinal anaesthesia while the others used general anaesthesia. 
Risk of bias for each study is presented in Figure 4.2. 
  
 
  
Figure 4.1: PRISMA flowchart for the included studies.  
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Figure 4.2: Risk of bias for the included studies. Green indicates low risk, 
yellow indicates unclear risk and red indicates high risk. 
 
 
 
 
 
 
 
 
 
 
	 208	
Study 
Mean 
age Sex N 
Intervention and 
comparison Country Type of anaesthesia Type of surgery 
Clarke et al. 2009a 60.2 39% 114 
600mg 2hrs before 
operation or 2hrs 
after Canada Spinal anaesthesia Total hip arthroplasty 
Khan et al. 2011 41.8 35% 175 
600mg, 900mg or 
1200mg 2hrs pre or 
immediately post-
incision via NG tube Iran General anaesthesia 
Single level lumbar 
laminectomy 
Metry et al. 2008 57.8 100% 101 
1200mg 2 hours 
before or 1200mg 
2hrs postoperatively Egypt General anaesthesia Mastectomy 
Pandey et al. 2005b 43.6 68% 60 
600mg 2hrs before or 
600mg post-incision India General anaesthesia Open donor nephrectomy 
 
 
Table 4.1: Characteristics of the included studies. mg=milligrams; hrs=hours; NG=naso-gastric.
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4.3.2 24-hour morphine consumption 	
Overall, four studies with 333 participants were included in the analysis. Pre-
emptive gabapentin did not reduce morphine consumption during the first 24-
hours postoperatively (MD -0.11mg; 95% CI -1.59mg to 1.36mg; Figure 4.3). 
There was no evidence of statistical heterogeneity (I2=0%; p=0.73). Due to the 
low number of included studies, analyses for publication bias or investigation 
of heterogeneity were not undertaken. There was not enough information to 
perform TSA. The quality of the evidence was moderate according to GRADE 
(downgraded owing to concerns over risk of bias). 
 
 
 
Figure 4.3: Forest plot of pre-emptive gabapentin effects on 24-hour morphine 
consumption. 
 
4.3.3 Pain scores one hour 	
Only one study reported pain scores at one hour (Pandey et al. 2005b). The 
study by Metry et al. (2008) was not included as the post-incision dose was 
administered two hours after surgery. Pre-emptive gabapentin did not reduce 
pain scores at one hour (MD -0.50; 95% CI -1.42 to 0.42). 
 
4.3.4 Pain scores two hours 	
No study reported pain scores at two hours. 
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4.3.5 Pain scores six hours 	
Overall, two studies with 107 participants reported pain scores at six hours. 
There was no significant reduction in pain scores with pre-emptive gabapentin 
(MD 0.20; 95% CI -0.20 to 0.59; Figure 4.4). There was no evidence of 
statistical heterogeneity (I2=0%; p=0.38). There was not enough information to 
perform TSA. The quality of the evidence was moderate according to GRADE 
(downgraded owing to concerns over risk of bias). 
 
 
 
Figure 4.4: Forest plot of pre-emptive gabapentin effects on pain scores at six 
hours. 
 
4.3.6 Pain scores 12 hours 	
Overall, four studies with 333 participants were included in the analysis. Pre-
emptive gabapentin did not reduce pain scores at 12 hours (MD -0.02; 95% -
0.37 to 0.33; Figure 4.5). There was evidence of moderate statistical 
heterogeneity (I2=64%; p=0.04). Due to small number of included studies, 
analyses for publication bias or investigation of heterogeneity were not 
undertaken. The quality of the evidence was low according to GRADE 
(downgraded owing to concerns over unexplained heterogeneity and risk of 
bias). 
 
 
 
Figure 4.5: Forest plot of pre-emptive gabapentin effects on pain scores at 12 
hours. 
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Figure 4.6: Trial sequential analysis of pain score at 12 hours. Performed 
assuming a mean difference of 1.5, a variance of 0.7, adjusted α=0.05, 1-
β=0.80 and a heterogeneity correction of 73. Blue line indicates cumulative Z 
score with values more than 0 indicating benefit with pre-emptive gabapentin.  
 
Trial sequential analysis showed that gabapentin did not cross the boundary for 
benefit (Figure 4.6). However, gabapentin did reach the required IS for a 
definitive answer (77 participants) and crossed the boundary for futility. On 
sensitivity analysis, assuming a variance of 3 increased the required IS (155 
participants).  
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4.3.7 Pain scores 24 hours 	
Overall, four studies with 333 participants were included in the analysis. Pre-
emptive gabapentin did not reduce pain scores at 24 hours (MD 0.00; 95% -
0.15 to 0.15; Figure 4.7). There was no evidence of statistical heterogeneity 
(I2=0%; p=0.99). Due to the low number of included studies, analyses of 
publication bias or investigation of heterogeneity were not undertaken. There 
was not enough information to perform TSA. The quality of the evidence was 
moderate according to GRADE (downgraded owing to concerns over risk of 
bias). 
 
 
 
Figure 4.7: Forest plot of pre-emptive gabapentin effects on pain scores at 24 
hours. 
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4.4 Discussion 	
4.4.1 Summary of results 	
This chapter found that pre-emptive gabapentin did not offer superior analgesic 
efficacy when compared with post-incision gabapentin. There was neither a 
reduction in pain scores during the first day postoperatively or any reduction in 
24-hour morphine consumption. There were too few studies to assess 
publication bias or investigate heterogeneity. Furthermore, type II errors cannot 
be excluded due to there being too few information to conduct TSA for many 
outcomes. The quality of the presented evidence is regarded as moderate to low 
according to GRADE. There were no studies that assessed preventive 
gabapentin and therefore no conclusions can be made on the efficacy of this 
analgesic strategy.  
 
4.4.2 Links with previous research 	
Previous reviews have been undertaken evaluating pre-emptive analgesia for 
postoperative pain control. Whilst the most recent review found a potential role 
for NSAIDS, epidural anaesthesia and local anaesthetic wound infiltration 
(Ong et al. 2005) and recent reviews have suggested a role for pre-emptive 
paracetamol (Doleman et al. 2015a), to the best of our knowledge, no previous 
review has evaluated the role of pre-emptive gabapentin. As the strategy of 
pre-emptive analgesia involves changing the timing of analgesic 
administration, it offers a simple and cost-effective solution to reducing acute 
postoperative pain (if effective). 
 
The results of this clinical review contradict findings obtained from in vitro 
experiments with gabapentinoids. Using a rat postoperative pain model, 
pregabalin (a similar medication that binds to the same site as gabapentin) 
administered before incision resulted in a longer duration of anti-hyperalgesia 
compared to post-incision administration (Field et al. 1997b). In another study, 
administration of intra-thecal gabapentin was more effective when 
administered before injection of formalin in reducing phase two responses, 
when compared to administration after formalin injection (Yoon and Yaksh 
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1999). However, these observations have not been replicated in the clinical 
studies included in our review, the reasons for which remain unclear. However, 
in a human volunteer study (Dirks et al. 2002a), gabapentin was effective both 
at reducing the development of and treating existing secondary hyperalgesia. 
These results may help explain why gabapentin was equally effective when 
given pre-incision or post-incision.   
 
With regards to the timing of gabapentin administration, although this review 
has found no benefit of pre-emptive administration in terms of reductions in 
postoperative pain, pre-emptive administration may offer other clinical and 
logistical advantages over post-incision administration. Pre-emptive gabapentin 
allows administration with the patient fully alert and capable of swallowing the 
tablet. Indeed, included studies that gave post-incision doses had to do so via a 
nasogastric tube (Khan et al. 2011) or two hours after surgery (Clarke et al. 
2009a; Metry et al. 2008). Therefore, post-incision administration may create 
the need for additional clinical procedures (nasogastric tube) or miss clinically 
significant reductions in postoperative pain found in chapter two (if 
administered two hours after surgery). Furthermore, reductions in pre-operative 
anxiety with gabapentin would be lost with post-incision dosing. The next 
chapter will examine the effects of gabapentin on the haemodynamic response 
to intubation, which may highlight further advantages of pre-operative dosing 
or identify adverse haemodynamic effects, which may suggest post-incision 
dosing to be the safest time of administration. 
 
4.4.3 Limitations 	
There are several limitations with this review. Firstly, included RCTs were 
clinically heterogeneous in terms of types of surgery, dose of gabapentin used 
and timing of gabapentin administration. With the low number of included 
studies, we were unable to explore such heterogeneity or undertake analyses 
for publication bias, which limits our findings. Secondly, as no studies 
evaluated preventive gabapentin administration, we could not make any 
conclusions on the efficacy of this strategy. Continuing gabapentin longer into 
the postoperative period may help further reduce peri-operative sensitisation 
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and offer superior analgesic activity when compared with pre-emptive 
administration.   
 
Thirdly, current studies may be underpowered for many outcomes, as we were 
not able to undertake TSA for the majority of pain scores and 24-hour 
morphine consumption. Therefore, type II errors cannot be excluded in our 
analyses. However, we were able to undertake this analysis for pain scores at 
12 hours, which suggested a small number of participants would be required 
for an appropriate IS. Because of this, future studies may be required to 
adequately resolve whether gabapentin exerts any pre-emptive effect. 
 
Lastly, although only one study received high risk of bias for one element on 
risk of bias assessments, only one study was regarded as low risk of bias for 
most elements (Metry et al. 2008). Again, there was unclear risk of bias for 
allocation concealment, which has previously been shown to over-estimate 
effect estimates in RCTs of identical interventions (Schulz and Grimes 2002a). 
Therefore, our results should be interpreted with caution. Such deficiencies in 
study conduct meant the quality of evidence derived from our results was at 
best, moderate quality.  
 
4.4.4 Conclusions 	
In conclusion, it appears from the limited data thus far that gabapentin exerts 
no pre-emptive effect for postoperative analgesia. However, future studies are 
still required due to low number of participants included in this review. Despite 
a lack of clinical efficacy on reducing postoperative pain, pre-emptive doses of 
gabapentin may have other clinical advantages and disadvantages, which may 
complicate the issue of when is the best time to administer peri-operative 
gabapentin.  
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Chapter 5 
Gabapentin for attenuating the 
haemodynamic response to 
endotracheal intubation 
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5.1 Introduction 	
Endotracheal intubation is the gold standard for securing the airway prior to 
surgery. However, this procedure may cause activation of the sympathetic 
nervous system and release of catecholamines with the resulting 
haemodynamic response causing increasing heart rate and blood pressure. This 
response does not cause problems in most patients. However, in high-risk 
patient groups such as those with pre-existing cardiovascular disease, such 
responses may increase the risk of myocardial ischaemia, myocardial infarction 
and mortality (Kovac 1996; POISE Study Group 2008). As the number of 
elderly patients undergoing surgery increases, adverse cardiovascular 
responses to endotracheal intubation may therefore present an increasing 
problem during the peri-operative period. Many agents have been used to 
attenuate this response, however few studies report clinically relevant 
outcomes such as morbidity or mortality (Khan and Ullah 2013). 
 
Increases in haemodynamic and sympathetic responses around the peri-
operative period increase myocardial demand leading to adverse cardiac 
outcomes. Triggers for this include intubation, extubation, surgery and pain 
(Devereaux et al. 2005). This led to RCTs evaluating agents such as beta-
blockers and clonidine in reducing peri-operative myocardial events. The 
POISE study (POISE Study Group 2008) found that metoprolol reduced 
myocardial infarction. However, there was an increase in overall mortality and 
stroke thought secondary to episodes of hypotension and bradycardia. 
Clonidine has also shown initial promise (Wallace et al. 2004), although the 
recent POISE 2 study showed no reduction in cardiac events or mortality and 
an increase in clinically significant hypotension and non-fatal cardiac arrest 
(Devereaux et al. 2014). Therefore, the search for alternative agents that do not 
produce such adverse effects is a clinically important issue for high-risk 
patients undergoing surgery.  
 
Randomised controlled trials have been published over the last decade 
indicating gabapentin may be useful for attenuating the haemodynamic 
response to intubation (Kong and Irwin 2008). However, these studies have 
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included a small number of participants and have not been conducted in 
multiple clinical populations. Moreover, it is as yet unknown whether such 
reductions in haemodynamic variables can translate into reductions in 
clinically relevant postoperative outcomes. 
 
Due to the disappointing results from the clinical trials of clonidine and beta-
blockers in reducing peri-operative myocardial events (Sear, Higham and Foex 
2015) this review aimed to evaluate whether gabapentin can attenuate the 
haemodynamic response to intubation and whether this can translate into 
reductions in myocardial ischaemia, myocardial infarction and ultimately 
reduce postoperative mortality. 
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5.2 Methods 	
5.2.1 Reporting standards and prospective registration 	
This review was undertaken in accordance with the PRISMA checklist (Moher 
et al. 2009). We prospectively registered the review on the PROSPERO 
website using the registration number CRD42015027012. 
 
5.2.2 Search strategy 	
We searched the following databases: MEDLINE (1946-2015), EMBASE 
(1974-2015), CINAHL (1981-2015), AMED (1985-2015) and CENTRAL. We 
searched for studies using the keywords in the title and abstract ‘gabapentin’ 
‘neurontin’ and ‘intubation’. The MeSH term ‘INTUBATION, 
INTRATRACHEAL’ was exploded and combined with the above terms. We 
also searched for unpublished studies from Clinicaltrials.gov, the ISRCTN 
registry and the WHO international clinical trials registry. Furthermore, we 
searched reference lists of identified studies and used Google Scholar to 
identify studies that had cited those included. We contacted the authors if 
further information was required. 
 
5.2.3 Inclusion criteria and outcomes 	
We included RCTs that compared gabapentin with placebo or no treatment in 
patients undergoing endotracheal intubation prior to surgery. We included 
adult patients only (>15 years old) undergoing any type of surgery. There were 
no restrictions on the basis of publication status or language. Where necessary, 
non-English language papers were translated using Google Translate. Two of 
the authors independently evaluated the identified studies against the inclusion 
criteria and agreement was reached by consensus. 
 
The primary outcomes were mortality, myocardial ischaemia and myocardial 
infarction. We defined mortality as early (<48 hours) and late (30-days). If 
studies reported more than one time-point, the earliest was included in the 
analysis. Myocardial ischaemia was defined as ST segment depression from 
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continuous ECG recordings. Myocardial infarction was defined as two of the 
following three criteria: chest pain, ECG ischaemic changes and/or >25% rise 
in high-sensitivity troponin measurements. Secondary outcomes included heart 
rate (HR), mean arterial blood pressure (MBP), systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) measured at one, five and 10 minutes after 
intubation. We also measured the following outcomes: arrhythmias, plasma 
catecholamine concentrations, hypotension (requiring treatment), bradycardia 
(requiring treatment) and tachycardia or hypertension (requiring treatment).  
 
5.2.4 Data extraction 	
Two authors extracted the following information onto an electronic database: 
study name, year of publication, mean age of participants, percentage of female 
participants, sample size, intervention, comparator, country in which the study 
was conducted, concurrent peri-operative medication, induction agents used 
(with dose), maintenance agents, laryngoscope and endotracheal tube used, 
participant population, type of surgery and duration of intubation (seconds). 
 
5.2.5 Risk of bias in included studies 	
Two study authors assessed risk of bias using the Cochrane tool for assessing 
risk of bias (Higgins et al. 2011) and agreement was reached by consensus. We 
assessed the following domains: randomisation, allocation concealment, 
blinding, attrition bias, selective outcome reporting and other sources of bias. 
These domains were assessed as low, unclear and high risk and presented in a 
risk of bias table. 
 
5.2.6 Statistical analysis 	
We presented continuous outcomes using the difference in means (MD) and 
dichotomous outcomes using risk ratios (RR). The precision of outcomes was 
presented with 95% confidence intervals (95% CI). We regarded differences of 
10% in dichotomous outcomes, 10mmHg in blood pressure and 5 beats per 
minute (bpm) in heart rate as clinically significant. Where data were not 
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presented, authors were contacted to provide further information. If no 
response was received, these results were estimated from published graphs. If 
standard deviations were not reported we estimated these from other studies in 
the meta-analysis (Higgins 2008). We used the GRADE criteria to assess the 
level of evidence for each outcome. Evidence was downgraded owing to any 
concerns regarding the indirectness of evidence, lack of precision in effect 
estimates, potential publication bias, unexplained heterogeneity and risk of bias 
in included trials. This was a qualitative downgrading from high quality to 
moderate, low or very low quality dependent on the concerns cited above. We 
made no statistical adjustment of results.  
 
Data was aggregated using a random-effects model due to substantial clinical 
heterogeneity in gabapentin dose and the baseline haemodynamic variables of 
the participants. Statistical heterogeneity was presented using the I2 statistic 
with a corresponding p value derived from the chi-squared statistic. We 
regarded I2 of >50% or p<0.1 as evidence of statistical heterogeneity. When 
more than ten studies were included in the meta-analysis, we assessed 
imprecise study effects, including possible publication bias using Egger’s 
linear regression test (Egger et al. 1997a). We regarded a one-tailed p<0.1 as 
evidence of imprecise study effects. All analyses were undertaken using 
Review Manager 5.3, STATA Version 14 and Comprehensive Meta-analysis 
V3.3. 
 
5.2.7 Meta-regression 	
Investigation of heterogeneity was undertaken using a method of moments, 
random-effects meta-regression (Thompson and Higgins 2002). Covariates 
included dose of gabapentin and baseline haemodynamic variables of the 
participants. We calculated the baseline haemodynamic measurements by 
taking the mean measurement from the gabapentin and control groups recorded 
before induction of anaesthesia (where reported). We assessed residuals for 
normality, linearity and heteroscedasticity. We used Cook’s distance to assess 
the model for influential cases and the VIF for evidence of multicollinearity. 
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We presented results as the R2 analogue with a corresponding p value for the 
model (significance level p<0.05).  
 
5.2.8 Sensitivity analysis 	
We conducted sensitivity analysis by including studies at low risk of bias 
(defined as low risk for randomisation, allocation concealment, blinding and 
attrition bias and no high risk domains), excluding studies where standard 
deviations were estimated and using one study-removed analysis.  
 
5.2.9 Trial sequential analysis 	
We performed TSA for all outcomes. We estimated control group incidences 
from both published literature and events from the studies included in each 
analysis. For continuous outcomes, we used both clinically important 
differences (from subjective clinical experience) and empirical estimates for 
the main results.  
 
We used estimates of variance from the studies included in the meta-analysis. 
For dichotomous outcomes we regarded RRR of 20% as clinically significant if 
incidence was above 10% and for low incidence events (≤10%) we used a 50% 
RRR. We conducted sensitivity analysis around these estimates by changing 
various assumptions regarding heterogeneity corrections, measures of variance 
or changing assumptions on the effect estimates. We calculated alpha spending 
monitoring boundaries using the O’Brien-Fleming method with a significance 
level of p<0.05. We used the DerSimonian and Laird method for calculating 
random-effects estimates. We also constructed futility boundaries with a 1-
β=0.80. For handling zero events, we used a constant value of 0.5. We applied 
a heterogeneity adjustment factor as the ratio between the fixed and random 
effects model. We conducted all analyses using TSA software from the 
Copenhagen Trial Unit (Version 0.9.5.5 beta). 
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5.3 Results 	
5.3.1 Characteristics of the included studies 	
We screened 95 studies identified from the searching of electronic databases 
and hand-searching of reference lists (Figure 5.1). Overall, 29 RCTs were 
included in the meta-analysis (Table 5.1). All the included studies enrolled 
ASA I or II patients with no pre-existing cardiac disease. Only one study 
included patients with hypertensive disease (Bala et al. 2015) and only one 
study used invasive blood pressure monitoring to record haemodynamic 
variables (Ali et al. 2009). There was clinical heterogeneity in the doses of 
gabapentin used, with doses ranging from 300-1200mg. Most studies 
administered gabapentin between 1 to 2 hours before surgery. In terms of risk 
of bias assessments, allocation concealment was rarely adequately reported. 
The risk of bias assessment for each included study is presented in Figure 5.2. 
 
 
 
 
Figure 5.1: PRISMA flowchart for the included studies. 
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Figure 5.2: Risk of bias in the included studies. Green indicates low risk, 
yellow indicates unclear risk and red indicates high risk. 
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Study name 
 
Mean 
age 
Female 
(%) N Intervention Comparator Country Type of surgery 
Abdel-Halim et al. 
2009 46.3 100% 80 
800mg gabapentin one hour before 
surgery 
1) No medication 2) 
16mg dexamethasone Egypt Mastectomy 
Aggarwal, Baduni 
and Jain 2015 36.6 83% 90 
1) 300mg gabapentin night before and 
day of surgery 2) 300mg gabapentin 
night before and 600mg day of surgery Placebo India 
Laparoscopic 
cholecystectomy 
Ali et al. 2009 29.5 46% 50 
1200mg gabapentin two hours before 
surgery Placebo Egypt 
Elective surgery 
(hernioplasty, 
arthroscopy, 
cholecystectomy and 
vitrectomy) 
Ali, Elnakera and 
Samir 2013 31.6 50% 60 
1) 800mg gabapentin two hours before 
surgery 2) 1200mg gabapentin two 
hours before surgery Placebo Egypt 
Elective cataract 
surgery 
Ayatollahi et al. 
2014 NR NR 30 
100mg gabapentin night before and 
800mg 90 minutes before surgery Placebo Iran Microlaryngeal surgery 
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Bafna, Goyal and 
Garg 2011 39.7 76% 90 
1) 600mg gabapentin one hour before 
surgery 2) 1000mg gabapentin one 
hour before surgery Placebo India Elective surgery 
Bala, Bharti and 
Ramesh 2015 54.6 68% 100 
1) 800mg gabapentin two hours before 
induction 2) 800mg night before and 
two hours before induction Placebo India Elective surgery 
Bhandari and 
Shahi 2013 42.6 NR 40 
900mg gabapentin two hours before 
induction Placebo India Elective surgery 
Bhandari et al. 
2014b 42.9 66% 40 
600mg gabapentin two hours before 
surgery Placebo India 
Laparoscopic 
cholecystectomy 
Bharti et al. 2013 46.5 100% 40 
600mg gabapentin two hours before 
surgery Placebo India 
Mastectomy for breast 
cancer 
Farzi et al. 2015 27.6 85% 103 
900mg gabapentin two hours before 
surgery Placebo Iran Septo-rhinoplasty 
Fassoulaki et al. 
2006b 42 100% 44 
400mg gabapentin TDS day before 
surgery and 6am on the day of surgery Placebo Greece 
Abdominal 
hysterectomy 
Iftikhar et al. 2011 36.5 40% 60 
800mg gabapentin one hour before 
surgery Placebo Pakistan Elective surgery 
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Kaya et al. 2008 43.5 53% 60 
800mg gabapentin two hours before 
surgery Placebo Turkey Elective surgery 
Kiran and Verma 
2008 33.8 54% 100 
800mg gabapentin night before and 
morning of surgery Placebo India Elective surgery 
Koç, Memis and 
Sut 2007 38.5 0% 80 
800mg gabapentin one hour before 
surgery 
1) Placebo 2) 8mg 
dexamethasone Turkey Varicocele surgery 
Kumari and 
Pathania 2009 30.7 49% 78 
900mg gabapentin two hours before 
induction Placebo India Elective surgery 
Marashi, Ghafari 
and Saliminia 2009 32.8 51% 75 
900mg gabapentin two hours before 
surgery 
1) Placebo 2) 0.2mg 
clonidine Iran 
Elective orthopaedic 
and general surgery 
Memiş et al. 2006 44.6 42% 89 
1) 400mg gabapentin one hour before 
surgery 2) 800mg gabapentin one hour 
before surgery Placebo Turkey Elective surgery 
Montazeri et al. 
2011 
 38 45% 96 
800mg gabapentin 90 minutes before 
surgery 
1) Placebo 2) 0.3mg 
clonidine Iran Elective surgery 
Neogi et al. 2012 40.4 63% 60 
900mg gabapentin two hours before 
induction Vitamin B India 
Laparoscopic 
cholecystectomy 
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Parida et al. 2015 37.9 58% 50 
800mg gabapentin two hours before 
surgery 
1) Placebo 2) 
Fentanyl India 
Elective non-cardiac 
surgery 
Sanabria Siacara 
and Pena 2013 31.5 37% 30 
600mg gabapentin one hour before 
surgery Clonidine 2mcg/kg Mexico Elective surgery 
Sharma et al. 2012 37.6 NR 120 
800mg gabapentin one hour before 
induction 
1) Placebo 2) 0.3mg 
clonidine 3) 400mg 
gabapentin and 
0.15mg clonidine Kashmir Elective surgery 
Shreedhara et al. 
2014 40.4 48% 90 
900mg gabapentin two hours before 
surgery 
1) Placebo 2) 0.2mg 
clonidine India Elective surgery 
Shrestha, 
Marhatta and 
Amatya 2009 33.8 NR 72 
1200mg gabapentin two hours before 
induction 
1) Placebo 2) 
Esmolol Nepal Elective surgery 
Singhal, Kaur and 
Arora 2014 32.8 63% 100 
900mg gabapentin 90 minutes before 
surgery Clonidine 0.2mg India Elective surgery 
Soltanzadeh et al. 
2012 28.4 50% 90 
900mg gabapentin two hours before 
surgery Placebo Iran Elective surgery 
Zia et al. 2012 36.7 40% 110 800mg gabapentin two hours before Placebo Pakistan Elective surgery (2-3 
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surgery hours) 
 
 
Table 5.1: Baseline characteristics of included studies. NR=not reported; mg=milligrams. 
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5.3.2 Mortality 	
None of the included studies reported mortality as an outcome. 
 
5.3.3 Myocardial infarction 	
None of the included studies reported myocardial infarction as an outcome. 
 
5.3.4 Myocardial ischaemia 	
Nine studies reported myocardial ischaemia (Aggarwal, Baduni and Jain 2015; 
Ali et al. 2009; Bafna, Goyal and Garg 2011; Bala, Bharti and Ramesh 2015; 
Kaya et al. 2008; Koc, Memis and Sut 2007; Memis et al. 2006; Montazeri et 
al. 2011; Parida et al. 2015). However, there were no events reported in any of 
the included studies. 
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5.3.5 MAP one minute 	
Overall, 18 studies with 1147 participants were included in the analysis. 
Gabapentin resulted in a clinically significant attenuation in the rise in MAP at 
one minute (MD -12.54mmHg; 95% CI -16.93 mmHg to -8.14 mmHg; Figure 
5.3). There was evidence of considerable statistical heterogeneity (I2=87%; 
p<0.001). The quality of the evidence according to GRADE was low 
(downgraded owing to concerns over unexplained heterogeneity and risk of 
bias). 
 
 
 
Figure 5.3: Forest plot of MAP at one minute. 
 
There was no clear asymmetry when observing funnel plots (Figure 5.4). 
Indeed, Egger’s linear regression test was not significant (p=0.14). Therefore, 
further tests of publication bias were not conducted. On meta-regression 
analysis, neither covariate (dose nor baseline MAP) predicted the efficacy of 
gabapentin. 
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Figure 5.4: Funnel plot of MAP at one minute. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.5: Trial sequential analysis of MAP at one minute. Performed 
assuming a mean difference of 10mmHg, a variance of 161, adjusted α=0.05, 
1-β=0.80 and a heterogeneity correction of 89. Blue line indicates cumulative 
Z score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.5). The results also reached the required IS for a 
definitive answer (454 participants). On sensitivity analysis, assuming a 
variance of 300 increased the required IS (847 participants). Assuming an 
empirical MD of 12.56mmHg still showed benefit with gabapentin while 
reducing the required IS (294 participants).  
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5.3.6 MAP five minutes 	
Overall, 21 studies with 1350 participants were included in the analysis. 
Gabapentin attenuated the rise in MAP at five minutes after intubation (MD -
9.31mmHg; 95% CI -13.14 mmHg to -5.49 mmHg; Figure 5.6). There was 
evidence of considerable statistical heterogeneity (I2=93%; p<0.001). The 
quality of evidence according to GRADE was low (downgraded owing to 
concerns over unexplained heterogeneity and risk of bias). 
 
 
 
Figure 5.6: Forest plot of MAP at five minutes. 
 
There was no obvious asymmetry on visual inspection of the funnel plot 
(Figure 5.7). However, Egger’s linear regression test showed evidence of 
possible publication bias (p=0.001). Despite this, the missing studies were 
missing from the left of the mean suggesting a bias against gabapentin for this 
outcome. When performing trim and fill analysis, two missing studies were 
added resulting in a larger attenuation with gabapentin (MD -10.52mmHg; 
95% CI -14.15mmHg to -6.89mmHg). When performing failsafe N, 1034 
negative studies would be required to observe a null effect with gabapentin. On 
meta-regression analysis, neither dose (p=0.27) nor baseline MAP (p=0.48) 
predicting the efficacy of gabapentin. 
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Figure 5.7: Funnel plot of MAP at five minutes. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.8: Trial sequential analysis of MAP at five minutes. Performed 
assuming a mean difference of 10mmHg, a variance of 59, adjusted α=0.05, 1-
β=0.80 and a heterogeneity correction of 95. Blue line indicates cumulative Z 
score with values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.8). In addition, the results for gabapentin 
reached the required IS for a definitive answer (412 participants). On 
sensitivity analysis, using the empirical MD did not change the results (IS 477 
participants). Assuming a variance of 100 increased the required IS (694 
participants).  
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5.3.7 MAP 10 minutes 	
Overall, 18 studies with 1244 participants were included in the analysis. 
Gabapentin attenuated the rise in MAP at 10 minutes (MD -8.14mmHg; 95% 
CI -11.05mmHg to -5.23mmHg; Figure 5.9). There was evidence of 
considerable statistical heterogeneity (I2=82%; p<0.001). The quality of the 
evidence was low according to GRADE (downgraded owing to concerns over 
unexplained heterogeneity and risk of bias). 
 
 
 
Figure 5.9: Forest plot of MAP at 10 minutes. 
 
Visual inspection of funnel plots showed no obvious asymmetry (Figure 5.10). 
Indeed, Egger’s linear regression test was not significant (p=0.36). Therefore, 
further analyses of publication bias were not conducted. On meta-regression 
analysis, neither gabapentin dose (p=0.14) nor baseline MAP (p=0.69) 
predicted the efficacy of gabapentin. 
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Figure 5.10: Funnel plot of MAP at 10 minutes. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.11: Trial sequential analysis of MAP at 10 minutes. Performed 
assuming a MD of 10mmHg, a variance of 111, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 84. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin.  
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.11). Gabapentin also reached the required IS for 
a definitive answer (216 participants). On sensitivity analysis, using an 
empirical MD of -8.14mmHg gave similar results (327 participants). Assuming 
a variance of 200 resulted in a larger IS, which the results with gabapentin 
achieved (389 participants).  
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5.3.8 HR one minute 	
Overall, 23 studies with 1471 participants were included in the analysis. 
Gabapentin resulted in a clinically significant attenuation of the HR response to 
intubation when compared to control (MD -8.64bpm; 95% CI -11.53bpm to -
5.75bpm; Figure 5.12). There was evidence of considerable statistical 
heterogeneity (I2=76%; p<0.001). The quality of evidence was moderate 
according to GRADE (downgraded owing to concerns over risk of bias). 
 
 
 
Figure 5.12: Forest plot of HR at one minute. 
 
Visual inspection of funnel plots revealed no obvious asymmetry (Figure 5.13). 
However, Egger’s linear regression test found evidence of statistically 
significant imprecise study effects (p=0.05). On trim and fill analysis, there 
were two missing studies to the left of the mean, suggesting a bias against 
gabapentin (adjusted MD -9.28bpm; 95% CI -12.1bpm to -6.46bpm). Failsafe 
N showed 232 studies would be required to observe a negative effect with 
gabapentin. 
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Figure 5.13: Funnel plot of HR at one minute. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
 
On meta-regression analysis, increasing gabapentin dose predicted greater 
attenuation of the HR response to intubation (R2=35%; p=0.006) (Figure 5.14). 
Baseline HR was not a significant predictor of gabapentin response (p=0.45). 
Regression diagnostics showed one study has a studentised residual above two 
and one study had one above three. No study had a Cook’s distance of more 
than one. Histograms of residuals showed they were approximately normally 
distributed although there was evidence of some negative skew. Predicted 
versus studentised residual plots showed possible evidence of 
heteroscedasticity.    
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Figure 5.14: Meta-regression plot. X-axis shows gabapentin dose (mg) and the 
Y-axis the MD in HR at one minute. 
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Figure 5.15: Trial sequential analysis of HR at one minute. Performed 
assuming a MD of 5bpm, a variance of 166, adjusted α=0.05, 1-β=0.80 and a 
heterogeneity correction of 79. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien Fleming 
boundary for benefit (Figure 5.15). Gabapentin also reached the required IS for 
a definitive answer (1013 participants). On sensitivity analysis, assuming an 
empirical MD of -8.64bpm, gabapentin both crossed the boundary for benefit 
and reached the required IS (344 participants). Assuming a variance of 300 
increased the required IS (1828 participants) which gabapentin did not reach.  
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5.3.9 HR five minutes 	
Overall, 25 studies with 1564 participants were included in the analysis. 
Gabapentin produced a clinically significant attenuation of the HR response to 
intubation (MD -6.20bpm; 95% CI -8.48bpm to -3.92bpm; Figure 5.16). There 
was evidence of considerable statistical heterogeneity (I2=76%; p<0.001). The 
level of evidence according to GRADE was moderate (downgraded owing to 
concerns over risk of bias). 
 
 
 
Figure 5.16: Forest plot of HR at five minutes.  
 
On visual inspection of funnel plots, there was no obvious asymmetry (Figure 
5.17). However, Egger’s linear regression test showed evidence of imprecise 
study effects (p<0.001). Despite this, trim and fill analysis showed the missing 
studies were from the left of the mean, suggesting a bias against gabapentin 
(adjusted MD -6.88bpm; 95% CI -9.07bpm to -4.70bpm). Failsafe N showed 
88 negative studies would be required to observe a negative effect with 
gabapentin.  
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Figure 5.17: Funnel plot of HR at five minutes. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
 
On meta-regression analysis, increasing gabapentin dose predicted greater 
attenuation of the HR response to intubation (R2=38%; p=0.02) (Figure 5.18). 
However, baseline HR was not a significant predictor (p=0.83). On regression 
diagnostics, only one study had a studentised residual of more than two and no 
study had a Cook’s distance of more than one. Residuals were approximately 
normally distributed on histograms. Predicted versus residual plots revealed 
possible evidence of heteroscedasticity. As only one predictor was used in the 
final model, no tests for multicollinearity were performed.   
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Figure 5.18: Meta-regression plot. X-axis shows gabapentin dose (mg) and the 
Y-axis the MD in HR at five minutes. 
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Figure 5.19: Trial sequential analysis of HR at five minutes. Performed 
assuming a MD of 5bpm, a variance of 70.5, adjusted α=0.05, 1-β=0.80 and a 
heterogeneity correction of 87. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.19). In addition, gabapentin reached the 
required IS for a definitive answer (669 participants). On sensitivity analysis, 
assuming an empirical MD of 6.2bpm did not change results (IS 436 
participants). Assuming a variance of 140 increased the required IS to 1324 
participants, which the results for gabapentin still reached. 
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5.3.10 HR 10 minutes 	
Overall, 22 studies with 1458 participants were included in the analysis. 
Gabapentin produced a clinically significant attenuation of the HR response 10 
minutes after intubation (MD -5.41bpm; 95% CI -7.26bpm to -3.55bpm; Figure 
5.20). There was evidence of moderate statistical heterogeneity (I2=46%; 
p=0.009). The quality of evidence was moderate according to GRADE 
(downgraded owing to concerns over risk of bias). 
 
 
 
Figure 5.20: Forest plot of HR at 10 minutes.  
 
There was no obvious asymmetry on visual inspection of funnel plots (Figure 
5.21). Indeed, Egger’s linear regression test was not statistically significant 
(p=0.19). On meta-regression analysis, baseline HR did not predict the efficacy 
of gabapentin (p=0.79). However, increasing gabapentin dose predicted greater 
attenuation of HR response to intubation (R2=52%; p=0.004) (Figure 5.22). On 
regression diagnostics, no study had a studentised residual of more than two 
and no study had a Cook’s distance of more than one. Histograms showed 
residuals were approximately normally distributed. Predicted versus 
studentised residual plots revealed some evidence of heteroscedasticity. 
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Figure 5.21: Funnel plot of HR at 10 minutes. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.22: Meta-regression plot. X-axis shows gabapentin dose (mg) and the 
Y-axis the MD in HR at 10 minutes. 
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Figure 5.23: Trial sequential analysis of HR at 10 minutes. Performed 
assuming a MD of 5bpm, a variance of 157, adjusted α=0.05, 1-β=0.80 and a 
heterogeneity correction of 49.5. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.23). In addition, gabapentin reached the 
required IS for a definitive answer (392 participants). On sensitivity analysis, 
assuming an empirical MD of 5.41bpm did not change results (IS 326 
participants). Assuming a variance of 300 increased the required IS (746 
participants), as did assuming a heterogeneity correction of 90 (1980 
participants), which gabapentin did not reach.  
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5.3.11 SBP one minute 	
Overall, 15 studies with 928 participants were included in the analysis. 
Gabapentin produced a clinically significant attenuation of the SBP response to 
intubation after one minute (MD -15.68mmHg; 95% CI -21.98mmHg to -
9.38mmHg; Figure 5.24). There was evidence of considerable statistical 
heterogeneity (I2=90%; p<0.001). The quality of evidence was low according 
to GRADE (downgraded owing to concerns over risk of bias and unexplained 
heterogeneity). 
 
 
 
Figure 5.24: Forest plot of SBP at one minute.  
 
Visual inspection of the funnel plot revealed no obvious asymmetry (Figure 
5.25). Indeed, Egger’s linear regression test was not statistically significant 
(p=0.27). Therefore, no sensitivity analyses for publication bias were 
undertaken. On meta-regression analysis, neither dose (p=0.59) nor baseline 
SBP (p=0.58) predicted the efficacy of gabapentin on SBP responses to 
intubation.  
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Figure 5.25: Funnel plot of SBP at one minute. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.26: Trial sequential analysis of SBP at one minute. Performed 
assuming a MD of 10mmHg, a variance of 218, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 91. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.26). In addition, gabapentin reached the 
required IS for a definitive answer (759 participants). On sensitivity analysis, 
assuming an empirical MD of 15.68mmHg, gabapentin crossed the boundary 
for benefit and reached the required IS (308 participants). Assuming variance 
of 400 increased the required IS (1386 participants) which gabapentin did not 
reach. 
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5.3.12 SBP five minutes 	
Overall, 15 studies with 921 participants were included in the analysis. 
Gabapentin produced a clinically significant attenuation of the SBP response 
five minutes following intubation (MD -10.03mmHg; 95% CI -15.59mmHg to 
-4.47mmHg; Figure 5.27). There was evidence of considerable statistical 
heterogeneity (I2=89%; p<0.001). The level of evidence was regarded as low 
quality according to GRADE (downgraded owing to concerns over risk of bias 
and unexplained heterogeneity). 
 
 
 
Figure 5.27: Forest plot of SBP at five minutes.  
 
Visual inspection of funnel plots revealed no obvious asymmetry (Figure 5.28). 
Indeed, Egger’s linear regression test was not statistically significant (p=0.43). 
Therefore, no sensitivity analyses for publication bias were undertaken. On 
meta-regression analysis, neither dose (p=0.30) nor baseline SBP (p=0.81) 
predicted the effects of gabapentin on SBP.  
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Figure 5.28: Funnel plot of SBP at five minutes. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.29: Trial sequential analysis of SBP at five minutes. Performed 
assuming a MD of 10mmHg, a variance of 181, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 90. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.29). In addition, gabapentin reached the 
required IS for a definitive answer (581 participants). On sensitivity analysis, 
assuming a variance of 300 increased the IS to 969 participants.  
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5.3.13 SBP 10 minutes 	
Overall, 13 studies with 855 participants were included in the analysis. 
Although gabapentin attenuated the SBP response 10 minutes following 
intubation (MD -8.78mmHg; 95% CI -15.63mmHg to -1.92mmHg; Figure 
5.30), this was not clinically significant. However, the CI could not exclude a 
clinically significant result. There was evidence of considerable statistical 
heterogeneity (I2=94%; p<0.001). The quality of evidence was low according 
to GRADE (downgraded owing to concerns over risk of bias and unexplained 
heterogeneity).  
 
 
 
Figure 5.30: Forest plot of SBP at 10 minutes.  
 
Visual inspection of funnel plots revealed no obvious asymmetry (Figure 5.31). 
Indeed, Egger’s linear regression test was not statistically significant (p=0.30). 
Therefore, further analyses for publication bias were not undertaken. On meta-
regression analysis, neither gabapentin dose (p=0.42) nor baseline SBP 
(p=0.92) predicted the efficacy of gabapentin. 
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Figure 5.31: Funnel plot of SBP at 10 minutes. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.32: Trial sequential analysis of SBP at 10 minutes. Performed 
assuming a MD of 10mmHg, a variance of 161, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 94. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.32). In addition, gabapentin reached the 
required IS for a definitive answer (827 participants). On sensitivity analysis, 
similar results were obtained with an empirical MD of -8.78mmHg although 
gabapentin did not reach the required IS (1070 participants). Assuming a 
variance of 300 increased the required IS (1540 participants).  
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5.3.14 DBP one minute 	
Overall, 14 studies with 892 participants were included in the analysis. 
Gabapentin produced a clinically significant attenuation of the DBP response 
one minute after intubation (MD -11.26mmHg; 95% CI -15.46mmHg to -
7.07mmHg; Figure 5.33). There was evidence of considerable statistical 
heterogeneity (I2=84%; p<0.001). The level of evidence was regarded as low 
quality according to GRADE (downgraded owing to concerns over risk of bias 
and unexplained heterogeneity). 
 
 
 
Figure 5.33: Forest plot of DBP at one minute.  
 
Visual inspection of funnel plots revealed no obvious asymmetry (Figure 5.34). 
Indeed, Egger’s linear regression test was not statistically significant (p=0.32). 
Therefore, no sensitivity analyses of publication bias were undertaken. On 
meta-regression analysis, neither gabapentin dose (p=0.97) nor baseline DBP 
(p=0.58) predicted the efficacy of gabapentin. 
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Figure 5.34: Funnel plot of DBP at one minute. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.35: Trial sequential analysis of DBP at one minute. Performed 
assuming a MD of 10mmHg, a variance of 148, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 85. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.35). In addition, the results for gabapentin 
reached the required IS for a definitive answer (323 participants). On 
sensitivity analysis, assuming an empirical MD of -11.26mmHg did not change 
results (IS 254 participants). Assuming a variance of 300 increased the 
required IS (654 participants). 
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5.3.15 DBP five minutes 	
Overall, 14 studies with 885 participants were included in the analysis. 
Gabapentin attenuated the DBP response five minutes following intubation 
(MD -7.40mmHg; 95% CI -10.90mmHg to -3.89mmHg; Figure 5.36). 
However, this result was not clinically significant. There was evidence of 
considerable statistical heterogeneity (I2=79%; p<0.001). The level of evidence 
was low quality according to GRADE (downgraded owing to concerns over 
risk of bias and unexplained heterogeneity).  
 
 
 
Figure 5.36: Forest plot of DBP at five minutes.  
 
Visual inspection of funnel plots revealed no obvious asymmetry (Figure 5.37). 
Indeed, Egger’s linear regression test was not statistically significant (p=0.24). 
Therefore, no sensitivity analyses for publication bias were undertaken. On 
meta-regression analysis, neither gabapentin dose (p=0.79) nor baseline DBP 
(p=0.98) predicted the efficacy of gabapentin. 
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Figure 5.37: Funnel plot of DBP at five minutes. X-axis shows the MD and 
the Y-axis shows the standard error of the MD. 
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Figure 5.38: Trial sequential analysis of DBP at five minutes. Performed 
assuming a MD of 10mmHg, a variance of 130, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 82. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.38). In addition, gabapentin results reached the 
required IS for a definitive answer (223 participants). On sensitivity analysis, 
assuming an empirical MD of -7.4mmHg did not change results (IS 408 
participants). Assuming a variance of 250 increased the IS (430 participants), 
which the results for gabapentin reached. 
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5.3.16 DBP 10 minutes 	
Overall, 13 studies with 855 participants were included in the analysis. 
Gabapentin attenuated the DBP response 10 minutes following intubation (MD 
-6.37mmHg; 95% CI -10.29mmHg to -2.45mmHg; Figure 5.39). However, this 
result was not clinically significant. There was evidence of considerable 
statistical heterogeneity (I2=89%; p<0.001). The quality of evidence was low 
according to GRADE (downgraded owing to concerns over risk of bias and 
unexplained heterogeneity). 
 
 
 
Figure 5.39: Forest plot of DBP at 10 minutes.  
 
Visual inspection of funnel plots revealed no obvious asymmetry (Figure 5.40). 
Indeed, Egger’s linear regression test was not statistically significant (p=0.30). 
Therefore, further sensitivity analyses for publication bias were not undertaken. 
On meta-regression analysis, neither gabapentin dose (p=0.24) nor baseline 
DBP (p=0.80) predicted the efficacy of gabapentin. 
 
 
 
 
 
 
	 268	
 
 
Figure 5.40: Funnel plot of DBP at 10 minutes. X-axis shows the MD and the 
Y-axis shows the standard error of the MD. 
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Figure 5.41: Trial sequential analysis of DBP at 10 minutes. Performed 
assuming a MD of 10mmHg, a variance of 93, adjusted α=0.05, 1-β=0.80 and 
a heterogeneity correction of 89. Blue line indicates cumulative Z score with 
values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis showed that gabapentin crossed the O’Brien-Fleming 
boundary for benefit (Figure 5.41). In addition, gabapentin reached the 
required IS for a definitive answer (275 participants). On sensitivity analysis, 
using an empirical MD of -6.37mmHg increased the IS, which gabapentin 
reached (669 participants). Assuming a variance 180 also increased the IS (522 
participants).  
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5.3.17 Catecholamines 	
Only one study reported serum catecholamine concentrations following 
intubation (Ali et al. 2009). Gabapentin resulted in a lower secretion of 
adrenaline one minute following intubation (MD -5 pg/ml; 95% -9.43 pg/ml to 
-0.57 pg/ml). However, at the same time point, the secretion of noradrenaline 
was higher with gabapentin compared to control (MD 65 pg/ml; 95% CI 46.51 
pg/ml to 83.49 pg/ml). 
 
5.3.18 Hypertension or tachycardia requiring treatment 	
Overall, five studies with 339 participants were included in the analysis. 
Gabapentin reduced the risk of patients requiring treatment for hypertension or 
tachycardia (RR 0.15; 95% CI 0.05 to 0.48; Figure 5.42). There was no 
evidence of statistical heterogeneity (I2=0%; p=0.80). The level of evidence 
was moderate quality according to GRADE (downgraded owing to concerns 
over risk of bias). Due to the low number of studies, tests for publication bias 
were not undertaken. Definitions for this outcome were as follows; SBP 
>200mmHg or >30% increase from baseline for more than 60 seconds (Ali et 
al. 2009; Memis et al. 2006); HR >130bpm, SBP >200mmHg or >30% 
increase from baseline for more than 60 seconds (Bala, Bharti and Ramesh 
2015); MAP or HR >20% of baseline (Bharti et al. 2013); MAP >110mmHg 
(Neogi et al. 2012).  
 
 
 
Figure 5.42: Forest plot of the risk of hypertension or tachycardia requiring 
treatment.  
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Figure 5.43: Trial sequential analysis of hypertension or tachycardia requiring 
treatment. Performed assuming an incidence of 15%, a RRR of 50%, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin. 
 
Trial sequential analysis could not be performed for RRR of 20% due to too 
little information. Therefore, it was conducted assuming a RRR of 50% (Figure 
5.43). Gabapentin crossed the O’Brien-Fleming boundary for benefit. 
However, it did not reach the required IS for a definitive answer (558 
participants). On sensitivity analysis, assuming an incidence of 10% meant 
gabapentin did not cross the boundary for benefit and did not reach the 
required IS (872 participants). Assuming a heterogeneity correction of 25 
increased the required IS (744 participants). 
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5.3.19 Hypotension requiring treatment 	
Only one study reported this outcome (Bala, Bharti and Ramesh 2015). There 
was an increase in the risk of hypotension with gabapentin (SBP <90mmHg or 
>30% from baseline lasting more than 60 seconds), although the CI overlapped 
the null result and would therefore be regarded as not statistically significant 
(RR 2.40; 95% CI 0.74 to 7.79).  
 
5.3.20 Bradycardia requiring treatment 	
Only one study reported this outcome (Fassoulaki et al. 2006). There was no 
increase in the risk of bradycardia (HR<40bpm) with gabapentin although the 
CI suggested a possible increase in risk (RR 3.00; 95% CI 0.13 to 69.87). 
 
5.3.21 Sensitivity analysis 	
Including only studies at low risk of bias left only two studies (Koc, Memis 
and Sut 2009; Parida et al. 2015), which resulted in no significant reductions 
for many outcomes. Excluding studies where standard deviations were 
estimated did not significantly affect results. One study-removed sensitivity 
analysis showed there were no influential studies in any of the analyses. 
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5.4 Discussion 	
5.4.1 Summary of results 	
This chapter found that no studies evaluated the use of gabapentin in high-risk 
patients undergoing surgery and consequently reported no incidences of any of 
the primary, clinically relevant outcomes. Despite this, gabapentin produced 
clinically significant attenuation in the rises in MAP, HR, SBP and DBP when 
compared to the control group (moderate to low quality evidence). In addition, 
gabapentin reduced the proportion of patients requiring treatment for 
hypertension or tachycardia. Following intubation, one study found gabapentin 
reduced circulating levels of adrenaline and increased noradrenaline. Adverse 
haemodynamic effects such as hypotension and bradycardia were rarely 
reported and data remains thus far limited, although confidence intervals 
suggest a possible increase. Increasing gabapentin dosages led to greater 
attenuation of HR responses on meta-regression analysis. 
 
5.4.2 Links with previous research 	
The haemodynamic response to intubation involves a stress response, which 
causes increases in catecholamine levels and subsequent increases in HR and 
blood pressure (Kovac 1996). In high-risk patients, such increases can lead to 
myocardial ischaemia and therefore myocardial infarction (Kovac 1996; Roy, 
Edelist and Gilbert 1979; Sloghoff and Keats 1985). In such patients, 
myocardial infarction occurs in around 5% and stroke in 0.5% (POISE Study 
Group 2008). Many agents have been used to attenuate the haemodynamic 
response to intubation and thus aim to reduce myocardial ischaemia (Khan and 
Ullah 2013). Although agents such as clonidine (Wijeysundera, Naik and 
Beattie 2003) and beta-blockers have shown promise in reducing peri-operative 
cardiac events, the large randomised controlled POISE studies showed an 
increase in mortality and stroke with peri-operative beta-blocker therapy 
(POISE Study Group 2008) and increases in clinically important hypotension 
and non-fatal cardiac arrest with clonidine (Devereaux et al. 2014). Therefore, 
the search continues for effective agents that can reduce peri-operative 
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myocardial events in high-risk patients without increasing adverse events such 
as hypotension and bradycardia and therefore all-cause mortality. 
 
Although peri-operative events such as intubation, extubation, surgery and pain 
can all contribute to increasing myocardial demand (Devereaux et al. 2005), 
our review only focused on the brief haemodynamic response following 
intubation and therefore caution is advised in extrapolating these results with 
any direct link with longer-term adverse cardiac events during the peri-
operative period, such as those studied in POISE. Despite this, gabapentin is 
known to reduce postoperative pain, attenuate the hemodynamic response to 
intubation and reduce catecholamine and cortisol responses postoperatively 
(Karbic et al. 2014). Therefore it may have longer-term effects on reducing 
myocardial demand in the postoperative period, which should be the focus of 
future studies. 
 
As observed in chapter two, gabapentin has proven efficacy as a peri-operative 
analgesic with reductions in pain scores and opioid consumption in various 
types of surgery. Other beneficial effects include reductions in pre-operative 
anxiety, vomiting, pruritus at the expense of increased sedation. Interestingly, 
these trials provide the only evidence of the possible haemodynamic effects of 
gabapentin in high-risk patients. In chapter two, when observing studies within 
these postoperative pain trials that included participants undergoing 
cardiothoracic surgery (which included high risk cardiac patients), the results 
suggested a reduction in postoperative arrhythmia with gabapentin (RR 0.55; 
95% CI 0.28 to 1.08).  
 
Our review suggests gabapentin may also be an effective agent in reducing the 
haemodynamic response to intubation. We found only one study that suggested 
this might be mediated by reductions in adrenaline when compared to control 
(Ali et al. 2009). Previous in vitro research has suggested that gabapentin may 
inhibit the release of catecholamines from adrenal chromaffin cells (Todd et al. 
2012), which may confirm this as a possible mechanism of action. 
Furthermore, a recent RCT has demonstrated that pre-operative gabapentin can 
reduce postoperative catecholamine (both adrenaline and noradrenaline) and 
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cortisol concentrations in women undergoing hysterectomy (Karbic et al. 
2014). However, the magnitude of difference between the groups in our review 
was around 8%, which may be regarded as clinically small. Another potential 
mechanism may relate to calcium channel inhibition. As calcium channel 
blockers can attenuate the haemodynamic response to intubation and share a 
target mechanism with gabapentin, this may produce similar effects in a 
clinical population (Cheng and Chiou 2006).  
 
On meta-regression analysis, we found that gabapentin dose influenced the 
attenuation of HR responses, with higher doses producing lower heart rates 
when compared with the control group. Our previous meta-regression has 
shown a similar effect when evaluating morphine reductions during the 
postoperative period.  However, baseline haemodynamic variables recorded 
before induction did not influence our results. This suggests that similar 
differences would be achieved regardless of the baseline blood pressure or HR 
of the participants. Despite this, it should be noted that most of the included 
studies included low risk, non-hypertensive patients and therefore the range of 
baseline values was limited. These meta-regression results, suggest future 
studies should aim to use higher doses in order to improve the absolute effects 
of gabapentin on HR responses. However, the oral route of gabapentin used in 
the included studies has implications for its use in high-risk patients, which 
may be prohibitive in emergency surgery. In addition, it is unclear whether 
titration of gabapentin dose would alter efficacy, an issue raised in the first 
POISE study. Moreover, it is unclear whether such increases in dose would 
affect the incidence of bradycardia and hypotension, which may have been 
responsible for the increased mortality in POISE. With regards to the 
pharmacokinetics of gabapentin, bioavailability is known to decrease with 
increasing dosages, therefore plasma concentrations may not reflect the dose 
administered (Stewart et al. 1993). 
 
Gabapentin was found to reduce the risk of hypertension or tachycardia that 
required treatment. This result is intuitive given the observed effects of 
gabapentin on HR and blood pressure. However, data from the studies included 
in this chapter are limited with regards to episodes of bradycardia or 
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hypotension, with wide CIs suggesting a possible increase in risk. Indeed, one 
study in the review excluded three patients from the analysis due to 
hypotension (Soltanzadeh et al. 2012) and one study excluded a patient for an 
episode of bradycardia (Fassoulaki et al. 2006). The former was not included 
in the meta-analysis, as it did not report whether these patients required 
treatment. As intra-operative hypotension may be associated with stroke (Ng, 
Chan and Gelb 2011), myocardial injury, acute kidney injury (Walsh et al. 
2013) and mortality (Bijker et al. 2009), future studies with gabapentin should 
aim to report these adverse outcomes. Although previous research in rats has 
shown no reductions in baseline haemodynamic variables with gabapentin 
administration (Yoon and Choi 2003), such effects are unknown in peri-
operative clinical practice. 
 
5.4.3 Limitations 	
There are several limitations with this chapter. Firstly, we were unable to 
provide any results for the primary outcomes owing to the inclusion of low risk 
patients resulting in zero incidences of these events or these outcomes not 
being evaluated in the included studies. Secondly, as previously discussed, 
there is limited evidence with regards to adverse events such as hypotension 
and bradycardia, which have the potential to cause fatal peri-operative events. 
The CI in our review suggested a possible increase and this warrants further 
study. Thirdly, many studies were at potential risk of bias, particularly for 
allocation concealment, which may bias the results of this review (Schulz and 
Grimes 2002a). Indeed, only two studies included in the review were deemed 
to be at low risk of bias for most domains, which limited the quality of the 
evidence. Although we found evidence of possible publication bias, this was at 
the expense of gabapentin, meaning effect estimates would more likely be 
underestimated should the assumption of a symmetric funnel plot hold.  
 
In addition to these issues with internal validity, many of the studies included 
in the review were conducted in non-G7 countries and therefore it is unclear 
how applicable our results are to North American and Western European 
populations. Very few of the included studies provided details of the 
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equipment used to obtain non-invasive blood pressure measurements. As 
values from oscillometric methods are algorithmically derived, these may vary 
between devices, which may introduce heterogeneity into our results. Also, this 
lack of information meant evaluating whether such devices are valid, precise 
and accurate was problematic. As the majority of the included studies 
measured blood pressure at discrete time-points, important hypotensive or 
hypertensive episodes may have been missed, as such discrete measurements 
may not reflect the average values occurring between such measurements.	
 
5.4.4 Conclusions 	
In conclusion, this review has found evidence that gabapentin reduces HR and 
blood pressure responses to intubation, which may be dose-dependent in 
relation to HR. However, data is limited with regards to adverse 
haemodynamic events and clinically relevant outcomes in high-risk patients. 
Therefore, future studies are required that recruit many more participants, are 
conducted with higher standards of internal validity while including high risk 
patients and measuring clinically-relevant outcomes such as myocardial 
ischaemia, infarction and mortality.  
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Chapter 6 
Meta-regression analysis of other 
multimodal analgesic adjuncts 
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6.1 Introduction 	
Meta-analyses have emerged as a useful method to summarise research 
findings and increase the statistical power of primary research studies. 
However, one of the major limitations of this form of analysis is the 
aggregation of trials conducted in both different populations and in different 
clinical circumstances. This is termed clinical heterogeneity. Such clinical 
heterogeneity, along with other methodological disparities, may give rise to 
statistical heterogeneity (Higgins and Thompson 2002). For example, if all 
studies within a meta-analysis were assessing the same agent from the same 
population, we would expect confidence intervals to overlap, as the only 
differences between studies would be due to sampling variance from the 
population. However, when clinical heterogeneity or methodological 
disparities occur, this can cause confidence intervals to vary by more than 
would be expected by chance, which can be quantified using measures such as 
the I2 statistic (Higgins and Thompson 2002).  
 
Unexplained statistical heterogeneity can increase the uncertainty surrounding 
effect estimates derived from meta-analyses and reduce the quality of evidence 
used to inform healthcare decisions (Guyatt et al. 2008). In addition, in the 
presence of statistical heterogeneity, effect estimates may be inaccurate and 
lead to erroneous conclusions on the clinical significance of a particular agent. 
Therefore, investigating the causes for heterogeneity is essential using 
techniques such as meta-regression analysis (Thompson and Higgins 2002). 
Baseline risk is a particular covariate that can help predict between-study 
heterogeneity in meta-analyses. However, conventional meta-regression 
analysis may be limited by bias caused by measurement error in the covariate 
and regression to the mean (Sharp, Thompson and Altman 1996; Sharp and 
Thompson 2000). Therefore, alternative analyses such as Bayesian meta-
regression are recommended (Achana et al. 2013). 
 
Heterogeneity is a particular problem in meta-analyses of analgesics used to 
prevent postoperative pain (Espitalier et al. 2013). Indeed, a previous review 
has suggested that type of surgery should be explored in these reviews 
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(Espitalier et al. 2013). However, even within the same type of surgical 
procedure, pain levels can be heterogeneous. In addition, differing analgesic 
protocols can further confound the association between type of surgery and the 
efficacy of the analgesic under study. Previous primary research has shown 
that the pain level experienced by a participant determines analgesic efficacy, 
with higher pain levels resulting in higher absolute pain score reductions 
following analgesic administration (Averbuch and Katzper 2003; Bjune et al. 
1996). We have previously demonstrated that using control group morphine 
consumption (baseline risk), we were able to predict a large degree of between-
study heterogeneity for 24-hour morphine consumption (Doleman et al. 2015a; 
Doleman et al. 2015b). 
 
This finding may have important clinical implications as meta-analyses are 
often used to inform clinical decision-making. However, any one finding from 
a meta-analysis of an analgesic adjunct may be confounded by the variable 
control group morphine consumption from the included trials. If control group 
morphine consumption is found to be a significant predictor of between-study 
heterogeneity, quoting regression parameter estimates from a fixed value of 
morphine consumption would allow more accurate comparisons between 
analgesics and help better inform clinical decision-making. In addition, 
explaining heterogeneity could improve the quality of systematic review 
evidence as per GRADE (Guyatt et al. 2008). With regards to clinical practice 
and RCT conduct, more targeted use of analgesic adjuncts in situations where 
expected postoperative morphine consumption is high would help improve 
their clinical significance and may help further reduce opioid adverse effects. 
 
 
 
 
 
 
 
 
	 281	
Therefore, the aims of this chapter were as follows: 1) to perform a meta-
epidemiological study of methods for investigating heterogeneity in reviews 
and methodological conduct in RCTs of analgesic adjuncts 2) to identify the 
prevalence of considerable statistical heterogeneity 3) investigate heterogeneity 
using control group consumption and other clinical and methodological 
covariates 4) utilise these principles to construct a league table of analgesic 
adjuncts assuming a fixed consumption of postoperative morphine to more 
accurately report efficacy.  
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6.2 Methods 	
6.2.1 Search strategy, reporting standards and registration 	
We reported this chapter in accordance with the PRISMA checklist (Moher et 
al. 2009). We prospectively registered the review on the PROSPERO website 
using the registration number CRD42016039109. The aim of the study search 
was to identify previous reviews of postoperative analgesic agents and perform 
a meta-epidemiological study of these with analyses of both the reviews 
themselves and through secondary analysis of the individual RCTs. We 
searched all databases from inception to May 2016: MEDLINE, EMBASE, 
CINAHL, AMED and the Cochrane Database of Systematic Reviews. We used 
the following search terms ‘postoperative AND pain’, ‘surgery’, ‘analgesi*’, 
‘morphine AND consumption’, ‘opioid AND consumption’ and we exploded 
the MeSH term ‘ACUTE PAIN’. We combined these terms with the specific 
generic term for the analgesic agent. We then limited our search to reviews and 
meta-analyses.  
 
6.2.2 Data extraction 	
We extracted data onto an electronic database. If results were not reported in 
the original meta-analysis, we extracted data from the original publications. In 
order to reduce selective reporting bias, if standard deviations were not 
reported, we estimated these from other studies in the analysis (Higgins and 
Green 2008). We did not attempt to calculate means and standard deviations 
from medians or inter-quartile ranges due to the high likelihood of non-normal 
data (Higgins and Green 2008). If results were not reported in the text, these 
were estimated from published graphs. We extracted the following data: study 
author, type of agent, postoperative opioid used and data used to calculate 
effect estimates.  
 
6.2.3 Inclusion criteria and outcomes 	
We had no language restrictions for inclusion in our review and we translated 
non-English language papers (Egger et al. 1997b). We included reviews that 
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included the following analgesic agents versus placebo for postoperative pain: 
paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS) and 
cyclooxygenase (COX) 2 inhibitors, tramadol, intravenous ketamine, alpha-2 
agonists (clonidine and dexmedetomidine), gabapentin, pregabalin, nefopam, 
lidocaine, magnesium and dexamethasone. We aimed to identify reviews of 
prophylactic administration (defined as first dose given before the onset of pain 
or agents added to postoperative analgesic regimens, such as PCA). We did not 
include reviews evaluating single dose analgesics for established postoperative 
pain or reviews in dental surgery as these are unlikely to report 24-hour 
morphine consumption. 
 
The outcome of interest was 24-hour opioid consumption. We chose opioid 
consumption as this serves as a surrogate measure for both how painful the 
procedure was and any concurrent analgesia used. In addition, as participants 
within these trials can use variable amounts of morphine to achieve a desired 
level of comfort, it may be more appropriate than pain score data, which may 
be confounded by variable morphine use between the groups. We only 
included primary studies where we could extract morphine consumption data. 
If studies reported dosage per kilogram (kg), we converted this to a 70kg 
weight. We also used data from the day of surgery or postoperative day one 
and analysed this as 24-hour data. If alternative opioids were reported, these 
were converted to morphine equivalents using the following conversion 
factors: oral to intravenous morphine (3:1) (Takahashi et al. 2003), 
pethidine/meperidine (10:1) (Stanley et al. 1996), ketobemidone (1:1) (Jylli et 
al. 2004), tramadol (20:1) (Marcou et al. 2005), fentanyl (1:100) (Galinski et 
al. 2005), remifentanil (1:100) (Glass, Gan and Howell 1999), piritramide 
(1:0.75) (Kay 1971), hydromorphone (1:3) (Dunbar et al. 1996), oral 
hydrocodone (2:1), intravenous oxycodone (1:1.5) (Lenz et al. 2009), oral 
oxycodone (2.5:1), papaveretum (1.5:1) (Loan, Dundee and Clark 1966), 
meptazinol (5:1) (Siegel et al. 1989), nalbuphine (1:1) (Yeh et al. 2008), 
propoxyphene (10:1) (Fraser and Isbell 1960), sublingual buprenorphine (1:25) 
(Maunuksela, Korpela and Olkkola 1988) and trimeperidine (2:1).  
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6.2.4 Risk of bias 	
We undertook assessment of RCTs from included reviews using the Cochrane 
risk of bias tool. For blinding to receive low risk, studies had to describe in 
enough detail study drugs and placebos that were identical or similar in 
appearance rather than simply describe the study as ‘double-blind’ (Schultz 
and Grimes 2002b). Outcome assessment also needed to be blinded to receive 
low risk. Attrition bias would receive high risk if patients were excluded from 
the analysis for reasons that may influence opioid consumption, such as those 
with uncontrolled pain or potential opioid adverse effects. Studies only 
received low risk for selective outcome reporting if outcomes were pre-stated 
in a published protocol or trial registration referenced in the included study. 
Other bias included baseline characteristic imbalances, which have been 
associated with influencing pain (for example gender and pre-operative pain) 
(Kalkman et al. 2003) or industry sponsorship (Lexchin et al. 2003).  
 
6.2.5 Statistical analysis 	
To quantify the degree of statistical heterogeneity we used the I2 statistic, with 
values exceeding 75% as evidence of considerable heterogeneity and those 
exceeding 50% as evidence of moderate statistical heterogeneity (Higgins and 
Thompson 2002). For the available data, we calculated the mean difference 
(MD) in morphine consumption (mg) with 95% confidence intervals (CI) using 
a random-effects model. In order to identify whether control group morphine 
consumption could explain the between-study heterogeneity we undertook 
meta-regression analysis (Thompson and Higgins 2002). This analysis is 
similar to conventional regression analysis, although it involves using study-
level covariates, such as the dose of the analgesic used in the trial as the 
predictor variable and the effect estimate as the outcome variable, with each 
study weighted for the precision of the results (lower standard errors having 
more weight).  
 
We performed meta-regression initially using control group morphine 
consumption as a covariate based on previous findings (Doleman et al. 2015a; 
	 285	
Doleman 2015b). We also used the following clinical covariates: dose or route 
of drug administration, type of surgery and type of anaesthesia. For type of 
surgery, where possible, we aimed to include procedure-specific evidence, if 
this was not possible we grouped procedures by specialty or anatomical 
location. In addition, we assessed whether measures of internal validity were 
responsible for statistical heterogeneity including: randomisation, allocation 
concealment, blinding and attrition bias. Except for attrition bias, these 
covariates were only included in models if they exaggerated effect estimates. 
Control group morphine consumption was initially added to the model, we then 
added other covariates to a multivariate model to adjust regression estimates 
for these confounding variables, if they significantly improved the model, in a 
stepwise approach (p<0.1).  
 
Due to the problems with analysing baseline risk using conventional meta-
regression, we also undertook Bayesian meta-regression (performed by a 
statistician) using Markov Chain Monte Carlo with Gibbs sampling (Achana et 
al. 2013). We used vague prior distributions and burnt in the MCMC chains for 
10,000 iterations and then used a sample of 50,000 iterations on which to base 
inferences. We checked convergence visually by looking at history plots of the 
sampled values. We present the results of regression parameters using the 
median estimate with 95% credible intervals (CrIs). 
 
For conventional meta-regression, we used a restricted maximum likelihood, 
random-effects model. We also used the Knapp-Hartung method to estimate p 
values for each covariate. We assessed linearity and heteroscedasticity from 
predicted versus residual plots and residuals were assessed for normality using 
histograms. We assessed outliers from studentised residual values and leverage 
using Cook’s distance (with values greater than one regarded as a cause for 
concern). We present results as the proportion of variation explained by the 
model (R2 analogue) with a corresponding p value. We undertook sensitivity 
analysis removing studies that had significant leverage on the model. We 
regarded p values for final models <0.005 as statistically significant following 
Sidak adjustment for multiple comparisons.  
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If we identified control group morphine consumption as a significant predictor 
of between-study heterogeneity, we produced a league table of analgesic 
adjuncts based on a fixed control group consumption of 50mg. We regarded a 
difference of >20mg as a large clinically significant difference, >10mg a 
moderate clinically significant difference and >5mg of small clinical 
significance. We were unaware of any literature regarding clinically significant 
reductions in morphine consumption. Therefore, we selected these values 
based on two (20mg) and one (10mg) standard dose of morphine. This analysis 
allows comparison of analgesic adjuncts when adjusted for the variable control 
group morphine consumption from the included RCTs in order to reduce 
confounding. Where dose or route of administration was found to be a 
significant predictor, we included results from the most effective clinical 
situation and specified this where appropriate. We present both Bayesian 
parameter estimates and adjusted conventional estimates with 95% CIs/CrIs. 
We conducted all analyses using Comprehensive Meta-analysis Version 3, 
STATA Version 14 and WinBUGS Version 1.4. 
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6.3 Results 	
6.3.1 Characteristics of reviews and randomised controlled trials 	
We included 344 RCTs with 28,130 participants (Table 6.1). We identified 
these studies from eight narrative reviews (Baidya et al. 2011; Chang et al. 
2014; De Kock and Lavand’homme 2007; Girard, Chauvin and Verleye 2016; 
Koh, Nguyen and Jahr 2015; Nossaman et al. 2010; Radvansky et al. 2015; 
Scott and Perry 2000), 25 systematic reviews (Andersen et al. 2014; Armand et 
al. 1998; Ben-Abraham 2001; Carstensen and Moller 2010; Chan, Cheung and 
Chong 2010; Choyce and Peng 2002; Clivatti, Sakata and Issy 2009; Dube and 
Granry 2003; Hyllested et al. 2002; Jebaraj et al. 2013; Jibril et al. 2015; 
Jouguelet-Lacoste et al. 2015; Macario and Royal 2011; Mathews et al. 2012; 
Mazzeffi, Johnson and Paciullo 2015; McCarthy and Megalla 2010; 
McCartney, Sinha and Katz 2004; Remerand et al. 2011; Romsing et al. 2004; 
Romsing et al. 2005; Schmid, Sandler and Katz 1999; Suzuki 2009; Wang et 
al. 2015; Zakkar, Fraser and Hunt 2013; Zemmel 2006) and 72 meta-analyses 
(Abdallah, Abrishami and Brull 2013; Achuthan et al. 2015; Afman, Welge 
and Steward 2006; Alayed et al. 2014; Albrecht et al. 2013; Apfel et al. 2003; 
Bai et al. 2015; Bainbridge et al. 2006; Bell et al. 2006; Blaudszun et al. 2012; 
De Oliveira et al. 2011; De Oliveira, Agarwal and Benzon 2012; De Oliveira et 
al. 2013; De Oliveira, Castro-Alves and McCarthy 2015; Doleman et al. 
2015a; Doleman et al. 2015b; Eipe et al. 2015; Elia and Tramer 2005; Elia, 
Lysakowski and Tramer 2005; Elia et al. 2008; Engelman and Marsala 2013; 
Evans, Lysakowski and Tramer 2008; Gobble et al. 2014; Gurusamy, Vaughan 
and Toon 2014; Heesen et al. 2015; Ho, Gan and Habib 2006; Hurley et al. 
2006; Hwang et al. 2016; Jessen, Korvenius and Moller 2016; Khan et al. 
2016; Kranke et al. 2004; Kranke et al. 2015; Lam et al. 2015; Laskowski et 
al. 2011; Lin and Pei 2012; Liu et al. 2012; Lysakowski et al. 2007; Marret et 
al. 2005; Marret et al. 2008; Mathiesen, Moiniche and Dahl 2007; McDaid et 
al. 2010; McNicol et al. 2003; Mishriky, Waldron and Habib 2015; Murphy et 
al. 2013; Ong et al. 2010; Peng, Wijeysundera and Li 2007; Peng et al. 2014; 
Remy, Marret and Bonnet 2005; Martinez, Guichard and Fletcher 2015; 
Romsing, Moiniche and Dahl 2002; Savoia, Loreto and Scibelli 2000; 
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Schnabel et al. 2013; Seib and Paul 2006; Stephens et al. 2015; Stevens, 
Woodman and Owen 2015; Stomatology and Yan 2015; Straube et al. 2005; 
Subramaniam, Subramaniam and Steinbrook 2004; Sun et al. 2012; Tiippana et 
al. 2007; Villasis-Keever, Rendon-Macias and Escamilla 2009; Ventham et al. 
2015; Vigneault et al. 2011; Waldron et al. 2013; Wei, Zhao and Li 2013; Wu 
et al. 2014; Wu, Huang and Sun 2015; Yang et al. 2014; Yao, Shen and Zhong 
2015; Yu et al. 2013; Zhang, Ho and Wang 2011; Zhong et al. 2015) (Figure 
6.1).  
 
There was evidence of considerable heterogeneity is 91% of analyses (95% CI 
74% to 100%). Of the included reviews that conducted a meta-analysis, 78% 
(95% CI 68% to 88%) investigated heterogeneity. In 75% (95% CI 65% to 
85%), investigation of heterogeneity was conducted using subgroup/sensitivity 
analysis and only 18% (95% CI 9% to 27%) conducted meta-regression. In 
32% (95% CI 21% to 43%) of meta-analyses, investigation of heterogeneity 
was based on type of surgery, 35% (95% CI 24% to 46%) used dose and 11% 
(95% CI 4% to 18%) used type of anaesthesia. In 31% (95% CI 20% to 42%) 
of meta-analyses, heterogeneity was investigated using methodological 
covariates. On risk of bias assessment of the individual RCTs, adequate 
randomisation was described in 58% (95% CI 53% to 63%) of studies, 
adequate allocation concealment in 29% (95% CI 24% to 34%), adequate 
blinding in 50% (95% CI 45% to 55%) and lack of attrition bias in 71% (95% 
CI 66% to 76%) (Figure 6.2 to 6.11 and Figure 2.2).  
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Table 6.1: Meta-regression estimates for each analgesic adjunct. Asterisk denotes statistical significance (p<0.1). CI=confidence interval; 
CrIs=credible intervals; N/A=not applicable; R2=proportion of between-study variance explained by model; I2=measure of variability in results 
due to between-study differences compared to sampling variance. 
 
Analgesic 
Studies 
(participants) 
I2 
R2 control 
morphine (p 
value) 
Intercept 
Beta coefficient and 
(95% CIs) 
Intercept 
Bayesian beta 
coefficient (median) 
and (95% CrIs) 
Paracetamol 25 (1812) 99% 
 
R2=79%; p<0.001 0.84 -0.39 (-0.49 to -0.29) 
 
 
0.77 
 
 
-0.38 (-0.48 to -0.28) 
NSAIDS and 
COX-2 inhibitors 86 (6937) 92% 
 
R2=81%; p<0.001 2.42 -0.35 (-0.41 to -0.30) 
 
 
2.56 
 
 
-0.36 (-0.41 to -0.30) 
Tramadol 11 (889) 90% R2=48%; p=0.03 2.93 -0.30 (-0.56 to -0.05) 2.96 -0.30 (-0.55 to -0.03) 
Ketamine 62 (4309) 95% R2=29%; p<0.001 -1.05 -0.18 (-0.25 to -0.10) 
 
-1.01 
 
-0.18 (-0.24 to -0.10) 
Alpha-2 agonists 33 (1930) 96% R2=66%; p<0.001 -0.52 -0.34 (-0.47 to -0.21)   
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-0.95 -0.32 (-0.44 to -0.19) 
Gabapentin 67 (5082) 97% R2=92%; p<0.001 1.12 -0.39 (-0.44 to -0.34) 
 
1.11 
 
-0.39 (-0.43 to -0.35) 
Pregabalin 34 (3201) 94% R2=58%; p<0.001 -2.62 -0.21 (-0.30 to -0.12) 
 
-2.91 
 
-0.20 (-0.28 to -0.11) 
Nefopam 5 (394) 38% N/A N/A N/A N/A N/A 
Lidocaine 22 (1319) 80% R2=62%; p<0.001 -0.25 -0.20 (-0.31 to -0.09) -0.29 -0.20 (-0.30 to -0.08) 
Magnesium 22 (1194) 90% R2=15%; p=0.02 -1.74 -0.17 (-0.31 to -0.03) -1.35 -0.19 (-0.34 to -0.04) 
Dexamethasone 16 (2163) 88% 
R2=100%; 
p<0.001 0.69 -0.19 (-0.23 to -0.14) 
 
0.86 
 
-0.18 (-0.24 to -0.12) 
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Table 6.2: League table of analgesic adjuncts assuming a 50mg consumption of morphine in the control group based on Bayesian parameter 
estimates. Random-effects mean difference, adjusted frequentist and Bayesian meta-regression parameter estimates are presented. For adjusted 
models, covariates are listed in parentheses. mg=milligrams; N/A=not applicable. 
 
Analgesic adjunct  
Mean difference on meta-
analysis Reduction in 24-hour  
morphine (adjusted) 
Reductions in 24-hour 
morphine (Bayesian; median 
with 95% CrIs) 
Gabapentin 
-8.6mg (-9.73mg to -7.46mg) 
-20.07mg (dose; 1200mg) 
-18.49mg (-19.90mg to -
17.07mg) 
Paracetamol 
-8.18mg (-10.57mg to -
6.73mg) 
-17.96mg (administration; 
intravenous and allocation) 
-18.39mg (-21.54mg to -
15.02mg) 
 
Alpha-2 agonists 
-10.7mg (-12.38mg to -
9.01mg) 
-18.39mg (administration; 
intravenous and attrition) 
-16.94mg (-20.09mg to -
13.57mg) 
NSAIDS and COX-2 inhibitors 
-11.09mg (-12.73mg to -
9.45mg) -15.31mg (none) 
-15.20mg (-16.54mg to -
13.81mg) 
Pregabalin 
 
-8.18mg (-9.6mg to -6.76mg) -11.36mg (allocation) 
-12.75mg (-15.23mg to -
10.11mg) 
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Tramadol 
-8.48mg (-11.88mg to -
4.89mg) -12.17mg (none) 
-11.99mg (-16.21mg to -
7.28mg) 
Magnesium 
-6.77mg (-8.39mg to -5.15mg) 
-3.91mg (allocation) 
-10.60mg (-14.19mg to -
7.10mg) 
Lidocaine 
-5.04mg (-7.42mg to -2.66mg) -9.15mg (administration; 
intravenous and attrition) 
-10.09mg (-13.49mg to -
6.36mg) 
Ketamine 
-8.13mg (-10.23mg to -
6.03mg) 
-7.75mg (allocation and 
blinding) 
-9.76mg (-12.15mg to -7.33mg) 
Dexamethasone 
-4.23mg (-5.79mg to -2.67mg) -5.18mg (type of surgery 
and blinding) 
-8.07mg (-9.79mg to -6.04mg) 
Nefopam 
-14.75mg (-19.34mg to -
10.17mg) N/A 
 
N/A 	
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Figure 6.1: PRISMA flowchart for the included studies. 
 
 
 
 
 
 
 
 
 
	 294	
 
Figure 6.2: Risk of bias for paracetamol RCTs. 
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Figure 6.3: Risk of bias for NSAIDS and COX-2 inhibitors RCTs. 
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Figure 6.4: Risk of bias for tramadol RCTs. 
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Figure 6.5: Risk of bias for ketamine RCTs. 
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Figure 6.6: Risk of bias for alpha-2 agonists RCTs. 
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Figure 6.7: Risk of bias for pregabalin RCTs. 
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Figure 6.8: Risk of bias for nefopam RCTs. 
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Figure 6.9: Risk of bias for lidocaine RCTs. 
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Figure 6.10: Risk of bias for magnesium RCTs. 
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Figure 6.11: Risk of bias for dexamethasone RCTs. 
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6.3.2 Paracetamol 	
The paracetamol analysis included 25 RCTs with 1812 participants (Table 6.1). 
There was evidence of considerable statistical heterogeneity (I2=99%). Control 
group morphine consumption was a significant predictor of between-study 
heterogeneity (R2=79%; p<0.001) (Figure 6.12). Bayesian meta-regression 
estimates were similar. The model was improved by the addition of route of 
administration (intravenous the most effective) and allocation concealment 
(low versus unclear risk) (R2=94%; p<0.001). The model was not improved by 
the addition of type of surgery (CABG, ENT, cholecystectomy, C-section, 
orthopaedic, hysterectomy and spinal surgery) (p=0.22), type of anaesthesia 
(p=0.95), randomisation (p=0.80), blinding (p=0.21) or attrition bias (p=0.97). 
When assuming a fixed consumption of morphine (50mg), intravenous 
paracetamol was the second most effective analgesic with a moderate clinically 
significant reduction in morphine consumption (-18.39mg; 95% CrIs -21.54mg 
to -15.02mg) (Table 6.2). When testing regression assumptions, there were no 
violations for this analysis. 
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Figure 6.12: Meta-regression plot for paracetamol. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
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6.3.3 NSAIDS and COX-2 inhibitors 	
The NSAIDS and COX-2 inhibitors analysis included 86 RCTs with 6937 
participants (Table 6.1). There was evidence of considerable statistical 
heterogeneity (I2=92%). Control group morphine consumption was a 
significant predictor of between-study heterogeneity (R2=81%; p<0.001) 
(Figure 6.13). Bayesian meta-regression estimates were similar. The addition 
of other clinical or methodological covariates failed to improve the model. 
These included type of surgery (abdominal, mixed arthroplasty, C-section, 
CABG, cholecystectomy, hip arthroplasty, hysterectomy, knee arthroplasty, 
mixed surgeries, orthopaedic, spinal surgery, thoracotomy, thyroid and 
tonsillectomy) (p=0.31), type of anaesthesia (p=0.18), COX-2 versus NSAID 
(p=0.83), type of administration (p=0.89), randomisation (p=0.47), allocation 
concealment (p=0.31), blinding (p=0.17) and attrition bias (p=0.84). When 
assuming a fixed consumption of morphine (50mg), NSAIDS and COX-2 
inhibitors were the fourth most effective analgesic with a moderate clinically 
significant effect (-15.20mg; 95% CrIs -16.54mg to -13.81mg) (Table 6.2). 
There were no violations to any of the assumptions for this model. 
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Figure 6.13: Meta-regression plot for NSAIDS and COX-2 inhibitors. X-axis 
is control group morphine consumption (mg) and Y-axis is MD for 24-hour 
morphine reductions (mg). 
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6.3.4 Ketamine 	
The intravenous ketamine analysis included 62 RCTs with 4309 participants 
(Table 6.1). There was evidence of considerable statistical heterogeneity in this 
analysis (I2=95%). Control group morphine consumption was a significant 
predictor of between-study heterogeneity (R2=29%; p<0.001) (Figure 6.14). 
Bayesian meta-regression parameter estimates were similar. The addition of 
blinding (low, unclear and high risk) and allocation concealment (low, unclear 
and high risk) significantly improved the model (R2=56%; p<0.001). However, 
the model was not improved by the addition of type of surgery (abdominal, 
arthroplasty, arthroscopy, C-section, cholecystectomy, ENT, gynaecology, 
hysterectomy, mixed surgeries, orthopaedic, spinal surgery and thoracotomy) 
(p=0.45), type of anaesthesia (p=0.44), dose (p=0.86) or attrition bias (p=0.45). 
Although the addition of randomisation improved the model in isolation, it was 
not an independent predictor on multivariate analysis. When assuming a fixed 
consumption of postoperative morphine (50mg), ketamine was the ninth most 
effective analgesic with a small clinically significant effect (-9.76mg; 95% CrIs 
-12.15mg to -7.33mg) (Table 6.2). There were no violations to the assumptions 
for this model. 
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Figure 6.14: Meta-regression plot for ketamine. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
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6.3.5 Alpha-2 agonists (clonidine and dexmedetomidine) 	
The alpha-2 agonists analysis included 33 RCTs with 1930 participants (Table 
6.1). There was evidence of considerable statistical heterogeneity (I2=96%). 
Control group morphine consumption was a significant predictor of between-
study heterogeneity (R2=66%; p<0.001) (Figure 6.15). Bayesian meta-
regression estimates were similar. The addition of route of administration 
(intravenous and spinal/epidural the most effective) and attrition bias (low, 
unclear and high risk) significantly improved the model (R2=75%; p<0.001). 
However, the model was not improved by the addition of type of surgery 
(abdominal, arthroplasty, C-section, CABG, ENT, gynaecology, hysterectomy, 
spinal surgery and cholecystectomy) (p=0.87), type of anaesthesia (p=0.53), 
clonidine versus dexmedetomidine (p=0.12), randomisation (p=0.87), 
allocation concealment (p=0.87) and blinding (p=0.60). When assuming a 
fixed consumption of postoperative morphine (50mg), alpha-2 agonists were 
the third most effective analgesics (-16.94mg; 95% CrIs -20.09mg to -
13.57mg) (Table 6.2). On testing assumptions, there was some evidence of 
heteroscedasticity for this analysis. 
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Figure 6.15: Meta-regression plot for alpha-2 agonists. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
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6.3.6 Gabapentin 	
The gabapentin analysis included 67 RCTs with 5082 participants (Table 6.1). 
There was evidence of considerable statistical heterogeneity (I2=97%). Control 
group morphine consumption was a significant predictor of between-study 
heterogeneity (R2=92%; p<0.001) (Figure 6.16). Bayesian meta-regression 
estimates were similar. The addition of peri-operative dose significantly 
improved the model (R2=93%; p<0.001). The model was not improved by the 
addition of type of surgery (abdominal, hysterectomy, breast, CABG, 
cholecystectomy, C-section, arthroplasty, arthroscopy, nasal, neurosurgery, 
orthopaedic, plastic surgery, spinal surgery, thoracotomy, thyroid and 
tonsillectomy) (p=0.36), randomisation (p=0.99), allocation concealment 
(p=0.84), blinding (p=0.15) or attrition bias (p=0.12). Although type of 
anaesthesia improved the model (p=0.08) it was not an independent predictor 
in the final model. When assuming a fixed consumption of postoperative 
morphine (50mg), gabapentin was the most effective analgesic with a moderate 
clinically significant effect (-18.49mg; 95% CrIs -19.90mg to -17.07mg) 
(Table 6.2). However, assuming a dose of 1200mg, this effect became a large 
clinically significant difference. On testing assumptions, residuals were 
leptokurtic and there was evidence of some heteroscedasticity. 
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Figure 6.16: Meta-regression plot for gabapentin. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
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6.3.7 Pregabalin 	
The pregabalin analysis included 34 RCTs with 3201 participants (Table 6.1). 
There was evidence of considerable statistical heterogeneity (I2=94%). Control 
group morphine consumption was a significant predictor of between-study 
heterogeneity (R2=58%; p<0.001) (Figure 6.17). Bayesian meta-regression 
estimates were similar. The addition of allocation concealment (low versus 
unclear risk) significantly improved the model (R2=78%; p<0.001). The model 
was not improved by the addition of type of surgery (abdominal, arthroscopy, 
breast, cardiac surgery, cholecystectomy, ENT, hysterectomy, laparoscopic 
abdominal, mixed surgeries, orthopaedic, spinal surgery and arthroplasty) 
(p=0.89), type of anaesthesia (p=0.58), peri-operative dose (p=0.84), 
randomisation (p=0.11) or attrition bias (p=0.70). Although blinding improved 
the model (p=0.01) it was not an independent predictor in the final model. 
When assuming a fixed consumption of postoperative morphine (50mg), 
pregabalin was the fifth most effective analgesic with a moderate clinically 
significant reduction in morphine consumption (-12.75mg; 95% CrIs -15.23mg 
to -10.11mg) (Table 6.2). On testing of assumptions, residuals were leptokurtic 
and there was evidence of heteroscedasticity. 
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Figure 6.17: Meta-regression plot for pregabalin. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
 
6.3.8 Nefopam 	
There were too few studies to investigate heterogeneity for nefopam.  
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6.3.9 Lidocaine 	
In the lidocaine analysis there were 22 RCTs with 1319 participants (Table 
6.1). There was evidence of considerable statistical heterogeneity (I2=80%). 
Control group morphine consumption was a significant predictor of between-
study heterogeneity (R2=62%; p<0.001) (Figure 6.18). Bayesian meta-
regression estimates were similar. The addition of route of administration 
(intravenous the most effective) and attrition bias (low versus unclear risk) 
significantly improved the model (R2=87%; p<0.001). The model was not 
improved by the addition of type of surgery (abdominal, breast, 
cholecystectomy, ENT and spinal surgery) (p=0.33), dose (p=0.99), allocation 
concealment (p=0.58) or blinding (p=0.18). Although randomisation was a 
significant predictor, it was not included as it did not exaggerate the effect 
estimate (p=0.06).  Assuming a fixed consumption of postoperative morphine 
(50mg), intravenous lidocaine was the eighth most effective analgesic with a 
moderate clinically significant reduction in morphine (-10.09mg; 95% CrIs -
13.49mg to -6.36mg) (Table 6.2). There were no violations when testing model 
assumptions. 
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Figure 6.18: Meta-regression plot for lidocaine. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
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6.3.10 Dexamethasone 	
In the dexamethasone analysis there were 16 RCTs with 2163 participants 
(Table 6.1). There was evidence of considerable statistical heterogeneity 
(I2=88%). Control group morphine consumption was a significant predictor of 
between-study heterogeneity (R2=100%; p<0.001) (Figure 6.19). Bayesian 
meta-regression estimates were similar. The addition of type of surgery 
(abdominal, cholecystectomy, ENT, hysterectomy, mixed surgeries, 
orthopaedic and spinal surgery) and blinding (low, unclear and high risk) 
significantly improved the model (R2=100%; p<0.001). The model was not 
improved by the addition of type of anaesthesia (p=0.63), dose (p=0.12), 
allocation concealment (p=0.18) or attrition bias (p=0.67). Although the 
addition of randomisation improved the model (p=0.1) when added to control 
group morphine consumption, it was not an independent predictor in the final 
model. Assuming a fixed consumption of postoperative morphine (50mg), 
dexamethasone was the least effective analgesic with a small clinically 
significant reduction (-8.07mg; 95% CrIs -9.79mg to -6.04mg) (Table 6.2). On 
testing assumptions, there was evidence of multicollinearity between unclear 
and high risk of bias for blinding and spinal, ENT and cholecystectomy 
surgeries. In addition, one study was highly influential in this analysis (Cook’s 
distance of 20), although removing this study had no effect on results.  
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Figure 6.19: Meta-regression plot for dexamethasone. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
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6.3.11 Magnesium 	
The magnesium analysis included 22 RCTs with 1194 participants (Table 6.1). 
There was evidence of considerable statistical heterogeneity (I2=90%). Control 
group morphine consumption was a significant predictor of between-study 
heterogeneity (R2=15%; p=0.02) (Figure 6.20). Bayesian meta-regression 
estimates were similar. The addition of allocation concealment (low versus 
unclear risk) significantly improved the model (R2=32%; p=0.006). The model 
was not improved by the addition of type of surgery (abdominal, cardiac 
surgery, cholecystectomy, hysterectomy, mixed surgeries, orthopaedic and 
spinal surgery) (p=0.69), type of anaesthesia (p=0.33), blinding (p=0.87) and 
attrition bias (p=0.97). Although dose (p=0.02) and randomisation (p=0.06) 
improved the model, they were not included, as they did not exaggerate the 
effect estimate. Assuming a fixed consumption of postoperative morphine 
(50mg), magnesium was the seventh most effective analgesic with a moderate 
clinically significant reduction in morphine consumption (-10.60mg; 95% CrIs 
-14.19mg to -7.10mg) (Table 6.2). There were no violations when testing 
regression model assumptions. 
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Figure 6.20: Meta-regression plot for magnesium. X-axis is control group 
morphine consumption (mg) and Y-axis is MD for 24-hour morphine 
reductions (mg). 
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6.3.12 Tramadol 	
The tramadol analysis included 11 RCTs with 889 participants (Table 6.1). 
There was evidence of considerable statistical heterogeneity (I2=90%). Control 
group morphine consumption was a significant predictor of between-study 
heterogeneity (R2=48%; p=0.03). Bayesian meta-regression estimates were 
similar. No other covariates improved the final model. These included type of 
surgery (abdominal, C-section, CABG, knee arthroplasty and TURP) (p=0.99), 
type of anaesthesia (p=0.47), route of administration (p=0.59), dose (p=0.25), 
randomisation (p=0.80), allocation concealment (p=0.22), blinding (p=0.87) 
and attrition bias (p=0.63). When assuming a fixed consumption of 
postoperative morphine (50mg), tramadol was the sixth most effective 
analgesic with a moderate clinically significant reduction in morphine 
consumption (-11.99mg; 95% CrIs -16.21mg to -7.28mg) (Table 6.2). There 
were no violations when testing regression model assumptions. 
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6.4 Discussion 	
6.4.1 Summary of results 	
In this chapter we report a novel, empirically derived, consistent and large 
predictor of between-study heterogeneity in meta-analyses of analgesic 
adjuncts. Control group morphine consumption (baseline risk) was a consistent 
predictor of between-study heterogeneity for all included meta-analyses. In 
addition, we found evidence that some methodological limitations explained 
some of the residual heterogeneity. Type of surgery or anaesthesia did not 
appear to be an independent predictor. Moreover, we have presented a method 
for more accurately reporting the efficacy of analgesics, which mitigates the 
variable morphine consumption from the included trials within systematic 
reviews. Furthermore, these models are able to adjust estimates for clinical and 
methodological confounding variables from the included studies.  
 
6.4.2 Links with previous research 	
Recent meta-analyses have attempted to explore heterogeneity using clinical 
covariates such as dose and type of surgery (Mishriky, Waldron and Habib 
2015).  However, these often report a low proportion of variation explained 
when compared to our results using control group morphine consumption 
(baseline risk). We derived this covariate from previous empirical studies 
suggesting larger reductions in pain scores following analgesic treatment with 
higher baseline pain scores. One study examined around 500 participants 
following dental extraction and found those with severe pain (3/3) had greater 
reductions in pain scores following treatment with ibuprofen compared to those 
with moderate pain (2/3) (Averbuch and Katzper 2003). Another study found 
paracetamol and codeine treatment following Caesarean section was only 
effective in those participants with severe pain (>6/10) (Bjune et al. 1996). 
Although it should be noted other factors in addition to the degree of pain may 
also influence postoperative opioid consumption such as access to PCA 
devices, concurrent analgesic protocols, patient characteristics (Ip et al. 2009) 
and the prescribing practices of attending medical professionals (which may be 
region dependent). 
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A previous study of postoperative pain reviews has found widespread 
statistical heterogeneity and suggested that this should be explored based on 
type of surgery or pain scores (Espitalier et al. 2013). This review 
recommended future meta-analyses should include only trials from the same 
surgical procedures or those with close acute postoperative pain levels and 
explore this using subgroup analysis. We would argue that postoperative 
analgesic consumption is a more appropriate covariate than type of surgery and 
meta-regression a more useful analysis than subgroup analysis as it allows 
reporting of the proportion of heterogeneity explained by the model (R2) as 
well as the ability to adjust for other confounding variables. In our previous 
meta-analysis with gabapentin, morphine consumption varied even within 
procedure-specific subgroups and type of surgery was a small determinant of 
heterogeneity between studies in relation to morphine consumption and pain 
scores (Doleman et al. 2015b). Our results suggest that expected postoperative 
morphine consumption (as a surrogate for pain, participant characteristics and 
concurrent analgesia) is a large determinant of heterogeneity between studies.  
 
Our results demonstrate that with control group morphine consumption held 
constant, type of surgery was not a significant predictor of between-study 
heterogeneity for nearly all analyses. Previous groups have argued that 
procedure-specific evidence is necessary when evaluating evidence derived 
from trials of analgesic agents (Kehlet et al. 2007). Our results suggest that the 
efficacy of analgesic agents is determined more by the degree of morphine 
consumption during the postoperative period rather than the type of surgery. 
Indeed, procedure-specific meta-analyses still suffer from considerable 
statistical heterogeneity (Yu et al. 2013). Therefore, we could find little 
empirical basis for conducting such procedure-specific reviews for analgesic 
adjuncts. Although we acknowledge that other interventions such as regional 
anaesthesia may have more relevance to procedure-specific evidence. 
 
When reporting the results from analgesics using a fixed consumption of 
postoperative morphine, we found the most effective analgesics were 
gabapentin, paracetamol, alpha-2 agonists, NSAIDS and COX-2 inhibitors, 
pregabalin, tramadol, magnesium and lidocaine, all with moderate clinically 
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significant effects. Ketamine and dexamethasone had small clinically 
significant effects. However, efficacy is not the only consideration when 
considering use of these agents. Adverse effects should also be considered. 
Agents such as paracetamol, where the incidence of adverse events is low may 
be preferable to agents that induce peri-operative adverse effects such as 
sedation with gabapentin. Moreover, our findings may still be influenced by 
publication bias (as with other meta-analyses) so should be interpreted with 
caution. 
 
6.4.3 Implications for clinical practice 	
In terms of the implications of our work for clinical practice, as meta-analyses 
are often used to inform clinical practice, reviews should present opioid 
reductions using a fixed consumption of morphine to more accurately reflect 
efficacy, as quoting the mean difference will be heavily influenced by the mean 
control morphine consumption in the included trials. In addition, indiscriminate 
use of analgesic adjuncts around the peri-operative period should be avoided, 
instead, clinicians can use information from small audits of mean opioid 
consumption and the regression parameters in our analysis to estimate the 
likely reduction in mean morphine consumption for samples of patients in that 
particular clinical situation. As all agents are associated with adverse effects, 
this more targeted use of analgesic adjuncts may help improve clinical 
significance and avoid inappropriate use of multiple agents where expected 
opioid reductions are small. Moreover, greater absolute reductions in morphine 
consumption may reduce the incidence of opioid adverse events, which a 
previous study has shown may be opioid dose-dependent (Zhao et al. 2004). 
 
6.4.4 Implications for primary research studies 	
In terms of RCT design, when studying analgesic agents for postoperative pain, 
trials should be conducted in surgeries where expected postoperative morphine 
consumption is anticipated to be high. For example, for intravenous 
paracetamol where the expected mean postoperative morphine consumption is 
either 70mg or 20mg in the first 24-hours postoperatively, the anticipated 
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reduction in morphine would be 26mg and 6mg respectively. Relying solely on 
the mean difference (8mg) may underestimate clinical significance in the 
context where postoperative morphine consumption is high.  
 
In terms of trial conduct, as with previous studies, we have found evidence that 
methodological limitations, in particular allocation concealment were 
associated with larger reductions in morphine for many adjuncts (Schultz and 
Grimes 2002a). Indeed, previous studies have shown similar results and found 
that inadequate or unclear allocation concealment can exaggerate effect 
estimates by around 40% (Schultz et al. 1995). Given that only 29% of the 
included trials reported adequate allocation concealment, this is a particular 
area of internal validity future studies should aim to address. Similarly, 
although less so, we found evidence that inadequate or unclear attrition bias 
and blinding exaggerated effect estimates. This also supports previous 
investigations, which have found exaggerated effect estimates in studies that 
were not blinded, although this was less severe than studies with inadequate or 
unclear allocation concealment (41% versus 17%; Schultz et al. 1995). Given 
only 50% of trials described adequate blinding of participants, researchers and 
outcome assessors, future trials should aim to conduct both adequate blinding 
procedures and full reporting of these in manuscripts. 
 
6.4.5 Implications for secondary research 	
In terms of secondary research studies, future meta-analyses of postoperative 
analgesic agents should aim to explore heterogeneity using control group 
morphine consumption, in addition to other sources of clinical heterogeneity 
such as dose or route of administration. Such explanation of statistical 
heterogeneity would lead to higher quality evidence derived from these 
reviews as per GRADE (Guyatt et al. 2008). Estimates from these reviews 
should be reported using a fixed consumption of morphine to avoid 
confounding by the variable consumption in the included primary studies. As 
an extension to this, residual confounding can be further reduced by 
incorporating other clinical and methodological covariates into these regression 
models to adjust estimates for differences in study design. As systematic 
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reviews are inherently observational (despite deriving data from randomised 
studies) (Smith and Carlisle 2015), more advanced and appropriate statistical 
methods are required (regression) that allows more accurate prediction (rather 
than using mean differences), while having the additional advantage of 
controlling for known confounders. For these reasons, future reviews of 
postoperative analgesics should avoid univariate subgroup analyses (due to 
confounding) and move towards multivariate regression models, which include 
control group morphine consumption (as is common practice in observational 
primary research). 
 
6.4.6 Limitations 	
There are several limitations with this review. Firstly, as alluded to in previous 
chapters, meta-regression analysis should be regarded as observational despite 
deriving data from randomised studies. Such analyses are prone to both 
residual confounding (from covariates we have not included in our models) and 
aggregation bias (as results are based on aggregated study estimates rather than 
from individual patients). For this reason, our implications for clinical practice 
focus on aggregated patient outcomes (from audits) rather than applying these 
to individual patients. Although it should also be noted that even with 
individual patient data, baseline risk cannot be determined for any individual 
patient as interventions are initiated before outcome measurement (24-hours). 
 
Secondly, we cannot rule out type I errors in our analyses. Although 
conventional to set a lower level of significance to covariate adjustment in 
regression models (p<0.1), this may also increase false positive results. Indeed, 
for some covariates, the results suggested the addition of certain covariates 
(such as dose for magnesium or randomisation for lidocaine) underestimated 
effect estimates, which appear to have no biologically plausible explanation. 
Therefore, type I errors seem likely. Thirdly, although our models can adjust 
for confounding variables, our analyses are limited to published primary 
research studies and are therefore still susceptible to publication bias. There are 
currently no methods that allow incorporation of true publication bias into our, 
and other models. Indeed, even identification of imprecise study effects 
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secondary to true publication bias is problematic and therefore this limits our 
findings. This will be the subject of the next chapter. 
 
Finally, more appropriate methods are available to compare the relative 
efficacy of analgesics, such as the use of network meta-analysis. However, as 
our search focussed on previously published reviews which generally included 
an intervention versus placebo, this made network meta-analysis unsuitable as 
this requires inclusion of trials where analgesic interventions were compared 
with each other. Therefore, future investigations may wish to conduct searches, 
which aim to include these studies and perform network meta-analysis adjusted 
for baseline risk. 
 
6.4.7 Conclusions  	
In conclusion, we have identified widespread, considerable statistical 
heterogeneity in meta-analyses of analgesic adjuncts. Moreover, we have 
demonstrated for the first time, an empirically-derived, consistent covariate 
responsible for a large proportion of between-study heterogeneity in meta-
analyses of analgesics for postoperative pain. Extending this principal, we have 
presented methods for more accurate presentation of the efficacy of analgesics 
that can adjust for other clinical and methodological covariates. Despite the 
limitations of our analysis, we recommend use of these principles in clinical 
practice, primary and secondary research studies. 
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Chapter 7 
Publication bias in analgesics for 
postoperative pain 
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7.1 Introduction 	
Meta-analyses have gained popularity within the academic community. The 
synthesis of results from all available studies results in increased precision in 
effect estimates and investigation of heterogeneity can generate new 
hypotheses and help direct future research. However, as many meta-analyses 
include data from published studies only, this makes them susceptible to bias 
(Sutton et al. 2000). Publication bias results from the preferential publication 
of studies with statistically significant results, which are both more likely to be 
published and are published faster than trials with negative findings (Hopewell 
et al. 2009; Stern and Simes 1997). Furthermore, within study publications, 
outcomes with statistically significant effects are more likely to be reported 
than non-significant results (Dwan et al. 2008).  
 
Ideally, a review will aim to mitigate the effects of publication bias by 
searching unpublished clinical trials databases (combined with wider editorial 
policies on mandatory registration of primary studies), grey literature sources 
and conference proceedings (Dickersin 1990; Thornton and Lee 2000). 
Following the analysis, methods exist to help authors identify the presence of 
possible publication bias (imprecise study effects) including observation for 
funnel plot asymmetry (Peters et al. 2008) and quantitative tests such as 
Egger’s linear regression test (Egger et al. 1997a; Sterne, Gavaghan and Egger 
2000). Indeed, use of this test has previously found that publication bias is the 
reason many meta-analyses conclusions and subsequent large RCTs disagree. 
In addition to identification of possible publication bias, tests exist that can 
adjust effect estimates if funnel plot asymmetry is found such as the trim and 
fill method (Duval and Tweedie 2000), although recommended only as a 
sensitivity analysis (Peters et al. 2007).  
 
It is as yet unknown how many reviews of analgesic adjuncts employ both 
methods to prevent and analyse to help identify publication bias. Furthermore, 
little is known about the prevalence of publication bias from the studies 
included in these reviews. Moreover, as we have recently described widespread 
between-study heterogeneity secondary to baseline risk in these trials (Chapter 
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6), it is unknown what influence this between-study heterogeneity has on 
evaluation of funnel plot asymmetry. Therefore, the aim of this chapter was to: 
1) perform a meta-epidemiological study to evaluate reviews for the use of 
methods to prevent and evaluate publication bias 2) perform a secondary 
analysis of RCTs included in these reviews for the presence of imprecise study 
effects (possible publication bias) 3) to evaluate the effects of baseline risk on 
funnel plot asymmetry and propose novel methods to overcome this issue.  
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7.2 Methods 	
7.2.1 Search strategy, registration and data extraction 	
We reported this review in accordance with the PRISMA checklist (Moher et 
al. 2009). We prospectively registered the review on the PROSPERO website 
using the registration number CRD42016043924. Our search strategy is 
described elsewhere (Section 6.2.1). We extracted data onto an electronic 
database. We initially searched for review articles in order to conduct a meta-
epidemiological study and then performed a secondary analysis of RCTs from 
within these reviews. If results were not reported in the original meta-analysis, 
we extracted data from the original publications. In order to reduce selective 
reporting bias, if standard deviations were not reported, we estimated these 
from other studies in the analysis. This is due to statistically non-significant 
results being less likely to be fully reported than significant results. If multiple 
subgroups were reported within a study (such as different doses), we used data 
from the most significant subgroup, as we assumed one statistically significant 
subgroup would increase the chances of that study being published. 
 
7.2.2 Inclusion criteria and outcomes 	
To reduce bias, we had no language or publication status restrictions for 
inclusion in our review. As described previously, we included reviews that 
included the following analgesic agents versus placebo for postoperative pain: 
paracetamol, NSAIDS and COX-2 inhibitors, tramadol, intravenous ketamine, 
alpha-2 agonists (clonidine and dexmedetomidine), gabapentin, pregabalin, 
lidocaine, magnesium and dexamethasone. We did not include nefopam as 
only five studies were previously identified, which precluded quantitative 
assessment of publication bias (Sterne et al. 2011). The outcome of interest 
was 24-hour morphine consumption as this outcome is commonly reported as a 
primary outcome. If studies reported dosage per kilogram, we converted this to 
a 70kg weight. We also used data from the day of surgery or postoperative day 
one and analysed this as 24-hour data. We converted alternative opioids to 
intravenous morphine-equivalents using the conversion factors reported 
previously (Section 6.2.3). 
	 335	
7.2.3 Statistical analysis 	
From the included reviews, we report the proportion of reviews searching 
unpublished clinical trials databases, grey literature databases and conference 
proceedings (Thornton and Lee 2000). In addition, if more than ten primary 
studies were included, we report the proportion of reviews assessing for 
possible publication bias through visual inspection for funnel plot asymmetry, 
quantitative evaluations such as Egger’s linear regression test and/or the 
proportion of studies attempting methods to correct for potential publication 
bias using trim and fill analysis. We only included meta-analyses in these 
descriptive outcomes (Sterne et al. 2011). We also report the number of 
included RCTs that were registered on clinical trial databases, as reported in 
the study publication. As clinicaltrials.gov was established in the year 2000, we 
only included trials published in or after 2010 to allow for study completion 
and publication. 
 
We then performed a secondary analysis of RCTs from within these reviews. 
We initially performed contour-enhanced funnel plots (Illustration 1.3), which 
add contours for statistical significance (we used p<0.01 and p<0.05 as contour 
regions) to help distinguish funnel plot asymmetry secondary to publication 
bias from other causes (such as methodological disparities in smaller studies) 
(Sutton et al. 2000). This is because publication of a particular study is 
dependent on the p value rather than just the direction of the result. Therefore, 
if funnel plot asymmetry is present and studies are located in regions of 
statistical significance, then this suggests publication bias is responsible rather 
than other causes. Secondly, we performed quantitative analysis for funnel plot 
asymmetry using Egger’s linear regression test (Illustration 1.1) with a one-
tailed p<0.1 regarded as evidence of imprecise study effects (Egger et al. 
1997a; Higgins and Green 2008).   
 
Thirdly, we constructed funnel plots, which we divided into subgroups based 
on the degree of control group morphine consumption (baseline risk). We 
defined these subgroups as follows: low consumption (<20mg), medium 
consumption (20-50mg) and high consumption (>50mg). This analysis aimed 
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to identify whether funnel plot asymmetry was secondary to underlying 
publication bias or whether between-study heterogeneity may be responsible. 
As funnel plots are frequently constructed from standard errors from individual 
studies and postoperative pain trials are approximately similar in sample size, 
larger control group morphine consumption is often accompanied by larger 
standard deviations. This relationship could lead to asymmetry in funnel plots 
due to a relationship between effect estimates and their associated standard 
errors. In order to test this formally, we performed a linear regression analysis 
with standard errors as the outcome variable and control group morphine 
consumption (baseline risk) as the predictor variable. Fourthly, we conducted 
sensitivity analysis using trim and fill analysis (Section 1.9.4 and Illustration 
1.2) and report the percentage change in effect estimates assuming a symmetric 
funnel plot using a random-effects model.  
 
Finally, we performed simulations to create eight hypothetical meta-analyses 
where no publication bias was present. These simulations attempted to recreate 
the conditions present in meta-analyses of analgesic adjuncts. Specifically, that 
both effect sizes and standard deviations were dependent on baseline risk (R 
code below).  
 
study.gen.br <- function(b.risk, t.diff, sd, n.arm) { 
response.c <- rnorm(n.arm, mean = b.risk, (sd+(0.5*b.risk))) 
response.t <- rnorm(n.arm, mean = b.risk + t.diff -0.5*b.risk, (sd+(0.5*b.risk))) 
m.c <- mean(response.c) 
m.t <- mean(response.t) 
sd.c <-sqrt(var(response.c)) 
sd.t <-sqrt(var(response.t)) 
n.c <- n.arm 
n.t <- n.arm 
values = data.frame(n.c, n.t, m.c, m.t, sd.c, sd.t) 
return(values) 
} 
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We then produced funnel plots for the simulated meta-analyses and performed 
Egger’s linear regression test (p<0.1 as evidence of imprecise study effects). 
Following this, we present an alternative method of constructing funnel plots 
using residual values (Figure 7.12) from the meta-regression of baseline risk to 
identify whether this could resolve any funnel plot asymmetry. All analyses 
were conducted using STATA Version 14.2 and Comprehensive Meta-
Analysis Version 3. Simulations were performed using R statistical package 
and performed by a statistician (Alex Sutton). 
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7.3 Results 	
7.3.1 Description of included studies and descriptive results 	
We included 344 RCTs with 25,348 participants in the final analysis. The 
references for the included reviews and the PRISMA flowchart have been 
reported previously (Section 6.3.1 and Figure 6.1). Of the included reviews that 
conducted a meta-analysis, 65% (95% CI 52% to 78%) evaluated included 
studies for imprecise study effects. In 53% of reviews (95% CI 39% to 67%), 
funnel plots were used and 43% (95% CI 29% to 57%) used quantitative 
methods such as Egger’s linear regression test. Only 6% (95% CI 0% to 13%) 
attempted to correct for imprecise study effects using trim and fill analysis. In 
16% (95% CI 7% to 25%) of meta-analyses, unpublished studies were sought 
from clinical trial databases, 9% (95% CI 2% to 16%) searched conference 
proceedings and 4% (95% CI 0% to 9%) searched grey literature databases. 
Since 2010, only 23% (95% CI 15% to 31%) of RCTs were registered on 
clinical trial databases. 
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7.3.2 Paracetamol 	
The paracetamol analysis included 25 RCTs. There was evidence of funnel plot 
asymmetry with a statistically significant Egger’s linear regression test 
(p=0.02). Contour-enhanced funnel plots showed that the majority of studies 
were in the region of statistical significance, suggesting publication bias as a 
cause rather than other factors (Figure 7.1).  
 
 
Figure 7.1: Contour-enhanced funnel plot for paracetamol. Areas represent: 
statistical non-significance (p>0.05; white) and areas of statistical significance 
(p<0.05; dark grey and p<0.01; light grey).  
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However, when re-examining funnel plots when studies were sub-grouped on 
the degree of control group morphine consumption, the plot showed a 
relationship between standard errors and baseline risk (Figure 7.2). On linear 
regression analysis, control group morphine consumption was a significant 
predictor of standard errors (R2=52%; p<0.001). On testing assumptions, one 
study had a studentised residual of more than three although no study had a 
Cook’s distance of more than one. Residuals were normally distributed and 
there was no evidence of heteroscedasticity. When performing trim and fill 
analysis, seven studies were trimmed which reduced effect estimates by 43%. 
 
 
 
Figure 7.2: Funnel plot for paracetamol. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
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7.3.3 NSAIDS and COX-2 inhibitors 	
The NSAIDS and COX-2 inhibitors analysis included 86 RCTs. There was 
evidence of funnel plot asymmetry with a statistically significant Egger’s linear 
regression test (p<0.001). Contour-enhanced funnel plots showed most of the 
studies were in regions of statistical significance suggesting publication bias as 
a cause rather than other factors (Figure 7.3). 
 
 
 
Figure 7.3: Contour-enhanced funnel plot for NSAIDS and COX-2 inhibitors. 
Areas represent: statistical non-significance (p>0.05; white) and areas of 
statistical significance (p<0.05; dark grey and p<0.01; light grey). 
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However, when re-examining funnel plots sub-grouped on the basis of control 
group morphine consumption, there appeared to be a relationship with studies 
with higher consumption having larger standard errors (Figure 7.4). When 
performing linear regression analysis, control group morphine consumption 
was a significant predictor of standard errors (R2=45%; p<0.001). On testing 
regression assumptions, residuals were normally distributed and there was no 
evidence of heteroscedasticity. One study had a studentised residual of more 
than three although no study had a Cook’s distance of more than one. When 
performing trim and fill analysis, 27 studies were trimmed which decreased 
effect estimates by 60%. 
 
 
 
Figure 7.4: Funnel plot of NSAIDS and COX-2 inhibitors. Studies are sub-
grouped based on control group morphine consumption (see legend). 
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7.3.4 Ketamine 	
The ketamine analysis included 62 RCTs. Although there was some funnel plot 
asymmetry, Egger’s linear regression was not statistically significant (p=0.17) 
(Figure 7.5). It was difficult to see in which regions studies were located. 
 
 
Figure 7.5: Contour-enhanced funnel plot for ketamine. Areas represent: 
statistical non-significance (p>0.05; white) and areas of statistical significance 
(p<0.05; dark grey and p<0.01; light grey). 
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When re-examining funnel plots with studies sub-grouped on the degree of 
control group morphine consumption, there appeared to be relationship 
between morphine consumption and study standard errors, although less so 
than with previous analyses (Figure 7.6). On linear regression analysis, control 
group morphine consumption predicted standard errors (R2=63%; p<0.001). 
On testing assumptions, residuals were normally distributed, although there 
was some evidence of heteroscedasticity. Two studies had a studentised 
residual of more than three and one study had a Cook’s distance of more than 
one. Deleting this data point reduced the variation explained (R2=45%; 
p<0.001). When performing trim and fill analysis, three studies were trimmed 
but this increased effect estimates by 8%. 
 
 
 
Figure 7.6: Funnel plot of ketamine. Studies are sub-grouped based on control 
group morphine consumption (see legend). 
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7.3.5 Alpha-2 agonists (clonidine and dexmedetomidine) 	
The alpha-2 agonists analysis included 33 RCTs. There was evidence of funnel 
plot asymmetry with a statistically significant Egger’s linear regression test 
(p=0.02). Contour-enhanced funnel plots showed most studies were located in 
regions of statistical significance suggesting publication bias rather than other 
causes (Figure 7.7). 
 
 
 
Figure 7.7: Contour-enhanced funnel plot for alpha-2 agonists. Areas 
represent: statistical non-significance (p>0.05; white) and areas of statistical 
significance (p<0.05; dark grey and p<0.01; light grey). 
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Again, when studies were sub-grouped based on the degree of control group 
morphine consumption, there appeared to be a relationship between morphine 
consumption and standard errors, with larger consumption having larger 
standard errors (Figure 7.8). Linear regression analysis showed control group 
morphine consumption was a significant predictor of standard errors (R2=55%; 
p<0.001). On testing regression assumptions, there was some positive skew on 
residual histograms although there was no evidence of heteroscedasticity. One 
study had a studentised residual of more than three although no study had a 
Cook’s distance of more than one. When analysing with trim and fill analysis, 
six studies were trimmed which decreased effect estimates by 22%. 
 
 
 
Figure 7.8: Funnel plot of alpha-2 agonists. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
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7.3.6 Gabapentin 	
The gabapentin analysis included 67 RCTs. There was evidence of funnel plot 
asymmetry with a statistically significant Egger’s linear regression test 
(p<0.001). Contour-enhanced funnel plots showed more studies in regions of 
statistical significance, suggesting publication bias as a cause rather than other 
causes (Figure 7.9). 
 
 
 
Figure 7.9: Contour-enhanced funnel plot for gabapentin. Areas represent: 
statistical non-significance (p>0.05; white) and areas of statistical significance 
(p<0.05; dark grey and p<0.01; light grey). 
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When re-examining funnel plots with studies sub-grouped on the basis of 
control group morphine consumption, there appeared to be a relationship 
between the degree of consumption and larger standard errors (Figure 7.10). 
On linear regression analysis, control group morphine consumption was a 
significant predictor of standard errors (R2=60%; p<0.001). On testing 
regression assumptions, residuals were normally distributed and there was no 
evidence of heteroscedasticity. Two studies had a studentised residual of more 
than three and one study had a Cook’s distance of more than one. However, 
deleting this study had no effect on the results. When analysing using trim and 
fill analysis, six studies were trimmed which decreased effect estimates by 
12%. 
 
 
 
Figure 7.10: Funnel plot of gabapentin. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
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7.3.7 Pregabalin 	
The pregabalin analysis included 34 RCTs. There was evidence of funnel plot 
asymmetry with a statistically significant Egger’s linear regression test 
(p<0.001). Contour-enhanced funnel plots showed most studies were located in 
regions of statistical significance suggesting publication bias as a cause rather 
than other factors (Figure 7.11). 
 
 
 
Figure 7.11: Contour-enhanced funnel plot for pregabalin. Areas represent: 
statistical non-significance (p>0.05; white) and areas of statistical significance 
(p<0.05; dark grey and p<0.01; light grey). 
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When re-examining funnel plots with studies sub-grouped on the basis of 
control group morphine consumption, there appeared to be a relationship 
between higher consumption and higher standard errors (Figure 7.12). On 
linear regression analysis, control group morphine consumption was a 
significant predictor of standard errors (R2=48%; p<0.001). On testing 
assumptions, residuals were normally distributed although there was some 
evidence of heteroscedasticity. No study had a studentised residual of more 
than three and no study had a Cook’s distance of more than one. When 
analysing using trim and fill analysis, two studies were trimmed although this 
increased effect estimates by 3%. 
 
 
 
Figure 7.12: Funnel plot of pregabalin. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
 
7.3.8 Nefopam 	
There were too few studies to investigate publication bias for nefopam. 
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7.3.9 Lidocaine 	
In the lidocaine analysis there were 22 RCTs. There was evidence of funnel 
plot asymmetry with a statistically significant Egger’s linear regression test 
(p=0.02). Contour-enhanced funnel plots showed most studies were in regions 
of statistical non-significance, suggesting other causes than publication bias 
(Figure 7.13). 
 
 
 
Figure 7.13: Contour-enhanced funnel plot for lidocaine. Areas represent: 
statistical non-significance (p>0.05; white) and areas of statistical significance 
(p<0.05; dark grey and p<0.01; light grey). 
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When re-examining funnel plots with studies sub-grouped on the basis of 
control group morphine consumption, there again appeared to be a relationship 
between higher consumptions and higher standard errors, although less so than 
with other analyses (Figure 7.14). On linear regression analysis, control group 
morphine consumption was a significant predictor of standard errors (R2=31%; 
p=0.007). On testing regression assumptions, there was some positive skew on 
residual histograms although there was no evidence of heteroscedasticity. One 
study had a studentised residual of more than three although no study had a 
Cook’s distance of more than one. When analysing using trim and fill analysis, 
no studies were trimmed. 
 
 
 
Figure 7.14: Funnel plot of lidocaine. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
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7.3.10 Dexamethasone 	
In the dexamethasone analysis there were 16 RCTs. There was evidence of 
funnel plot asymmetry with a statistically significant Egger’s linear regression 
test (p=0.09). However, when examining contour-enhanced funnel plots, most 
studies were in regions of statistical non-significance suggesting other causes 
than publication bias (Figure 7.15). 
 
 
Figure 7.15: Contour-enhanced funnel plot for dexamethasone. Areas 
represent: statistical non-significance (p>0.05; white) and areas of statistical 
significance (p<0.05; dark grey and p<0.01; light grey). 
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When re-examining funnel plots sub-grouped on the degree of control group 
morphine consumption there appeared to be a relationship between higher 
consumption and higher standard errors, although medium consumption (20-
50mg) appeared to have the largest standard errors (Figure 7.16). However, on 
linear regression analysis, control group morphine consumption was not a 
significant predictor of standard errors (R2=18%; p=0.1). On testing regression 
assumptions, residuals were normally distributed although the data appeared to 
violate the assumption of linearity. No study had a studentised residual of more 
than three although one study had a Cook’s distance of more than one. 
Deleting this study resulted in a significant prediction (R2=40%; p=0.01). 
When analysing using trim and fill analysis, two studies were trimmed which 
increased effect estimates by 11%. 
 
 
 
Figure 7.16: Funnel plot of dexamethasone. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
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7.3.11 Magnesium 	
The magnesium analysis included 22 RCTs. There was some evidence of 
funnel plot asymmetry although Egger’s linear regression test was not 
statistically significant (p=0.21) (Figure 7.17). Most studies were in regions of 
statistical significance. 
 
 
 
Figure 7.17: Contour-enhanced funnel plot for magnesium. Areas represent: 
statistical non-significance (p>0.05; white) and areas of statistical significance 
(p<0.05; dark grey and p<0.01; light grey). 
 
When re-examining funnel plots sub-grouped on control group morphine 
consumption, there was a relationship between higher consumption and higher 
standard errors (Figure 7.18). However, on linear regression analysis control 
group morphine consumption was not a significant predictor of standard errors 
(R2=5%; p=0.34). On testing regression assumptions, residuals were positively 
skewed although there was no evidence of heteroscedasticity. One study had a 
studentised residual of more than three although no study had a Cook’s 
distance of more than one. When analysing using trim and fill analysis, one 
study was trimmed which increased effect estimates by 3%. 
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Figure 7.18: Funnel plot of magnesium. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
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7.3.12 Tramadol 	
The tramadol analysis included 11 RCTs. There was some evidence of funnel 
plot asymmetry although Egger’s linear regression test was not statistically 
significant (p=0.23) (Figure 7.19). Most studies were in regions of statistical 
significance. 
 
 
 
Figure 7.19: Contour-enhanced funnel plot for tramadol. Areas represent: 
statistical non-significance (p>0.05; white) and areas of statistical significance 
(p<0.05; dark grey and p<0.01; light grey). 
 
When re-examining funnel plots sub-grouped on the basis of control group 
morphine consumption, there appeared to be a relationship between higher 
consumption and higher standard errors (Figure 7.20). However, on linear 
regression analysis, control group morphine consumption was not a significant 
predictor of standard errors (R2=23%; p=0.14). On testing regression 
assumptions, there was some positive skew on residual histograms although 
there was no evidence of heteroscedasticity. No study had a studentised 
residual of more than three and no study had a Cook’s distance of more than 
one. When analysing using trim and fill analysis, no studies were trimmed. 
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Figure 7.20: Funnel plot of tramadol. Studies are sub-grouped based on 
control group morphine consumption (see legend). 
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7.3.13 Simulated meta-analyses 
 
We simulated eight meta-analyses with no publication bias where both effect 
sizes and standard deviations were dependent on baseline risk (Figure 7.21; 
analysis performed in collaboration with Professor Alex Sutton). When 
observing the figure below (from top left), funnel plots using mean differences 
on the X-axis and standard errors (on a reverse scale) on the Y axis (A on 
Figure 7.21) demonstrate funnel plot asymmetry (all p<0.001 on Egger’s linear 
regression test). The corresponding meta-analyses using residual values on the 
X axis (B on Figure 7.21) resolve this asymmetry (p=0.1 to p=0.99).  
 
 
 
Figure 7.21: Funnel plots of simulated meta-analyses. Shows both traditional 
axes using mean differences and standard errors (A) and novel axes using 
residuals and standard errors (B). 
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7.4 Discussion 
7.4.1 Summary of results 
 
This chapter has identified widespread evidence of imprecise study effects 
(using traditional methods) in meta-analyses of analgesic adjuncts, despite the 
use of various search strategies and wide inclusion criteria in our review. We 
found evidence that only a small proportion of included reviews employed 
methods aimed at preventing possible publication bias despite around half 
employing methods to identify imprecise study effects. When adjusted for a 
symmetric funnel plot, in some cases effect estimates were adjusted by a large 
degree. However, when examining the relationship between control group 
morphine consumption (baseline risk) and imprecision, for most analgesics 
there was a significant relationship between baseline risk and standard errors 
implying that funnel plots may be an inaccurate method to assess publication 
bias where values are dependent on baseline risk. Indeed, when we simulated 
similar meta-analyses where no publication bias was present, funnel plot 
asymmetry was evident for all analyses (p<0.001). Moreover, we have 
presented a novel method to correct this artifactual asymmetry using meta-
regression residuals. 
 
7.4.2 Links with other research 	
The prevalence of publication bias within meta-analyses is estimated to be 
around 25%-40% (Egger et al. 1997a; Sterne, Gavaghan and Egger 2000). 
Within the anaesthesia literature, using a sample of systematic reviews from 
leading anaesthetic journals, the prevalence of publication bias has been 
estimated to be 50-80% (Hedin et al. 2016). This has important implications 
for the validity of systematic review findings, as publication bias has been 
found to be the cause when meta-analyses and subsequent large RCTs disagree 
(Egger et al. 1997a). Meta-analyses are frequently used to inform clinical 
decision-making and guidelines; therefore using invalid data may lead to the 
use of ineffective or even harmful interventions in clinical practice. 
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Due to the consequences of publication bias, methods were developed to help 
identify it. We found that only around 50% of included reviews attempted to 
detect potential publication bias. However, of more concern is the small 
number of included reviews that employed methods aimed at preventing 
publication bias. Only 16% of reviews searched unpublished clinical trial 
databases and 9% searched conference proceedings. Prevention is the most 
important step in reducing the effects of publication bias and therefore future 
reviews need to ensure such methods are employed to produce more valid 
findings. Despite the employment of the above methods for preventing 
publication bias, these methods would only be successful if trial investigators 
registered their studies on clinical trial databases. Taking a sample of studies 
published since 2010 (to allow a decade for conduct and publication since the 
inception of clinicaltrials.gov), only 23% were registered on such databases. 
Methods for preventing publication bias can only succeed if all trials are 
registered. Thankfully, leading journals are now using clinical trial registration 
as a condition of publication. However, this requirement also needs to be 
universally adopted by lower impact journals.  
 
Although there is a wealth of research into the use of funnel plots and 
quantitative tests for the detection of imprecise study effects, little work has 
been conducted on research using continuous outcomes such as morphine 
consumption (Higgins and Green 2008). Moreover, less work has been 
undertaken examining continuous outcomes with considerable heterogeneity 
and variation in effect estimates dependent on baseline risk. The construction 
of conventional funnel plots uses effect estimates on the x-axis and standard 
errors (in reverse order) on the y-axis as a measure of imprecision. The theory 
is that smaller studies (with higher standard errors) are more likely to show 
exaggerated results and as study size gets larger (and hence standard error 
smaller), the results should converge closer to the mean effect derived from the 
meta-analysis. Therefore, unpublished smaller studies can be identified as 
missing from one side of the base of the funnel plot, suggesting possible 
publication bias. 
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However, the outcome of morphine consumption presents problems for this 
underlying assumption. We have previously demonstrated that the results from 
any one study are dependent on control group morphine consumption (with 
higher baseline risk having larger reductions in morphine consumption). In 
addition, the trials included in our meta-analyses are often small (50-100 
participants) and therefore standard error calculations will be more dependent 
on standard deviations than for larger studies (as SE = SD / √N). As there is a 
tendency for studies with higher control group morphine consumption to have 
larger standard deviations there is a dependency between the mean difference 
(larger with higher baseline risk) and the standard errors (larger with higher 
baseline risk). This could create an asymmetric funnel plot even in the presence 
of no publication bias (analogous to a rotated scatter plot). Indeed, for most 
analyses, baseline risk was a significant predictor of standard errors on linear 
regression analysis. Moreover, when we simulated meta-analyses where no 
publication bias was present, funnel plot asymmetry was evident in all 
analyses. Therefore, we would argue that traditional funnel plots are not a 
reliable method to detect imprecise study effects for morphine consumption 
and that this finding may also extend to other, similar continuous outcomes 
whose results are dependent on baseline risk (such as pain scores). 
 
This dependency can also present issues for meta-analyses of continuous 
outcomes. If the results from a meta-analysis vary with baseline risk, this will 
cause issues with the weighting of individual studies when calculating pooled 
effect estimates. As studies with lower baseline risk (lower control group 
morphine consumption) with have lower standard errors, they will receive a 
higher percentage weight than studies with higher baseline risk (using the 
inverse-variance method). This will mean effect estimates will be lower than 
the true average effect, leading to an underestimation of efficacy. Therefore, 
this further suggests meta-regression estimates from a fixed consumption of 
morphine may give a more accurate representation of efficacy than mean 
differences. 
 
Assuming that funnel plot asymmetry is secondary to publication bias using 
conventional analyses may have serious consequences for the results of a meta-
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analysis. For example, when performing tests to adjust for funnel plot 
asymmetry (trim and fill analysis), effect estimates changed for some analyses 
by 12-60%. This has the potential to have a significant effect on meta-analysis 
conclusions. However, it should be noted that our findings of funnel plot 
asymmetry did not extend to all analgesic adjuncts. For tramadol, magnesium 
and ketamine there was no evidence of imprecise study effects. 
 
7.4.3 Implications for research and clinical practice 	
Clearly, the issues highlighted above have implications for the interpretation of 
results derived from meta-analyses. Incorrect conclusions regarding the 
presence of publication bias could lead to unnecessary downgrading of 
evidence as per GRADE (Guyatt et al. 2008). In addition, the conduct of trim 
and fill analysis could reduce effect estimates and significantly alter a reviews 
conclusions, which may be inappropriate. These factors need to be considered 
when performing meta-analyses using postoperative morphine consumption. 
Furthermore, these findings may also extend to similar outcomes, such as pain 
scores, which may also be dependent on baseline risk (Doleman et al. 2015a). 
 
In terms of conduct of future meta-analyses, as we have demonstrated that 
traditional funnel plots may be an inaccurate method for assessing publication 
bias in analyses dependent on baseline risk, we suggest future reviews utilise 
the methods presented in this chapter. Namely, funnel plots should be 
constructed using meta-regression residual values on the X-axis and standard 
errors on the Y-axis. These can then be formally tested using Egger’s linear 
regression test. However, further simulation studies are required to test this 
novel method under a variety of assumptions. 
 
Finally, in terms of future primary and secondary study conduct, more reviews 
should aim to employ methods that aim to prevent potential publication bias by 
searching clinical trial databases, conference proceedings and grey literature 
databases. However, this also requires RCTs to register on clinical trial 
databases and trial investigators to engage with review authors when 
unpublished trial data is requested. Furthermore, the practice of journals 
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making clinical trial registration a condition of publication should be extended 
to all journals in order to help reduce publication bias.  
 
7.4.4 Limitations 
The first limitation of this chapter is the use of previously published reviews 
with variable search strategies. The fact that only a small number of included 
reviews searched for unpublished studies means our sample would be more 
likely susceptible to publication bias. However, our aim was to both perform a 
meta-epidemiological study of existing reviews and identify any publication 
bias present in the current literature, which made our search strategy 
appropriate for this aim. Secondly, some of our analyses contained a low 
number of primary studies, which may render quantitative tests for publication 
bias underpowered. Finally, trim and fill analysis may perform poorly under 
the conditions of large between-study heterogeneity, which was present in our 
review (Peters et al. 2007).   
 
7.4.5 Conclusions 
We found that only a small amount of included reviews used methods aimed at 
preventing publication bias and around half used methods aimed at detecting it. 
Using conventional methods, we found evidence of widespread imprecise 
study effects for most analgesics used to prevent postoperative pain. However, 
due to an association between baseline risk and standard errors, this finding 
may be a result of statistical artefact as demonstrated in our simulations of 
meta-analyses where no publication bias was present. Therefore, future reviews 
should employ our alternative methods presented in this chapter. 
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Chapter 8 
Type I and II errors in reviews of 
analgesics: a trial sequential analysis 
of low risk of bias studies 
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8.1 Introduction 	
Type I and II errors have received widespread attention when conducting 
primary research studies. Sample size calculations can ensure that studies have 
sufficient power to detect true differences between groups and reduce type II 
errors (Moher, Dulberg and Wells 1994), while avoiding (or correcting for) 
multiple comparisons can help reduce type I errors (Bender and Lange 2001). 
However, such issues with error have only recently received attention for 
systematic reviews and meta-analyses. Trial sequential analysis, which is based 
on group sequential methods for primary RCTs, can both calculate an adequate 
IS (analogous to sample size calculations) and adjust for multiple comparisons 
that can occur if hypothetic reviews are performed after the publication of each 
subsequent trial (analogous to adjustment for multiple comparisons) (Borm and 
Donders 2009; Imberger et al. 2015; Pogue and Yusuf 1998; Thorlund et al. 
2009). 
 
Although we have previously identified 344 published RCTs evaluating 
multimodal analgesic agents, these were of varying risk of bias. While we can 
confidently infer that sufficient data exist to limit type I and type II errors, it is 
as yet unclear whether there exists sufficient data from low risk of bias trials. 
We have previously shown that measures of internal validity such as allocation 
concealment (Schultz and Grimes 2002a), blinding (Schultz and Grimes 
2002b) and attrition bias can exaggerate effect estimates. Therefore, it is 
necessary to establish the evidence base for trials at low risk of bias. With this 
in mind, the aim of this chapter is to evaluate whether sufficient evidence 
exists to exclude type I and type II errors in analyses of low risk of bias trials 
for analgesic adjuncts. 
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8.2 Methods 	
8.2.1 Search strategy and data extraction 	
The search strategy for this analysis is discussed elsewhere (Section 6.2.1). We 
did not register this review, as it was a post hoc analysis based on previous 
observations and results. We extracted data from previous results in chapter 
six. Risk of bias for each study has been reported previously (Figure 6.2 to 
6.11). We regarded trials at low risk of bias if they received low risk for 
randomisation, allocation concealment (Schultz and Grimes 2002a), blinding 
(Schultz and Grimes 2002b) and attrition bias (Juni and Egger 2005), while not 
receiving any high risk of bias for other elements.  
 
8.2.2 Statistical analysis 	
We performed a trial sequential analysis for all analgesics included in chapter 
six. The outcome of interest was 24-hour morphine consumption. If alternative 
opioids were reported, these were converted to morphine-equivalents using the 
previously reported conversion factors (Section 6.2.3). As we have previously 
identified that reductions in morphine consumption are dependent on control 
group consumption, we used empirical mean differences from the included 
studies rather than specify clinically significant differences based on mean 
values. We used empirical estimates of variance and heterogeneity corrections 
(D2) from the included studies in the analysis. If this figure was <50%, we 
conducted sensitivity analysis using heterogeneity corrections of 50% and 
80%. These corrections would incorporate the uncertainty from the included 
studies to increase a required IS in the presence of high between-study 
heterogeneity (reduce type II errors). We constructed alpha spending 
monitoring boundaries using the O’Brien-Fleming method with a significance 
level of p<0.05 (reduce type I errors). We used the DerSimonian and Laird 
method for calculating random-effects estimates. We also constructed futility 
boundaries using a 1-β=0.80 where possible. We conducted all analyses using 
TSA software from the Copenhagen Trial Unit (version 0.9.5.5 beta). 
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8.3 Results 	
8.3.1 Paracetamol 	
There were two low risk of bias trials included in the analysis. The results from 
these trials failed to cross either the conventional or O’Brien-Fleming 
boundary for statistical significance (Figure 8.1). In addition, the results failed 
to reach the required IS for a definitive answer (386 participants). 
 
 
Figure 8.1: Trial sequential analysis of low risk of bias trials for paracetamol. 
Performed assuming an empirical MD of -2.14mg, variance of 9.4, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 83.2. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with 
paracetamol. 
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8.3.2 NSAIDS and COX-2 inhibitors 	
The NSAIDS and COX-2 inhibitors analysis included three low risk of bias 
trials. The results failed to cross the conventional or O’Brien-Fleming 
boundary for statistical significance (Figure 8.2). In addition, the results failed 
to reach the required IS (534 participants). 
 
 
Figure 8.2: Trial sequential analysis of low risk of bias trials for NSAIDS and 
COX-2 inhibitors. Performed assuming an empirical MD of -8.3mg, variance 
of 6.9, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 99.3. Blue 
line indicates cumulative Z score with values more than 0 indicating benefit 
with NSAIDS and COX-2 inhibitors. 
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8.3.3 Ketamine 	
The ketamine analysis included 11 trials at low risk of bias. Although the 
ketamine analysis crossed the boundary for conventional statistical 
significance, it did not cross the adjusted O’Brien-Fleming boundary for 
statistical significance (Figure 8.3). In addition, the ketamine analysis failed to 
reach the required IS for a definitive answer (1602 participants). 
 
 
Figure 8.3: Trial sequential analysis of low risk of bias trials for ketamine. 
Performed assuming an empirical MD of -5.31mg, variance of 41, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 97.1. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with ketamine. 
 
 
 
 
 
 
	 371	
8.3.4 Alpha-2 agonists 	
The alpha-2 agonists analysis included only one RCT. The results crossed the 
conventional boundary for statistical significance (Figure 8.4). However, 
O’Brien-Fleming and boundaries for futility or IS could not be calculated due 
to too few information. 
 
 
Figure 8.4: Trial sequential analysis of low risk of bias trials for alpha-2 
agonists. Performed assuming an empirical MD of -12.5mg, variance of 162, 
adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line 
indicates cumulative Z score with values more than 0 indicating benefit with 
alpha-2 agonists. 
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8.3.5 Gabapentin 	
The gabapentin analysis included seven RCTs. The results crossed both the 
conventional boundary for statistical significance and the O’Brien-Fleming 
boundary (Figure 8.5) and also reached the required IS (341 participants). 
 
 
Figure 8.5: Trial sequential analysis of low risk of bias trials for gabapentin. 
Performed assuming an empirical MD of -7.59mg, variance of 33, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 94.4. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with gabapentin. 
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8.3.6 Pregabalin 	
The pregabalin analysis included three RCTs. O’Brien-Fleming boundaries 
could not be constructed for an empirical MD of -11.04mg (Figure 8.6). 
However, the results crossed the conventional boundary for statistical 
significance. 
 
 
Figure 8.6: Trial sequential analysis of low risk of bias trials for pregabalin. 
Performed assuming a MD of -11mg, variance of 19.5, adjusted α=0.05, 1-
β=0.80 and a heterogeneity correction of 69.9. Blue line indicates cumulative Z 
score with values more than 0 indicating benefit with pregabalin. 
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8.3.7 Nefopam 	
There was only one low risk of bias trial for nefopam. Boundaries could not be 
constructed for an empirical MD of -17.5mg (Figure 8.7). However, results did 
cross the conventional boundary for statistical significance. 
 
 
Figure 8.7: Trial sequential analysis of low risk of bias trials for nefopam. 
Performed assuming a MD of -17.5mg, variance of 41, adjusted α=0.05, 1-
β=0.80 and a heterogeneity correction of 0. Blue line indicates cumulative Z 
score with values more than 0 indicating benefit with nefopam. 
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8.3.8 Lidocaine 	
The lidocaine analysis included six RCTs at low risk of bias. Although the 
results crossed the conventional boundary for statistical significance, they did 
not cross the O’Brien-Fleming boundary (Figure 8.8). In addition, the results 
did not reach the required IS for definitive answer (490 participants). 
Assuming a heterogeneity correction of 50% and 80%, the required ISs were 
980 and 2450 participants respectively.  
 
 
Figure 8.8: Trial sequential analysis of low risk of bias trials for lidocaine. 
Performed assuming an empirical MD of -4.94mg, variance of 380, adjusted 
α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line indicates 
cumulative Z score with values more than 0 indicating benefit with lidocaine. 
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8.3.9 Dexamethasone 	
There was only one low risk of bias trial in the dexamethasone analysis. 
Although the results crossed the conventional boundary, they did not cross the 
O’Brien-Fleming boundary for statistical significance. In addition, the results 
failed to reach the required IS (Figure 8.9). Assuming a heterogeneity 
correction of 50% and 80% resulted in an IS of 218 and 545 participants 
respectively. 
 
 
 
Figure 8.9: Trial sequential analysis of low risk of bias trials for 
dexamethasone. Performed assuming an empirical MD of -4.67mg, variance of 
75, adjusted α=0.05, 1-β=0.80 and a heterogeneity correction of 0. Blue line 
indicates cumulative Z score with values more than 0 indicating benefit with 
dexamethasone. 
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8.3.10 Magnesium 	
There was only one low risk of bias trial for magnesium. There was too little 
information from this trial to conduct TSA. The results from this trial did not 
cross the conventional boundary for statistical significance.  
 
8.3.11 Tramadol 	
There were no low risk of bias trials for tramadol and therefore TSA could not 
be performed. 
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8.4 Discussion 	
8.4.1 Summary of results 	
Although a large number of RCTs have been published evaluating multimodal 
analgesic agents, only 36 RCTs (approximately 10%) were at low risk of bias. 
Only the results for gabapentin crossed boundaries for benefit adjusted for 
multiple comparisons (reduce type I errors). In addition, only the results from 
gabapentin were able to reach the required IS for a definitive answer (reduce 
type II errors). Ultimately, there is currently insufficient evidence from low 
risk of bias trials to be confident of the effects of any multimodal analgesic 
agents currently used in clinical practice. 
 
8.4.2 Links with previous research 	
Randomised controlled trials are the gold standard for assessing the efficacy of 
interventions. However, issues with trial conduct have the potential to bias the 
results from these trials. We have previously demonstrated that this bias has the 
potential to exaggerate effect estimates using meta-regression analysis. 
Allocation concealment is a process where researchers cannot foresee the 
group to which subsequent participants will be allocated and has the potential 
to cause selection bias. A review of four empirical studies has shown that trials 
with inadequate or unclear allocation concealment exaggerated effects up to 
40% (Schultz et al. 1995; Schultz and Grimes 2002a). With regards to 
blinding, if participants are un-blinded to the intervention, they become subject 
to placebo effects, which may influence an outcome with a psychological 
element, such as pain (Turner et al. 1994). Indeed, a previous paper has 
expressed concerns over lack of blinding of outcome assessment, especially for 
subjective outcomes such as pain scores (Schultz and Grimes 2002b).  
 
An under-recognised problem with meta-analyses is the potential for spurious 
conclusions due to type I and type II errors. A proposed solution was the use of 
trial sequential monitoring boundaries and calculation of information sizes to 
help reduce these errors (Thorlund et al. 2008). With a focus on anaesthesia, a 
previous review of 50 anaesthetic meta-analyses has found that only 12% of 
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meta-analyses had a power of >80% and only 32% maintained a type I error of 
<5% using TSA (Imberger et al. 2015). Our analysis of low risk of bias trials 
has demonstrated that despite the multitude of published studies, for most 
multimodal analgesic agents, there is not enough data to be confident of 
excluding type I and type II errors. 
 
8.4.3 Limitations 	
As our classification of risk of bias was determined from published reports, 
unclear risk of bias assignments may have included, in reality, both trials with 
high risk and low risk for each element (although high risk are likely to 
predominate). This may have diluted the true extent of these methodological 
differences and led to under or overestimations in results. In addition, our 
sample of RCTs was limited to those published in previous meta-analyses with 
variable search strategies, therefore the possibility of missing studies limits our 
results. However, we can be confident that our samples include at least as 
many studies as the previously published meta-analyses sampled and thus more 
extensive than the current literature. 	
8.4.4 Conclusions 	
In conclusion, we have demonstrated that there is currently insufficient 
evidence from low risk of bias trials for multimodal analgesic agents to 
confidently exclude type I and type II errors. Therefore, further adequately 
powered, low risk of bias trials are required to exclude such errors in current 
meta-analyses. 
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Chapter 9 
Discussion 
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9.1 Summary of thesis results 	
This thesis started with a general discussion surrounding patient-centred 
outcomes that negatively affect patients around the peri-operative period. 
These negative outcomes include postoperative pain, vomiting, pruritus, pre-
operative anxiety and the associated adverse effects of opioids (Apfelbaum  et 
al. 2003). This led to a proposed solution to these outcomes; the use of 
multimodal analgesia, which aims to both treat postoperative pain and lower 
opioid consumption with the aim of reducing the adverse effects of opioids. 
One such multimodal agent is gabapentin, which reduces pain via multiple 
mechanisms and has found favour in the treatment of postoperative pain, 
supported by a wealth of clinical trials published over the last decade. Due to 
the extensive published trials on gabapentin, this thesis used systematic review 
and meta-analysis as the most appropriate methodology to answer various 
clinical questions surrounding the use of gabapentin. The chapter concluded 
with a discussion of various systematic review methodologies that aim to 
reduce bias and error. 
 
The second chapter of the thesis evaluated the use of gabapentin in treating 
acute and chronic postoperative pain. Gabapentin had variable effects on pain 
scores and opioid consumption. Our meta-regression model helped identify 
clinical situations where gabapentin may be more effective including patients 
with higher postoperative morphine consumption or pain scores, increasing 
gabapentin dosages and those undergoing procedures under general 
anaesthesia. However, we did find evidence of imprecise study effects, which 
may be caused by publication bias. Despite strong evidence supporting its use 
in acute postoperative pain, there was little evidence that gabapentin is 
effective for chronic postoperative pain. Although future trials are required to 
confirm these findings. 
 
The third chapter aimed to focus on a variety of peri-operative outcomes 
including gabapentin adverse events and opioid side effects. We found 
evidence that gabapentin reduced postoperative nausea, vomiting, pruritus and 
pre-operative anxiety. However, gabapentin increased the risk of postoperative 
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sedation. Despite this, when focusing on the patient-centred outcome of patient 
satisfaction, although only a few studies reported this outcome, those patients 
who had received gabapentin reported higher satisfaction than those who 
received placebo. To help explain this finding, we cited evidence from the 
literature that demonstrated sedation is ranked below pain and vomiting for 
events patients fear the most during anaesthesia (Macario et al. 1999). We also 
highlighted that gabapentin may have other benefits following surgery, 
although data is limited to a small number of studies, which requires future 
trials to resolve this. We also found further evidence of imprecise study effects 
in this chapter. However, for sedation and dizziness, there was a bias against 
gabapentin suggesting that these effects may be overestimated should the 
assumption of a symmetric funnel plot hold. 
 
The fourth chapter aimed to examine the optimum timing of gabapentin 
administration. The theoretical underpinning of pre-emptive analgesia suggests 
that initiating analgesic interventions before surgical incision can improve 
postoperative pain compared to the same intervention given after surgical 
incision. We found a small number of studies focusing on this comparison and 
found no evidence of a pre-emptive analgesic effect with gabapentin. No 
studies evaluated a preventive effect of gabapentin (doses continued 
postoperatively). However, given that oral administration of gabapentin has 
effects on pre-operative anxiety and can be given with the patient fully alert, 
pre-operative dosing may be a more convenient time of administration. 
Although as later identified in chapter five, concerns over adverse intra-
operative haemodynamic effects need to be resolved before recommending this 
as this optimum time to administer gabapentin. 
 
The fifth chapter shifted focus from pain and adverse events and focused on a 
novel clinical effect of gabapentin in attenuating the haemodynamic response 
to endotracheal intubation. This haemodynamic response can cause myocardial 
ischaemia in high-risk patients and may therefore lead to increased 
postoperative mortality. Although we found evidence of successful attenuation 
of this haemodynamic response with gabapentin, none of the included studies 
included high-risk patients or studied clinically relevant outcomes such as 
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myocardial infarction or mortality. Furthermore, there was little data 
concerning adverse haemodynamic effects such as bradycardia and 
hypotension, which have been associated with increased postoperative stroke 
and mortality. As already discussed, the findings of this chapter have 
implications for gabapentin use as an analgesic agent, as theoretically, 
haemodynamic effects could affect important patient outcomes. 
 
Chapter six aimed to extend the principal that the efficacy of analgesic adjuncts 
is determined by the level of morphine consumption in the control group 
(baseline risk), by applying meta-regression analysis to published RCTs of 
multimodal analgesic adjuncts. In addition, we performed a meta-
epidemiological study of published reviews and RCTs to check adherence to 
methods recommended to investigate heterogeneity and measures of internal 
validity in published RCTs. For the included reviews, we found most studies 
investigated heterogeneity, although a small number used meta-regression. For 
the included RCTs, only a third described adequate allocation concealment, 
which has previously been shown to exaggerate effect estimates (Schultz and 
Grimes 2002a). On meta-regression analysis, we found evidence that for all of 
these analgesic adjuncts, a large proportion of the between-study variance 
could be explained by the control group morphine consumption (baseline risk), 
a surrogate marker for both how painful the surgery is, participant 
characteristics and the concurrent analgesics used. We also found evidence of 
exaggerated effect estimates in the presence of methodological limitations such 
as inadequate allocation concealment, blinding and attrition bias. Furthermore, 
we could find little empirical evidence to support the conduct of procedure-
specific meta-analyses. Using these findings, we presented a league table of 
analgesics and presented novel methods to more accurately report opioid 
consumption that reduces confounding present using current methods.  
 
Chapter seven used the same sample of meta-analyses and RCTs to perform a 
meta-epidemiological study and a secondary analysis of RCTs to identify the 
extent of funnel plot asymmetry and thus possible publication bias within the 
current literature. We found that only a small number of included reviews used 
methods to prevent publication bias (such as searching grey literature, clinical 
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trial databases and conference proceedings) and around half used qualitative 
and quantitative methods to help identify imprecise study effects. On analysing 
the included RCTs, although there was quantitative and qualitative evidence of 
funnel plot asymmetry (imprecise study effects) for most analgesic agents, this 
may be a product of statistical artifact from the association between baseline 
risk and standard errors. As trials with larger control group morphine 
consumption have larger associated standard deviations and most trials are of 
similar sample sizes, funnel plot asymmetry may not reflect true underlying 
publication bias. Indeed, our simulation studies of meta-analyses where no 
publication bias was present showed funnel plot asymmetry in all analyses, 
which was corrected using novel funnel plots of meta-regression residuals on 
the X axis.  
 
Chapter eight was the final analysis, this chapter used trial sequential analysis 
of low risk of bias studies to identify whether there was sufficient evidence to 
reject type I and type II errors on meta-analysis. There is currently insufficient 
data to exclude such errors and therefore we recommend further conduct of 
low risk of bias studies. This is especially important following our previous 
findings of the association between exaggerated effect estimates and 
limitations in methodological conduct in the included trials. 
9.2 Suggestions for future research 	
Although meta-analytic methods have advantages over primary research 
studies by including a larger amount of information (thus increasing precision), 
they have associated disadvantages, such as publication bias. Therefore, larger, 
prospectively registered RCTs are still required to substantiate the conclusions 
of this review in regards to postoperative pain, opioid side effects and 
gabapentin adverse events.  
 
Such trials would need to be larger than those published thus far to be able to 
detect differences in dichotomous outcomes such as chronic pain, vomiting and 
sedation. Such studies should ensure adequate randomisation, allocation 
concealment, blinding and full intention-to-treat analysis to improve on those 
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published previously. Especially in light of findings of exaggerated effect 
estimates with trials at higher risk of bias for analgesics used to treat 
postoperative pain. Such large trials are the only way to resolve issues of 
publication bias, although such trials would need to ensure prospective 
registration on clinical trial databases to help reduce problems with not 
publishing negative study results. We would advise such trials aim to recruit 
participants undergoing surgery where postoperative morphine consumption is 
expected to be high, in procedures performed under general anaesthesia and 
aim to use higher doses of gabapentin (600-1200mg). Such studies should also 
include other patient-centred outcomes where evidence is scarce, such as those 
presented in chapter three.  
 
In terms of the haemodynamic effects of gabapentin, as gabapentin in known to 
reduce heart rate and blood pressure responses to endotracheal intubation and 
is also known to reduce postoperative pain and catecholamine secretion (all 
known to increase myocardial demand with links to cardiac complications), 
future studies should be conducted in high risk patients to identify if 
gabapentin can reduced myocardial ischaemia, arrhythmias, myocardial 
infarction and mortality. Such trials will require careful monitoring for adverse 
haemodynamic effects (such as hypotension and bradycardia), which have the 
potential to increase mortality. Similar to studies for postoperative pain, such 
trials need to ensure low risk of bias for measures of internal validity and are 
adequately powered to detect differences in such dichotomous outcomes. This 
is especially true for mortality, where postoperative incidence is low and likely 
to require thousands of participants. Therefore, initial smaller trials may wish 
to measure surrogate outcomes such as episodes of myocardial ischaemia or 
arrhythmias on ECG recordings, which would require smaller numbers of 
patients and help prove the initial concept that gabapentin can reduce 
myocardial ischaemia in high-risk patients. 
 
With regards to our findings in relation to higher control group consumption 
predicting larger reductions in postoperative morphine consumption, this has 
implications for clinical practice, primary research studies and future meta-
analyses. Meta-analyses of analgesic adjuncts may wish to use meta-regression 
	 386	
to help explain the inherent statistical heterogeneity present in most of these 
reviews using the covariates presented in this thesis. This may help increase the 
quality of the evidence derived from these reviews as per GRADE. Moreover, 
we recommend future meta-analyses of analgesics report reductions in 
morphine at one specified time-point and report models based on a fixed 
consumption of morphine (50mg). An additional advantage of this method is 
the ability to add other clinical and methodological covariates used in this 
thesis to reduce confounding. This would also allow clinicians to more 
appropriately assess the clinical significance of findings from these reviews, as 
results can be directly compared across interventions. 
 
As previously stated for gabapentin, future RCTs of analgesic adjuncts may 
wish to target surgeries where morphine consumption is expected to be high to 
improve the absolute effects of the intervention. Due to the inherent bias and 
confounding of meta-regression analysis, future primary research may wish to 
explore the relationship between the efficacy of analgesic adjuncts and the pain 
experienced by the participant. However, such studies would only be possible 
when using analgesics to treat established postoperative pain, where baseline 
pain recordings are possible. Or alternatively, if interventions are given before 
outcome measurement, trials could recruit participants at high and low risk of 
severe postoperative pain, then randomise them within these groups and 
identify whether the intervention causes larger reductions in pain in one group 
compared to the others (as those in the severe group would be expected to have 
higher pain scores compared the low risk group). 
 
Our findings of exaggerated effect estimates in studies with lower 
methodological conduct means future trials should aim to reduce these inherent 
biases and conduct low risk of bias research. In addition, future meta-analyses 
of analgesic adjuncts should use TSA to help reduce type I and type II errors in 
low risk of bias research. Rejection of such errors from low risk of bias trials 
may be achieved in future reviews as further trial evidence is accrued.   
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9.4 Conclusion of thesis 
	
This thesis has demonstrated the benefit of gabapentin for preventing acute 
postoperative pain, lowering opioid consumption, reducing the incidence of a 
number of opioid adverse events and in attenuating the haemodynamic 
response to intubation. We have used meta-regression analysis to demonstrate 
that gabapentin may be more effective in groups of participants at higher 
baseline risk. In addition, we have shown that this finding extends to other 
analgesic adjuncts. Furthermore, we have shown how this dependency on 
baseline risk affects meta-analyses in general by confounding results when 
presented as mean differences and producing funnel plot asymmetry even in 
the presence of no publication bias. Moreover, we have presented novel 
methods of presenting effect estimates and assessing publication bias that 
resolves the above concerns and recommend use of these methods in future 
meta-analyses. 
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